Book

FINAL PROGRAM

FINAL PROGRAM

TABLE OF CONTENTS

CONFERENCE INFORMATION

Welcome Letter .......................................................................................................................................................... 04Committees ................................................................................................................................................................... 06About ISBD ..................................................................................................................................................................... 08General Information ................................................................................................................................................ 09Program at a Glance ............................................................................................................................................... 12Keynote Speakers ..................................................................................................................................................... 20Samuel Gershon Junior Investigator Award ........................................................................................ 21CME/CPD Accreditation ....................................................................................................................................... 22Interactive Application .......................................................................................................................................... 25Information for Presenters ................................................................................................................................ 27Poster Overview ......................................................................................................................................................... 30Venue Floor Plans ..................................................................................................................................................... 31

SCIENTIFIC PROGRAM

Tuesday March 18, 2014 ....................................................................................................................................... 33Wednesday March 19, 2014 ............................................................................................................................... 45Thursday March 20, 2014 .................................................................................................................................... 65Friday March 21, 2014 ........................................................................................................................................... 87Posters .............................................................................................................................................................................. 99Index of Authors ...................................................................................................................................................... 131

RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT

Acknowledgements .............................................................................................................................................. 141Industry Symposia Program .......................................................................................................................... 143List of Exhibitors ..................................................................................................................................................... 147Exhibition Map .......................................................................................................................................................... 147Exhibitor and Sponsor Profiles .................................................................................................................... 148

04

WELCOME LETTER

On behalf of the Scientific Program, Steering and Local Organizing Committees of the 16th Annual Conference of the International Society for Bipolar Disorders (ISBD), we would like to welcome you to Seoul for what has over the past 20 years become the premier international conference on bipolar disorders.

The origin of the conference began in 1994 when Dr David Kupfer and Dr Ellen Frank from the University of Pittsburgh organized the International Conference on Bipolar Disorder (ICBD), the first international meeting entirely focused on bipolar disorder. Since then, the ICBD had built its reputation as an excellent conference for clinicians, researchers, patients and family members through its 9 biennual conferences in Pittsburgh and the last one in Miami in 2013.

In 1999, together with Dr Samuel Gershon, also from Pittsburgh, Dr Kupfer and Frank also founded the International Society for Bipolar Disorders (ISBD), which since then organized 5 biennial meetings across the world, from Sydney toEdinburgh, Delhi, Sao Paulo and Istanbul, which have gained recognition as the representative international conference on bipolar disorders.

In 2013, the biennial ICBD and the biennial conference of the ISBD have merged into the Annual Conference of the International Society for Bipolar Disorders, and collectively we have now the 16th Annual Conference on Bipolar Disorders.

The Scientific Program Committee kept the traditions from both conferences, which include Keynote Lectures, Concurrent Parallel Symposia, Rapid Oral Communications, Poster sessions and Industry Sponsored Satellite Symposia. In addition, we have continued the relatively new format of the last two meetings (Istanbul and Miami) with Early Morning Brainstorming Sessions and Pre-Conference Courses.

The programs include all aspects of clinical and research activities on bipolar disorders, from diagnosis to treatment, from basic research to psychosocial rehabilitation, from children to late life, to meet interests of all participants and to enhance discussion. The core of the program, the concurrent parallel symposia, is divided and designated into tracks (clinical manifestation, treatment, neurobiology, imaging, cultural, and advocacy) to allow participants to follow all symposia meeting their specific different interests.

05

ISBD has a tradition to work with patients and their families to overcome the burden of bipolar disorder. This will be highlighted in the program on the last day, when advocacy sessions and lessons from the West will enhance supportive activities in the Asian regions which still suffer from strong stigma against bipolar disorder.The meeting in Seoul was planned to promote bipolar disorders in Asia, and to facilitate mutual understanding of the psychosocial environment surrounding bipolar disorders between the East and the West. The Scientific Program Committee worked with the Regional Organizing Committee to develop a Regional Satellite Symposium and a Regional Poster Session to promote bipolar disorder among Asian clinicians and researchers.

We hope all of you enjoy the diversity and inspiration of the program. Also, we recommend that you explore the dynamic cultural diversities of Seoul and Korea beyond Seoul, including sites that offer opportunities for breathtaking scenery as well as quiet contemplation, that will extend your understanding of yin and yang, harmony and balance, which is also essential for understanding of bipolar disorder.

Kyooseob Ha, MD, PhD Willem Nolen, MD, PhD

VP for Education, ISBD President, ISBDChair, Scientific Program Committee Co-chair, Scientific Program Committee

06

COMMITTEES

CONFERENCE CHAIRSWillem Nolen, MD, PhD Chair, Steering Committee Co-Chair, Scientific Program CommitteeKyooseob Ha, MD, PhD Chair, Scientific Program Committee Co-Chair, Steering CommitteeYeon Ho Joo, MD, PhD Chair, Regional Organizing Committee STEERING COMMITTEEWillem Nolen, Chair, MD, PhD - The NetherlandsKyooseob Ha, Co-Chair, MD, PhD - KoreaMichael Berk, MD - AustraliaYeon Ho Joo, MD, PhD - KoreaManuel Sanchez de Carmona, MD - MexicoLakshmi Yatham, MBBS, FRCPC, MRCPsych - Canada

SCIENTIFIC PROGRAM COMMITTEEKyooseob Ha, Chair, MD, PhD - KoreaWillem Nolen, Co-Chair, MD, PhD - The NetherlandsCarlo Altamura, MD - ItalyRobert Belmaker, MD - IsraelMichael Berk, MD - Australia Hyun Sang Cho, MD, PhD - KoreaSophia Frangou, MD, PhD - USAMark Frye, MD - USAFlavio Kapczinski, MD, PhD - Brazil Tadafumi Kato, MD, PhD - JapanLars Vedel Kessing, MD, PhD, DMSc. - DenmarkDavid Kupfer, MD - USABeny Lafer, MD - BrazilCarlos Lopez Jaramillo, MD - Colombia Gin Malhi, MD - AustraliaAndrew Nierenberg, MD - USA Aysegul Ozerdem, MD, PhD - Turkey Manuel Sanchez de Carmona, MD - Mexico Lakshmi Yatham, MBBS, FRCPC, MRCPsych - Canada L. Trevor Young, MD, PhD - Canada

07

REGIONAL ORGANIZING COMMITTEEYeon Ho Joo, Chair, MD, PhD - KoreaYong Min Ahn, MD, PhD - Korea Yuan-Hwa Chou, MD, PhD - TaiwanB. Handoko Daeng, MD - IndonesiaYiru Fang, MD, PhD - ChinaTae Hyon Ha, PhD - KoreaShigenobu Kanba, MD, PhD - JapanSe Joo Kim, MD, PhD - KoreaOng Hui Koh, MD - MalaysiaHeon-Jeong Lee, MD, PhD - KoreaM.S. Reddy, MD - IndiaY.C. Janardhan Reddy, MD - India Pichet Udomratn, MD - ThailandMichael Ming - Cheuk Wong MB, BS, MRCPsych UK, FHKCPsych, FHKAM Psychiatry - Hong Kong Xin Yu, MD, PhD - China

ISBD EXECUTIVE COMMITTEEWillem Nolen, MD, PhD - The Netherlands PresidentSophia Frangou, MD, PhD - USA Vice-President, GovernanceAndrew Nierenberg, MD - USAVice-President, ResearchKyooseob Ha, MD, PhD - South KoreaVice-President, Education Robert Belmaker, MD - IsraelVice-President, Global Outreach Manuel Sánchez de Carmona, MD - MexicoSecretary/Treasurer

08

ABOUT ISBD

HISTORY

Bipolar disorder is a severe and debilitating mental illness, which has only recently started to receive the necessary attention from society, researchers, practitioners, government, and private funding agencies. In response to the need for further awareness, education, and research on this severe mental illness, the International Society for Bipolar Disorders was created. The Society has as its missions the promotion of awareness of this condition in society at large, promotion of awareness and education about this condition among mental health professionals, fostering research on all aspects of bipolar disorder, and promotion of international collaboration in this area. The International Society for Bipolar Disorders was launched at the 3rd International Conference on Bipolar Disorders, in Pittsburgh, PA, June 17, 1999, by David J. Kupfer, M.D., Founding President. Material distributed to all of the delegates at the conference contained an invitation letter and an enrolment form. The first issue (September, 1999) of Bipolar Disorders - An International Journal of Psychiatry and Neurosciences, the official journal of the Society, contained a similar enrolment form. The Journal was accepted into the Institute of Scientific Indexing in 2000, was accepted into Medline and Index Medicus in 2001, and received the impact factor of 5.221 in 2010, ranking it 10th out of 126 rated psychiatric journals. The Society is growing in membership with an elected board representing 17 countries. The ISBD is a major source for emerging research and clinical data on bipolar disorders and is the only bipolar focused, research-oriented Society working to bring this data to patients, families, and other mental health professionals working on the front lines of bipolar care.

INTERNATIONAL SOCIETY FOR BIPOLAR DISORDERS

P.O. Box 7168 Pittsburgh, PA 15213 United States of AmericaPhone: (412) 802-6940 Fax: (412) 802-6941 www.isbd.org

http://www.isbd.org/

09

GENERAL INFORMATION

CONFERENCE VENUE

COEX World Trade Center (North Entrance) Samseong-Dong Gangnam-gu Seoul 135-731www.coex.co.kr

REGISTRATION HOURS

The Registration Desks are situated in the Grand Ballroom Foyer and will be open as follows:Tuesday March 18, 2014 08:00 – 20:30Wednesday March 19, 2014 06:30 – 19:00Thursday March 20, 2014 06:30 – 18:30Friday March 21, 2014 06:30 – 15:00

NAME BADGES

Upon registration, you will receive your name badge. You are kindly requested to wear your name badge at all times during the Conference in order to have access to the conference halls and exhibition area.

PRE-CONFERENCE COURSES

Pre-Conference Courses held on Tuesday March 18th require a ticket for entry. To purchase a ticket please approach the registration desk. Kindly note that space is limited and tickets will be sold on a first-come, first-served basis.

EXHIBITION OPENING HOURS

The exhibition will be open as follows:Tuesday March 18, 2014 09:00 – 20:30Wednesday March 19, 2014 08:00 – 18:30Thursday March 20, 2014 08:00 – 18:30

INTERNET STATIONS

Free internet and email facilities will be available to all Conference participants in the exhibition area during the exhibition opening hours only. Conference abstracts will also be available for viewing from the stations. Please be considerate of fellow participants when using these facilities.

10

WI-FI

Coex is a free Wi-Fi zone. Please be aware that public Wi-Fi capacity may have a limited number of simultaneous connections.

REFRESHMENTS

Self-served tea and coffee will be available in the Exhibition Area at the breaks indicated in the Scientific Program. Lunch boxes will be served to the attendees of the lunchtime industry symposia, in the session hall. Early morning brainstorming sessions will also include light refreshments.

CME/CPD CERTIFICATE OF ATTENDANCE

CME/CPD Certificate of Attendance will be available for participants after the Conference. Your certificate will be delivered electronically after completing the educational evaluation and credit claiming procedure online via the link you will receive following the Conference. The process will take 5-10 minutes. We thank you for your feedback as it is an important part of the CME/CPD accreditation process and helps improve future educational offerings.

For further information on how to obtain your CME Certificate of attendance, please refer to the CME/CPD Accreditation pages in this Final Program.

CONFERENCE ABSTRACTS

ISBD 2014 Conference Abstracts will be published as an online supplement to Bipolar Disorders: An International Journal of Psychiatry and Neurosciences.To access the abstracts please visit: http://wileyonlinelibrary.com/journal/bdi

WELCOME RECEPTION

All registered participants are invited to join us for the Welcome Reception which will take place in the Exhibition Area on Tuesday, March 18 at 19:30 - 20:30.

ISBD MEMBERSHIP MEETING

All ISBD members are invited to attend the ISBD Membership Meeting. This meeting will take place on Wednesday, March 19, 18:00 – 19:00 in Hall F.

NOTICE BOARD/MESSAGES

Updates and notifications will be posted during the Conference on a notice board in the Exhibition Area in the Grand Ballroom Foyer at the Conference venue. Participants are also welcome to use this space to place messages for colleagues.

11

LIABILITY AND INSURANCE

The Conference Secretariat and Organizers cannot accept liability for personal accidents or loss of or damage to private property of participants. Participants are advised not to leave their personal belongings unattended in session halls and throughout the Conference venue.

SAFETY AND SECURITY

Please do not leave any bags or suitcases unattended at any time, whether inside or outside session halls.

SMOKING POLICY

This is a non-smoking event. Participants are kindly requested to refrain from smoking in all public areas.

EMERGENCY TELEPHONE NUMBERS

119 - Fire, Emergency and Ambulance112 - Police

CONFERENCE SECRETARIAT

1-3 Rue de Chantepoulet, PO Box 1726CH-1211 Geneva 1SwitzerlandTel: +41 22 908 0488Fax: +41 22 906 9140E-mail: [email protected] Website: www.isbd2014.com

mailto:[email protected]

http://www.isbd2014.com/

12

Time Hall A Hall B Hall C Hall D Hall E Hall F Poster Area

8:00 Registration Opens Registration Opens

9:00State of the Art in Diagnosing, Assessing and

Treating Bipolar Disorder: A Training course to improve

your skills as a bipolar expert

9:30 The 6th Conference of the Asian Network of

Bipolar Disorder East Asian

Bipolar Forum

The Korean Academy of Child and Adolescent

Psychiatry Symposium

Southeast Asia and South Asia Bipolar Forum11:30 Lunch Break

12:30

Lunch Break The Korean

Academy of Child and Adolescent

Psychiatry Symposium (Continued)

Lunch Break13:00

Proper use of Mood

Stabilizers in Long Term Treatment of Bipolar Disorders

Treatment of Bipolar Disorders

During Pregnancy and Post-Partum

13:30 Experience from Latin America

State of the Art in Diagnosing, Assessing and

Treating Bipolar Disorder: Continued

15:00 Coffee Break Regional Poster Session (Poster Area)

Regional Poster Session

15:30Industry Symposium (not included in main

event CME/CPD credit)

17:00 Opening & Awards Ceremony

18:00 Keynote Lecture 1 Keynote Lecture 2

19:30 Welcome Reception (Exhibition Area)

PROGRAM AT A GLANCE

The 6th Conference of the Asian Network of Bipolar DisorderThe Korean Academy of Child and Adolescent Psychiatry SymposiumPre-Conference Courses

13

Time Hall A Hall B Hall C Hall D Hall E Hall F Poster Area

8:00 Registration Opens Registration Opens

9:00State of the Art in Diagnosing, Assessing and

Treating Bipolar Disorder: A Training course to improve

your skills as a bipolar expert

9:30 The 6th Conference of the Asian Network of

Bipolar Disorder East Asian

Bipolar Forum

The Korean Academy of Child and Adolescent

Psychiatry Symposium

Southeast Asia and South Asia Bipolar Forum11:30 Lunch Break

12:30

Lunch Break The Korean

Academy of Child and Adolescent

Psychiatry Symposium (Continued)

Lunch Break13:00

Proper use of Mood

Stabilizers in Long Term Treatment of Bipolar Disorders

Treatment of Bipolar Disorders

During Pregnancy and Post-Partum

13:30 Experience from Latin America

State of the Art in Diagnosing, Assessing and

Treating Bipolar Disorder: Continued

15:00 Coffee Break Regional Poster Session (Poster Area)

Regional Poster Session


event CME/CPD credit)

17:00 Opening & Awards Ceremony


19:30 Welcome Reception (Exhibition Area)

Day 1 - Tuesday 18th March

14

Time Hall A Hall B Hall C Hall D Hall F Poster Area

7:00 Lithium Phobia: Science or Superstition?

Clinical and Therapeutic Peculiarities of Bipolar

Disorder in Late Life

8:30 Prescription Pattern in the Treatment

of Bipolar Affective Disorder: What the Real World is Like

Bipolar Disorder in Children and

Adolescents, Compared with Adult

Bipolar Disorder

Molecular Mechanisms of

Bipolar Disorder

Applications of Novel Imaging Techniques to Gain

New Insights into Bipolar Disorder

Rapid Communications I

10:00 Mid-Morning Break Mid-Morning Break


12:00 Industry Symposium (not included in main

event CME/CPD credit)Lunch Break Lunch Break

13:30 What do we Know About Lithium’s

Role in Maintenance Treatment of Bipolar

Disorder, 60 Years After its Discovery?

The Bipolar “Pro-drome”: Can we

Identify At-Risk Indi-viduals? An ISBD Task

Force Report

The Involvement of Mitochondria in

Bipolar Disorder and its Treatment

The Potential Clinical and Therapeutic Relevance

of Imaging and Cognitive Studies in Bipolar Disorder

Rapid Communications II

15:00 Afternoon Break Afternoon Break

15:30

Clinical Guidelines for Bipolar Disorder

Unique Features of Bipolar Disorder in

Older AdultsAn ISBD Task Force Report

Diet, Exercise, and Weight: Modifiable Drivers of Disease

Severity and Progression in People with Mood Disorders?

Crossing Borders in Cognitive Assessment of

Bipolar Disorders

17:00Poster Session I

18:00ISBD Membership Meeting

18:30

PROGRAM AT A GLANCE

Symposia SessionsBrainstorming Sessions

15

Time Hall A Hall B Hall C Hall D Hall F Poster Area

7:00 Lithium Phobia: Science or Superstition?

Clinical and Therapeutic Peculiarities of Bipolar

Disorder in Late Life

8:30 Prescription Pattern in the Treatment

of Bipolar Affective Disorder: What the Real World is Like

Bipolar Disorder in Children and

Adolescents, Compared with Adult

Bipolar Disorder

Molecular Mechanisms of

Bipolar Disorder

Applications of Novel Imaging Techniques to Gain

New Insights into Bipolar Disorder

Rapid Communications I





13:30 What do we Know About Lithium’s

Role in Maintenance Treatment of Bipolar

Disorder, 60 Years After its Discovery?

The Bipolar “Pro-drome”: Can we

Identify At-Risk Indi-viduals? An ISBD Task

Force Report

The Involvement of Mitochondria in

Bipolar Disorder and its Treatment

The Potential Clinical and Therapeutic Relevance

of Imaging and Cognitive Studies in Bipolar Disorder

Rapid Communications II


15:30

Clinical Guidelines for Bipolar Disorder

Unique Features of Bipolar Disorder in

Older AdultsAn ISBD Task Force Report

Diet, Exercise, and Weight: Modifiable Drivers of Disease

Severity and Progression in People with Mood Disorders?

Crossing Borders in Cognitive Assessment of

Bipolar Disorders

17:00Poster Session I

18:00ISBD Membership Meeting

18:30

Day 2 - Wednesday 19th March

Symposium Tracks: Treatment Track I Clinical Manifestation Neurobiology Track I Imaging Track I Cultural Track

16

Hall A Hall B Hall C Hall D Hall F Poster Area

7:00 New Psychosocial Treatments for

Bipolar Disorder

How to Manage Bipolar Disorder in Pregnancy and

Postpartum Disorder

Staging and Profiling Bipolar Disorder: Conceptual

and Clinical Approaches

8:30The Challenge of

Designing Clinical Trials An ISBD Task

Force Report

Neuroendocrine Challenges and

Gender Differences in Bipolar Disorder

An ISBD Task Force Report

Investigations of Bipolar Disorders with the Forefront

Neurophysiologucal Methods

Structural, Functional and Neuroreceptor imaging in

Affective Disorders

Socio-Cultural Challenges in the Management of Bipo-

lar Disorder





13:30 New Medical Treat-ments Targeting

Cognitive Dysfuntion in Bipolar Disorder

Metabolic Syndrome and Bipolar Disorder

Bipolar Disorder and Neuroinflammation: What Can we See?

Identifying Mood Disorder and Correlates in Youth from Different Cultures


15:30 Predictors and Moderators of Psy-

chosocial Treatment Outcome for Bipolar

Depression

Suicide in Bipolar Disorder;


Glutamatergic System in Bipolar Disorders:

From Etiology to Treatment

Samuel Gershon Award Winners

Cultural Issues and Bipolar Disorder in China

17:00Poster Session II

PROGRAM AT A GLANCE


17

Hall A Hall B Hall C Hall D Hall F Poster Area

7:00 New Psychosocial Treatments for

Bipolar Disorder

How to Manage Bipolar Disorder in Pregnancy and

Postpartum Disorder

Staging and Profiling Bipolar Disorder: Conceptual

and Clinical Approaches

8:30The Challenge of

Designing Clinical Trials An ISBD Task

Force Report

Neuroendocrine Challenges and

Gender Differences in Bipolar Disorder


Investigations of Bipolar Disorders with the Forefront

Neurophysiologucal Methods

Structural, Functional and Neuroreceptor imaging in

Affective Disorders

Socio-Cultural Challenges in the Management of Bipo-

lar Disorder





13:30 New Medical Treat-ments Targeting

Cognitive Dysfuntion in Bipolar Disorder

Metabolic Syndrome and Bipolar Disorder

Bipolar Disorder and Neuroinflammation: What Can we See?

Identifying Mood Disorder and Correlates in Youth from Different Cultures


15:30 Predictors and Moderators of Psy-

chosocial Treatment Outcome for Bipolar

Depression

Suicide in Bipolar Disorder;


Glutamatergic System in Bipolar Disorders:

From Etiology to Treatment

Samuel Gershon Award Winners

Cultural Issues and Bipolar Disorder in China

17:00Poster Session II

Day 3 - Thursday 20th March

Symposium Tracks: Treatment Track I Clinical Manifestation Neurobiology Track I Imaging Track I Cultural Track

18

Time Hall A Hall B Hall C Hall D Hall F

7:00 Transcranial Magnetic Stimulation Biomarker

and Therapeutic Stuides in Bipolar Disorder

Stigma as Perceived by Patients with Bipolar Disorder. Cultural Differences between The Netherlands and Japan

8:30

The Future Care of Bipolar Disorder: Trialogical Approaches

Bipolar Depression: Phenomenology, Brain Imaging

and Predictors of Treatment Response

Inflammatory Markers and New Therapeutic Challenge in Bipolar

Disorder

Rapid Communications III


10:30

Keynote Lecture 7 Keynote Lecture 8



13:30

Self-management in Bipolar Disorder

Different Aspects of Mixed Depression

Genetic Studies on Bipo-lar Disorders

Korean Advocacy Meeting

(In Korean)Rapid Communications IV

15:00 Adjourn Adjourn

15:30Korean Advocacy

Meeting (In Korean)

PROGRAM AT A GLANCE


19

Time Hall A Hall B Hall C Hall D Hall F

7:00 Transcranial Magnetic Stimulation Biomarker

and Therapeutic Stuides in Bipolar Disorder

Stigma as Perceived by Patients with Bipolar Disorder. Cultural Differences between The Netherlands and Japan

8:30

The Future Care of Bipolar Disorder: Trialogical Approaches

Bipolar Depression: Phenomenology, Brain Imaging

and Predictors of Treatment Response

Inflammatory Markers and New Therapeutic Challenge in Bipolar

Disorder

Rapid Communications III


10:30

Keynote Lecture 7 Keynote Lecture 8



13:30

Self-management in Bipolar Disorder

Different Aspects of Mixed Depression

Genetic Studies on Bipo-lar Disorders

Korean Advocacy Meeting

(In Korean)Rapid Communications IV

15:00 Adjourn Adjourn

15:30Korean Advocacy

Meeting (In Korean)

Day 4 - Friday 21st March

Symposium Tracks: Treatment Track I Clinical Manifestation Neurobiology Track I Imaging Track I Cultural Track I Advocacy Track

20

KEYNOTE SPEAKERS

TUESDAY, MARCH 18

18:00 - 19:30 Hall A The Role of Biomarkers in Clinical Practice: Lessons from Bipolar Disorder L. Trevor Young, MD., PhD., Canada The Neuroimaging Studies in Subjects at Ultra-High Risk for Psychosis Jun Soo Kwon, M.D., Ph.D., South Korea

WEDNESDAY, MARCH 19

10:30 - 12:00 Hall A Neurobiological Basis of Bipolar Disorder Tadafumi Kato, MD., PhD., Japan Early Intervention in Bipolar Disorder in a Moor Disorder Clinic Lars Vedel Kessing, MD., PhD., DMSc., Denmark

THURSDAY, MARCH 20

10:30 - 12:00 Hall A Novel Therapies: Translation, Validation and Implementation Michael Berk, MD., Australia Clinical Staging in Bipolar Disorder Flavio Kapczinski, MD., PhD., Brazil

FRIDAY, MARCH 21

10:30 - 12:00 Hall A Psychoeducation and other psychological interventions: Class effect or specific treatment modalities? Francesc Colom, PsyD., MSc., PhD., Spain Grassroots Advocacy; Hope, Resources, Support Muffy Walker, USA

21

SAMUEL GERSHON JUNIOR INVESTIGATOR AWARD

The International Society for Bipolar Disorders (ISBD) recognizes the vital role of developing the next generation of leaders in the field of bipolar disorders and offers 4 awards for original research publication submissions. In order to promote research interest in bipolar disorders in developing countries, two of the awards are reserved for those from low and middle-income countries, as defined by the 2013 World Bank Classification. The awards are presented in conjunction with the 16th Annual Conference of the International Society for Bipolar Disorders) to be held in Seoul, South Korea from 18-21 March 2014.

These awards are open to psychiatric trainees, postgraduate students, and junior faculty up to and including the Assistant Professor rank from around the world, independent of age, nationality, sex, or race.

THE 2014 SAMUEL GERSHON AWARD WINNERS

Cecilia Berlanga I MexicoFernando Goes I USAGislaine Reus I BrazilManpreet Kaur Singh I USA

These award winners will be presenting their research in a special session for Samuel Gershon Award Winners.

Thursday, March 20 I 15:30 - 17:00 I Hall D

22

CME/CPD ACCREDITATION

COMMITMENT TO THE HIGHEST STANDARDS IN CME/CPD

Kenes is committed to being a valuable and knowledgeable partner in the design and delivery of educationally strong, independent, transparent, and effective CME/CPD programmes. Kenes is a proud member of the Good CME Practice Group (gCMEp), a member organization contributing to improving health outcomes by:

• Championing best practice in CME• Maintaining and improving standards• Mentoring and educating• Working in collaboration with critical stakeholders

Membership in the Good CME Practice Group illustrates the Kenes commitment to high standards and knowledgeable partnership with its clients in the design and delivery of educationally strong, independent, transparent, effective and financially viable medical events.

EDUCATIONAL OBJECTIVES

After participating in this educational event, learners should be able to:

• Address individual needs in compliance with their Continuous Professional Development (CPD) plan

• Evaluate the most important aspects of diagnosis and treatment of Bipolar Disorders

• Discuss new research outcomes related to Bipolar Disorders • Enhance the dialogue between psychiatrists and researchers as a means of

further developing individual expertise • Discuss how to optimize psychiatric care • Analyze the pros and cons of different treatments in psychiatric care related to

Bipolar Disorders

TARGET AUDIENCE

ISBD 2014 is the global meeting place for international scientists and clinicians in the field of Psychiatry, especially Bipolar Disorders. Because of the diverse, clinically focused educational offering, participants are able to tailor the curriculum to meet the needs of international clinicians of all levels of experience.

23

ACCREDITATION STATEMENT AND CREDIT DESIGNATION

The Annual Conference of the International Society for Bipolar Disorders (ISBD) is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. Each medical specialist should claim only those hours of credit that he/she actually spent in the educational activity.

AMERICAN MEDICAL ASSOCIATION (AMA)

Through an agreement between European Union of Medical Specialists and the American Medical Association, physicians may convert EACCME credits to an equivalent number of AMA PRA Category 1 Credit™. Information on the process to convert EACCME credit to AMA credit can be found at www.ama-assn.org/go/internationalcme.

THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF CANADA

Live educational activities, occurring outside of Canada, recognized by the UEMS-EACCME for ECMEC credits are deemed to be Accredited Group Learning Activities (Section 1) as defined by the Maintenance of Certification programme of The Royal College of Physicians and Surgeons of Canada. For more information, visit: www.royalcollege.ca

24

TO RECEIVE YOUR CME/CPD CERTIFICATE OF ATENDANCE

Your CME/CPD certificate will be available after the Conference. Your CME/CPD certificate will be delivered electronically after completing the educational evaluation and credit claiming procedure. The process will take 5-10 minutes. We thank you for your feedback as it is an important part of the CME/CPD accreditation process and helps improve future educational offerings.

BEFORE FRIDAY APRIL 18:

• Follow the link in the email notification sent at the end of the event, or visit the CME/CPD Accreditation page on the event website

• Complete the anonymous online evaluation • You will be automatically directed to the credit claim system• Login with your unique User ID

(included in your registration package or on your badge)• Indicate the number of hours you attended• Your CME/CPD certificate will be automatically emailed to the address provided• Retain the certificate for your personal records

DISCLOSURE AND RESOLUTION OF PERSONAL CONFLICTS OF INTEREST

In accordance with all CME/CPD accreditation criteria and standards for commercial support, we are committed to ensuring balance, independence, objectivity, and scientific rigor in its CME/CPD activities. Those in control of the educational content disclose all relevant relationships (financial or other) with any commercial interest that they or their spouse/partner have had within the past 12 months. If an individual refuses to disclose, they are disqualified from participating. Disclosure information is evaluated and conflicts of interest resolved. Disclosure is made to participants prior to the activity. Participants are asked to evaluate the objectivity and independence. Off-label or investigational use of a therapeutic product is also disclosed.

• Disclosure slide – all speakers have been asked to present a disclosure slide in their presentations

• All submitters have been asked to complete Disclosure information on submission of the abstracts

INDUSTRY SUPPORT DISCLOSURE

This event is supported, in part, by funding from industry. All support is managed in strict accordance with CME/CPD accreditation criteria and standards for commercial support. Appropriate acknowledgement of all supporting organizations is made in the programme guide, on the event website, and with signage during the event. Disclosure is made to participants prior to the activity. Industry support information is available on page 142 and also on the Conference website at www.isbd2014.com

http://www.isbd2014.com/

25

INFORMATION AT YOUR FINGERTIPS!

PAPERLESS SCIENTIFIC PROGRAM ON SMARTPHONES AND TABLETS

The ISBD Mobile website transforms smart phones and tablets into dedicated tools for active meeting participation – making it easy for delegates to access the essential meeting content and information they need – meeting agendas, delegate lists, posters, abstracts and faculty presentations. With the ISBD Mobile web site delegates can search for the information they need. For example, sessions and presentations can be searched by day and time, venue location, topic and faculty. http://isbd.meetingxpert.net

The paperless application is designed for cross platform access via laptop and mobile devices such as Smartphones, iPhone, Android etc. Access to the application is via your browser. Please contact our support at [email protected] for assistance.

SCHEDULER – YOUR ITINERARY PLANNER

Scheduler is a new, smart application that helps you choose, plan and optimize your conference itinerary – allowing you to make the most out of your meeting. The Scheduler makes it easy to select and prioritize the sessions you want to attend, the presentations or posters you want to see, and the meetings with colleagues you’d like to arrange.

In preparation for the upcoming conference, the improved version of the itinerary planner means each participant will receive a personal name and password via a-mail. The scheduler allows you to browse sessions, presentations or search for names and words in the title, author list or the body of the abstracts. By clicking on the ‘+’ icon, you can add them to your personal itinerary and by clicking on ‘–‘ you can remove them. Your schedule is saved automatically in MY ISBD. You will also be able to add personal meetings on the calendar mode.

Once you have compiled your program, you can either import it into the calendar on your personal device or export it as a PDF. The Scheduler can also be accessed on your personal device via the conference mobile web site (view the short video for instructions). Video: http://www.youtube.com/watch?v=I5nqChfTCWk

26

E-BOOK

ISBD 2014 E-Book offer delegates a convenient and enjoyable way to access conference content on the move. Available on any smart device such as Apple or Android, mobile website and via browser – the e-book enables the meeting

organizer to publish content in a structured way using keyword indexing and a customized view. Delegates can add bookmarks or highlight texts. Text is searchable and can be hyperlinked, enabling readers to jump back-and-forth between chapters or the index. The E-Book will allow organizers to make content available for usage by participants even after the event.http://ebooks.meetingxpert.net/isbd

CARING FOR THE ENVIRONMENT

ISBD 2014 and appointed Conference organizer Kenes International are devoted to promoting environmentally friendly practice in all of our operations. Our responsibility to our Conference participants, staff, environment and society is paramount in all of our decisions, policies and practices. We continue to learn and strive to integrate new practices all the time. Here are a few of the practices we have undertaken for this Conference:

Reducing print: The Final Program and Conference Abstracts are published in online electronic versions rather than printed books.

Recycling onsite: Please recycle paper, plastic and glass items.

Paperless Scientific Program - Smartphone and Online Application: The Scientific Program of the 16th Annual Conference of the International Society for Bipolar Disorders is available via the paperless application designed for cross platform access via laptop, mobile devices such as Smartphones, iPhone, Android etc. Participants will have full access to the scientific program and the posters including the abstracts. The application has smart search possibilities within the scientific program by session type, hall or the faculty. The paperless application gives the participant the power to choose and plan and, therefore, make the most out of the conference.

To view the ISBD 2014 Scientific Program on your personal device, please visit: http://isbd.meetingxpert.net

27

INFORMATION FOR PRESENTERS

Please check the Scientific Program in case of last minute scheduling changes.

ORAL PRESENTATIONS

All speakers presenting in sessions are requested to submit their presentations to the Speakers’ Ready Room at least 1 hour before the start of their session. The Speakers’ Ready Room is located on the 1st floor of the Conference Center.

SPEAKERS READY ROOM HOURS

Tuesday March 18, 2014 08:00 – 20:30Wednesday March 19, 2014 06:30 – 19:00Thursday March 20, 2014 06:30 – 18:30Friday March 21, 2014 06:30 – 15:00

DATA PRESENTATION

If using a PowerPoint (or any other computer) presentation, please note you need to bring it on a CD, a DVD or on a “disk on key” Memory stick (using the USB port in the computer) and load it on one of the Meeting’ computers in the Speakers’ Ready Room, at least 1 hour before the start of the session.

Please note that the Conference computers in the session halls are being supplied with Office 2010.

If combining video films with PowerPoint, please make sure to check it in the session hall where your lecture is taking place during a coffee or lunch break prior to your session, at least 30 minutes before the start of the session - even after checking it in the Speakers’ Ready Room.

Alternatively you may supply your own laptop computer. In such a case please confirm that it has a VGA socket for external signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

28

IMPORTANT NOTE FOR MACINTOSH USERS:

In order to use MAC presentations on a PC compatible computer please note that you need to prepare it according to the instructions below, before bringing it to the Speakers’ Ready Room:

1. Use a common font, such as Arial, Times New Roman, Verdana etc. (special fonts might be changed to a default font on a PowerPoint based PC).

2. Insert pictures as JPG files (and not TIF, PNG or PICT - these images will not be visible on a PowerPoint based PC).

3. Use a common movie format, such as AVI and WMV (MOV files from QuickTime will not be visible on a PowerPoint based PC). Alternatively you may use your own Macintosh laptop computer. In such a case please confirm you provide it with a VGA adaptor for external signal and come to check it first in the Speakers’ Ready Room as soon as you arrive and later on in the session hall where your lecture is taking place during the coffee or lunch break prior to your session, at least 30 minutes before the start of the session.

Please note that VHS Video projection, 35 mm’ slide projection and Overhead projection (projection of transparencies) will not be available.

Please note: in compliance with EACCME requirements all speakers are requested to include a slide disclosinig conflicts of interest at the beginning of their presentation

29

POSTER PRESENTATIONS

Please see the Scientific Program for the board number on which you should display your poster. Posters should be hung on the day of your presentation and must be removed by the end of sessions on the same day.

Posters will be on display on three days:

Regional Poster Session: Tuesday March 18, 2014 15:00 - 15:30

Poster Session I: Wednesday March 19, 2014 17:00 - 18:30

Poster Session II: Thursday March 20, 2014 17:00 - 18:30

REGIONAL POSTER SESSION

This poster session will be held on Tuesday March 18, 2014 in the Poster Area between 15:00-15:30. During this time presenters are requested to stand by their posters.

This session will showcase presentations from Asian scholars, and researchers from Asian Regions on topics related with bipolar disorder, and other areas of psychiatry, including schizophrenia, depression, and anxiety disorders.

Regional Posters may be mounted from 08:30 AM on Tuesday 18th March and should be displayed until the end of the day. Please check the Final Program for the poster board number allocated to you.

POSTER SESSION I & POSTER SESSION II

These poster sessions will be held on Wednesday, March 19 and Thursday, March 20 respectively in the Poster Area. These posters will be on display all day with the poster sessions occuring between 17:00-18:30 each evening.

Presenters are requested to stand by their posters during the Poster Session between 17:00-18:30. Presenters are able to set up their posters from 06:45 on the day of presentation. Posters should be removed after 18:30 at the conclusion of the Poster Session on the day of presentation.

30

POSTER OVERVIEW

Date of Presentation Session Poster TopicBoard

No.

Tuesday, March 18

Regional Posters Presentations from Asian scholars, and researchers from Asian Regions on topics related with bipolar disorder, and other areas of psychiatry, including schizophrenia, depression, and anxiety disorders.

1 - 65

Wednesday, March 19

Session I Biological Topics

Animal Models 1

Biomarkers 2 - 14

Child and Adolescent 15 - 17

Chronobiology 18 - 21

Clinical Case Studies 22 - 23

Comorbidities 24 - 26

Diagnosis 27

Early Intervention/Prodrome 28 - 29

Miscellaneous 30 - 37

Neurobiology 38 - 48

Neuroimaging 49 - 60

Other Interventions 61

Pharmacological Interventions 62 - 76

Womens’ Health 77

Thursday, March 20

Session II Non-Biological Topics

Child and Adolescent 1 - 5

Chronobiology 6

Clinical Case Studies 7 - 12

Clinical Trials Methodology 13

Cognition 14 - 33

Comorbidities 34 - 43

Diagnosis 44 - 51

Early Intervention/Prodrome 52 - 54

Elderly 55 - 56

Gender Issues 57 - 58

Miscellaneous 59 - 71

Neurobiology 72

Neuroimaging 73

New Technologies 74 - 75

Psychosocial Intervention 76 - 86

Social functioning 87 - 89

Womens’ Health 90

31

VENUE FLOOR PLANS

Re

gis

tra

tio

n A

re

a

05

06

04

09

07

En

tra

nc

e L

ev

el

EN

TR

AN

CE

Po

ste

r A

re

a

03

A

11

08

Ha

ll A

Ha

ll B

Ha

ll C

32

Fir

st

Le

ve

l

Me

eti

ng

Ro

om

1M

ee

tin

gR

oo

m 2

Ha

ll D

Ha

ll E IS

BD

Offi

ce

Ha

ll F

Me

eti

ng

Sp

ea

ke

rs

'R

ea

dy

Ro

om

Ro

om

3

SCIENTIFIC PROGRAMTuesday, March 18, 2014

SAVE THE DATE

35SCIENTIFIC PROGRAM TUESDAY, MARCH 18, 2014

SCIENTIFIC PROGRAM TUESDAY, MARCH 18, 2014

9:30 - 9:40 Hall B

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER: OPENING REMARKS

P. Udomratn, Chairman ANBD 1W. Nolan, Chairman ISBD 2

9:40 - 11:00 Hall B

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER: EAST ASIAN BIPOLAR FORUM: MANAGEMENT OF BIPOLAR DISORDER IN ASIA

Chairpersons: S. Kanba (Japan) 3 M. Wong (Hong Kong, China) 4

9:45 PATTERN OF PHARMACOTHERAPY BY EPISODE TYPE FOR PATIENTS WITH BIPOLAR DISORDERS AND ITS CONCORDANCE WITH TREATMENT GUIDELINES 5J.H. Baek (USA)

10:10 GUIDELINE CONCORDANCE OF PHARMACOLOGICAL TREATMENT OF BIPOLAR DISORDERS IN CHINA 6Y. Fang (China)

10:35 COGNITIVE IMPAIRMENT IN BIPOLAR DISORDER 7Y.W.E. Cheung (Hong Kong, China)

36 SCIENTIFIC PROGRAM TUESDAY, MARCH 18, 2014

11:00 - 12:30 Hall B

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER: SOUTHEAST ASIA AND SOUTH ASIA BIPOLAR FORUM: BIPOLAR DISORDER IN SOUTHEAST AND SOUTH ASIA, CLINICAL CHARACTERISTICS AND BIOLOGICAL TREATMENT

Chairpersons: P. Udomratn (Thailand) 8 M.S. Reddy (India) 9

11:00 NEUROCOGNITIVE FUNCTIONING, CLINICAL PROFILES, AND PSYCHOPATHOLOGY IN BIPOLAR DISORDER AND SCHIZOPHRENIA: CLARIFYING CONCEPTS OF DICHOTOMY VERSUS CONTINUUM 10K. Sim (Singapore)

11:20 IRRITABILITY AS A CRITERION: DANGEROUS POTHOLE IN THE DIAGNOSIS OF BIPOLAR DISORDER 11M.S. Reddy (India)

11:40 PRESCRIPTION PATTERN OF DRUG TREATMENT IN BIPOLAR DISORDER IN SINGAPORE 12Y.M. Mok (Singapore)

12:00 ELECTROCONVULSIVE TREATMENT IN BIPOLAR DISODER: EXPERIENCE FROM MALAYSIA 13O.H. Koh (Malaysia)

12:30 - 13:30

LUNCH BREAK


13:30 - 15:00 Hall B

THE 6TH CONFERENCE OF THE ASIAN NETWORK OF BIPOLAR DISORDER: EXPERIENCE FROM LATIN AMERICA: ISBD GLOBAL NETWORK - STORIES OF SUCCESS IN EDUCATION, RESEARCH AND COMMUNITY INVOLVEMENT

Chairperson: M. Sanchez de Carmona (Mexico) 14

13:30 COMMUNITY INVOLVEMENT WITH THE MEXICAN BIPOLAR POPULATION, EDUCATION IN DIFFERENT LEVELS 15M. Sanchez de Carmona (Mexico)

13:50 BIPOLAR CLINICAL GUIDELINES IN PRIMARY CARE SETTING 16D. Quiroz (Chile)

12:10 ISBD AS A FRAME TO ENCOURAGE PUBLICATION OF LOCAL RESEARCH IN BIPOLAR DISORDERS - AN INTERNATIONAL JOURNAL OF PSYCHIATRY AND NEUROSCIENCES 17S. Strejilevich (Argentina)

12:30 THE CONSTRUCTION OF A NETWORK OF RESEARCH IN BIPOLAR DISORDER IN BRAZIL 18F. Kapczinski (Brazil)


9:30 - 9:40 Hall C

THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIA: OPENING REMARKS

J. S. Lee (President KACAP) 19Y.H. Joo (Chairman ISBD, Korea) 20

9:40 - 11:30 Hall C

THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIUM: CONCURRENT MEDICAL CONDITIONS WITH PEDIATRIC BIPOLAR DISORDER

Chairpersons: T.W. Park (Korea) 21 K. Chang (USA) 22

9:40 PEDIATRIC CASES OF MOOD DISORDER DUE TO GENERAL MEDICAL CONDITION 23H.W. Kim (Korea)

10:15 INITIAL EVALUATION FOR THE FIRST-EPISODE MANIA 24Y.S. Joung (Korea)

10:50 PEDIATRIC AUTOIMMUNE NEUROPSYCHIATRIC DISORDER 25K. Chang (USA)

11:30 - 12:30

LUNCH BREAK


12:30 - 15:00 Hall C

THE KOREAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY SYMPOSIUM: PEDIATRIC BIPOLAR DISORDER: UPDATE

Chairpersons: S.C. Cho (Korea) 26 E. Youngstrom (USA) 27

12:30 PEDIATRIC BIPOLAR DISORDER AND DISRUPTIVE MOOD DISORDER IN DSM-5 28B.N. Kim (Korea)

13:05 LONG-TERM F/U RESULTS OF THE BIPOLAR OFFSPRING 29B. Birmaher (USA)

13:40 NEUROIMAGING FINDINGS OF BIPOLAR OFFSPRING 30M. Singh (USA)

14:15 BIOMARKERS OF PEDIATRIC BIPOLAR DISORDER 31B. Goldstein (Canada)


9:00 - 16:00 Hall D

PRE-CONFERENCE COURSE: STATE-OF-THE-ART IN DIAGNOSING, ASSESSING AND TREATING BIPOLAR DISORDER: A TRAINING COURSE TO IMPROVE YOU SKILLS AS A BIPOLAR EXPERT

Bipolar disorder is a heterogeneous clinical condition, confronting clinicians with diagnostic dilemmaís and complex treatment decisions. This course provides an overview for clinicians who are relatively new in the field of bipolar disorder, addressing diagnosis in adults and children using the new DSM-5 classification and going beyond that in real world clinical practice, how to assess and how to treat (psychologically and pharmacologically) patients with bipolar disorder. The course will include 6 sessions of 45 or 60 minutes each, consisting of short presentations by experts on the topics, each followed by or alternated with extensive discussions and including exercises using clinical case vignettes, to ensure much interaction with the course participants. Basic elements as well as some controversial issues and common pitfalls are presented and interactively illustrated with clinical examples. Participants are encouraged to present questions and dilemmas from their own clinical experience.

9:00 DIAGNOSIS, ASSESSMENT OF BIPOLAR DISORDER IN ADULTS 32R. Kupka (The Netherlands)

9:45 DIAGNOSIS AND ASSESSMENT OF BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS 33E. Youngstrom (USA)

10:30 BREAK

11:00 PSYCHOEDUCATION 34F. Colom (Spain)

11:45 PSYCHOTHERAPY 35F. Colom (Spain)

12:30 LUNCH BREAK

13:30 ACUTE PHARMACOTHERAPY FOR BIPOLAR DEPRESSION 36W. Nolen (The Netherlands)J. Calabrese (USA) 37

14:30 MAINTENANCE PHARMACOTHERAPY 38W. Nolen (The Netherlands)J. Calabrese (USA) 39

15:30 INTEGRATION AND GENERAL DISCUSSION 40R. Kupka (The Netherlands)


13:00 - 16:30 Hall E

PRE-CONFERENCE COURSE: PROPER USE OF MOOD STABILIZERS IN LONG TERM TREATMENT OF BIPOLAR DISORDERS

Pharmacological treatment with mood stabilizers is essential for the long-term (relapse-preventive) treatment of bipolar disorder. More than 60 years since the breakthrough of identifying lithium salts as having antimanic and prophylactic activity, modern research serves to further substantiate lithiumís position at the front-line in the treatment of bipolar disorder. The drug continues to prove itself as an effective mood stabilizer, which also possesses unique anti-suicidal and antidepressant properties. Despite the successes achieved through application of lithium treatment, the drug remains an ineffective option for a proportion of bipolar patients. Not all patients are so-called ëlithium respondersí and it has become a task of great importance to be able to establish whether or not a given patient will benefit from its treatment. It is also important to establish whether even non-responders to mood stabilizing effects of lithium may still benefit from some of the other actions of this element (e.g., from its ìanti-suicideî effects). Anticonvulsants and some of the atypical antipsychotic medications are alternatives as are other additional medications in the long-term treatment of bipolar disorder. The major questions are who is getting which medication, at which point, and what algorithm can be offered in case a patients fails to first/second and further options, monotherapy vs, combination therapy.

Presentors: M. Gitlin (USA) 41 M. Bauer (Germany) 42


13:00 - 16:30 Hall F

PRE-CONFERENCE COURSE: TREATMENT OF BIPOLAR DISORDER DURING PREGNANCY AND THE POST-PARTUM: CLINICAL PEARLS AND GUIDELINES

Treatment of bipolar disorders in women who are pregnant, are planning on becoming pregnant, or who choose to nurse remains one of the most difficult of therapeutic challenges in our field. While it is clear that some primary mood stabilizers are associated with increased risk of congenital malformations, other adverse neonatal effects, and poorer compatibility with breast feeding, it is also clear that relapse risk is increased if treatment is stopped. In recognition of these challenges, recently developed guidelines have been developed with the dual aims of minimizing fetal/neonatal medication exposure and exposure to untreated disease. However, there is uncertainty regarding the reproductive and lactation safety for most commonly prescribed treatments for bipolar disorders, and their effectiveness for treating or preventing acute mood episodes during the antepartum and post-partum period. Specific content areas will include the following: (a) Review of effectiveness data for pharmacological and non-pharmacological treatments of bipolar disorder in pregnancy; (b) update on reproductive and lactation safety data for the major bipolar pharmacotherapies; (c) review of recommendations from published guidelines addressing the treatment of bipolar disorder during pregnancy and post-partum period; and (d) overview of management strategies for women with bipolar disorder who desire to nurse their infant.

Presentor: A. Ozerdem (Turkey) 43

13:00 PRE-PREGNANCY PLANNING FOR WOMEN WITH BIPOLAR DISORDERS 44B. Frey (Canada)

13:30 TREATMENT OPTIONS FOR BIPOLAR DISORDERS IN PREGNANT WOMEN: CURRENT STATE OF EVIDENCE 45F. Akdeniz (Turkey)

14:00 THE COMPARATIVE FETAL AND OBSTETRIC SAFETY OF BIPOLAR PHARMACOTHERAPIES 46W. Bobo (USA)

14:30 PSYCHOSOCIAL NEEDS AND A PREVENTION PLAN FOR THE PREGNANT AND POSTPARTUM PERIOD OF BIPOLAR WOMEN 47A. Stevens (The Netherlands)B. Geerling (The Netherlands) 48

15:00 COFFEE BREAK

15:15 DISCUSSANT 49N. Rasgon (USA)


15:00 - 15:30

COFFEE BREAK AND POSTER VIEWING

15:30 - 17:00 Hall A

INDUSTRY SATELLITE SYMPOSIUM

not included in main event CME/CPD credit

17:00 - 18:00 Hall A

OPENING AND AWARDS CEREMONY

17:00 WELCOME BY PRESIDENT, ISBD 50W. Nolen

WELCOME BY PRESIDENT, KOREAN NEUROPSYCHIATRIC ASSOCIATION 51Y.H. Kim

WELCOME BY CHAIRMAN, ISBD KOREA 52Y.H. Joo

INTRODUCTION TO CONFERENCE, CHAIR OF SCIENTIFIC COMMITTEE 53K. Ha

17:30 GERSHON AWARDS 54G. Malhi, Chairman Awards CommitteeM. Sanchez de Carmona, President-elect ISBD 55

17:40 WORLD BIPOLAR DAY: INTRODUCTION 56W. Nolen, President ISBDP. Udomratn, Chairman ANBD 57


18:00 - 19:30 Hall A

KEYNOTE LECTURE

Chairpersons: W. Nolen (The Netherlands) 58 Y.H. Kim (Korea) 59

18:00 THE ROLE OF BIOMARKERS IN CLINICAL PRACTICE: LESSONS FROM BIPOLAR DISORDER 60

L.T. Young (Canada)

18:45 THE NEUROIMAGING STUDIES IN SUBJECTS AT ULTRA-HIGH RISK FOR PSYCHOSIS 61

J.S. Kwon (Korea)

19:30 - 20:30 Exhibition area

WELCOME RECEPTION

SCIENTIFIC PROGRAMWednesday, March 19, 2014

46 SCIENTIFIC PROGRAM WEDNESDAY, MARCH 19, 2014

SCIENTIFIC PROGRAM WEDNESDAY, MARCH 19, 2014

7:00 - 8:30 Hall D

BRAINSTORMING SESSION: LITHIUM PHOBIA: SCIENCE OR SUPERSTITION?

In a curious paradox, the use of lithium for the treatment of bipolar disorder appears to be declining even as evidence of its efficacy increases, as does knowledge regarding its safety. Recent meta-analyses confirm the benefits of maintenance lithium treatment, along with reduced sucidality and, possibly, diminished risk of developing dementia. Sodium Valproate, on the other hand, continues to be the most widely used mood stabiliser despite scarse evidence for its effectiveness. Being an element, lithium cannot be patented and the consequent lack of pharmaceutical industry interest in its promotion is probably the single most important factor in its under-use. ìThe use of lithium appears to be in decline, possibly because of insufficient training of psychiatrists in the use of lithium therapy and the aggressive marketing of alternative medications that are patentable and therefore more profitable.” Empirical studies in USA Canada, Germany, Switzerland and Austria have demonstrated this unfortunate trend. In fact, either as a result of a deliberate disinformation campaign or simply due to ignorance, there appears to be an almost superstitious fear of lithium, with the risks of renal damage and hypothyroidism being magnified beyond belief. The proposed brainstorming session aims to review the present state of our knowledge in this area, identify the drivers of lithium phobia, and discuss remedial strategies.

Chairperson: D. Goel (New Zealand) 62

7:00 LITHIUM: IS IT EFFECTIVE? IS IT SAFE? 63

S. Kumar (New Zealand)

7:45 LITHIUM: THE WAY FORWARD 64

M. Isaac (Australia)

47SCIENTIFIC PROGRAM WEDNESDAY, MARCH 19, 2014

7:00 - 8:30 Hall F

BRAINSTORMING SESSION: CLINICAL AND THERAPEUTIC PECULIARITIES OF BIPOLAR DISORDER IN LATE LIFE

Although Bipolar Disoder (BD) among the elderly is only slightly less common than among younger age groups, it has received much less attention from clinicians and researchers. Geriatric BD has sometimes been considered as a manic-like presentation related to a physical condition, thereby raising the need to differentiate between late and early onset of the illness. A closer relation to BD albeit with some clinical and treatment differences has been reported recently even for late onset patients (1). Furthermore, the use of some pharmacological treatments in this population requires especial considerations. Unfortunately there are no current evidence-based recommendations for managing BD in late life and little is known about recommended medications or doses in older patients.Clinical features of BD in the elderly, including differences between types I and II and between patients with early- vs late-onset will be presented. A discussion related to the need of increasing its recognition and improving an adequate follow-up of these patients will follow. Finally we will discuss aspects related to specific treatment strategies for acute affective episodes and for maintenance treatment.

Chairperson: J.M. Montes (Spain) 65

7:00 CLINICAL FEATURES OF BIPOLAR DISORDER IN LATE LIFE 66

V. Balanzá-Martínez (Spain)

7:45 THERAPEUTIC STRATEGIES FOR GERIATRIC BIPOLAR DISORDER 67

J. Goikolea (Spain)


8:30 - 10:00 Hall A

SYMPOSIUM SESSION - TREATMENT: PRESCRIPTION PATTERN IN THE TREATMENT OF BIPOLAR AFFECTIVE DISORDER: WHAT THE REAL WORLD IS LIKE

Bipolar affective disorder is a mood disorder with different presentation at different phase of the illness. There is no universally agreed protocol in the treatment of this disorder. Instead there are different treatment guidelines and recommendations proposed by different organizations, e.g the CANMAT and WFSBP guidelines. Despite the presence of guidelines and recommendations, the pattern of drug use still different from place to place. Also the use of drugs may deviate from the guidelines in the real world. This symposium tries to look at the prescription pattern in different parts of the world so that we can have an idea of how drug treatment is like in the global perspective. Also we can have an idea of to what extend we are following the treatment guidelines. We will have three papers in this symposium. The first paper looks at the pattern of drug treatment in the outpatient clinics in Hong Kong. The second paper describes a multicentre study in the Netherland which investigates the treatment of ìcare as usualî patients with bipolar disorder in various outpatient treatment settings, and its concordance with current treatment guidelines in relationship to symptomatic and functional outcome. The third paper reports data from an ongoing, long-term naturalistic study in Europe and North-America and explored drug treatment patterns in bipolar disorder using six months of daily self-reported data on psychotropic drug intake from patients who received ìtreatment as usualî. These three studies show that the prescription pattern can be quite different. For example, the three studies each have either Valproate, Lithium or Lamotrigine as the most commonly prescribed mood stabilizers. Further collaboration is needed to understand the reasons behind the discrepancy.

Chairpersons: M.C.M. Wong (Hong Kong, China) 68 C.Y. Kim (Korea) 69

8:30 PRESCRIPTION PATTERN IN THE TREATMENT OF BIPOLAR AFFECTIVE DISORDER IN OUTPATIENTS IN HONG KONG 70

M. Wong, Y.W.E. Cheung (Hong Kong China)

9:00 TREATMENT OF BIPOLAR DISORDER IN THE NETHERLANDS AND CONCORDANCE WITH TREATMENT GUIDELINES: A LONGITUDINAL, NON-INTERVENTIONAL, NATION-WIDE STUDY 71

J.W. Renes, E.J. Regeer, W.A. Nolen, R.W. Kupka (The Netherlands)

9:30 DRUG TREATMENT PATTERNS IN BIPOLAR DISORDER: POLYPHARMACY IS COMMONPLACE 72

M. Bauer (Germany)


8:30 - 10:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: BIPOLAR DISORDER IN CHILDREN AND ADOLESCENTS COMPARED WITH ADULT BIPOLAR DISORDER

Over the past 15 there has been substantial growth in the evidence base regarding bipolar disorder among children and adolescents. Whereas controversies arguably exceeded data until recently, the accumulation of findings regarding the phenomenology, assessment, course, treatment, and neurobiology of child and adolescent bipolar disorder has coincided with increasing consensus among researchers in the field regarding important topics. For example, discrete manic/hypomanic episodes are the foundation of diagnosing bipolar disorder among children and adolescents, as they are among adults. Although manic episodes among most youth have elation/euphoria, the small subset of youth with episodic irritable-only mania/hypomania have comparable demographic, clinical, and familial characteristics compared to youth with elation /- irritability. Neurobiological research has identified numerous key findings that overlap with adult bipolar disorder, as well as some distinguishing findings (most notably, small amygdalae). Treatment-related findings are generally continuous with those observed among adults, with some exceptions, such as greater relative efficacy of second-generation antipsychotics, and greater relative sensitivity to their metabolic side effects. Despite recent progress, there remains a perception of sparse data that is belied by the voluminous literature. This symposium provides a critical review and selective synopsis of the extant literature as it relates to developmental similarities and differences in bipolar disorder across childhood, adolescence, and adulthood. Three presentations will review epidemiology and phenomenology, including screening instruments and assessment approaches (Dr. Youngstrom), longitudinal course and outcome (Dr. Birmaher), including recent findings extending into young adulthood, and biology and treatment (Dr. Goldstein).

Chairpersons: R. Post (USA) 73 Y.S. Kwak (Korea) 74

ADVANCES IN EPIDEMIOLOGY AND ASSESSMENT ENABLE FAST AND FRUGAL METHODS OF DETECTION WITHOUT OVER DIAGNOSIS 75

E. Youngstrom, B. Goldstein (USA)

WHAT HAPPENS OVER TIME WITH YOUTH THAT HAVE BEEN DIAGNOSED WITH BIPOLAR SPECTRUM DISORDERS? 76

B. Birmaher, B. Goldstein (USA)

UPDATE ON BIOLOGICAL AND TREATMENT FINDINGS AMONG CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER 77

B. Goldstein (Canada)


8:30 - 10:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: MOLECULAR MECHANISMS OF BIPOLAR DISORDER

There have been a number of hypotheses on the molecular biological basis of bipolar disorder. Among them, circadian rhythm dysregulation, ion transport dysfunction/intracellular signaling abnormalities, inflammation and oxidative stress/mitochondrial dysfunction are popular hypotheses. In this session, neurobiological studies of bipolar disorder using animal models, cellular models, or clinical samples, will be presented. (Comments: Whereas many of sessions in ISBD2014 will be focused on the clinical aspects, a symposium focusing on recent progress in biological research will be useful for clinicians to update the knowledge on the causes of bipolar disorder.)

Chairpersons: T. Kato (Japan) 78 E.J. Joo (Korea) 79

8:30 FROM ION PUMP DYSFUNCTIONS TO ABNORMALITIES IN SIGNAL TRANSDUCTION PATHWAYS IN BIPOLAR DISORDER: OAUBAIN RAT MODEL FOR MANIA 80

S.K. Kim, Y.S. Kim, Y.M. Ahn (Korea)

9:00 CIRCADIAN RHYTHM DISTURBANCES IN BIPOLAR DISORDER: APPROACHES USING ANIMAL MODELS 81

S. Honma, A. Natsubori, Y. Yamanaka, A. Toyomaki, T. Inoue, K. Honma (Japan)

9:30 OXIDATIVE STRESS AND INFLAMMATION IN BIPOLAR DISORDER: THE PUTATIVE ROLE OF ACTIVATED MICROGLIAL CELLS 82

F.K. Kapczinski (Brazil)


8:30 - 10:00 Hall D

SYMPOSIUM SESSION - IMAGING: APPLICATIONS OF NOVEL IMAGING TECHNIQUES TO GAIN NEW INSIGHTS INTO BIPOLAR DISORDER

Advances in imaging technology and related analytic strategies allow sophisticated testing of neurobiological models of disease pathology in psychiatric disorders. Research that highlights innovative approaches applying MR imaging techniques, that include highly resolved 2-D and 3-D structural magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), magnetization transfer and multi-nuclear magnetic resonance spectroscopy (MRS), to systematically investigate bipolar disorder will be presented. A particular focus of this symposium will be on the longitudinal characterization of metabolic, functional and structural changes associated with treatment, and how characterization of treatment effects provides a strategic approach for advancing models of pathophysiology underlying Bipolar Disorder. Dr. In Kyoon Lyoo will present work investigating bipolar disorder that applies cortical thickness measurements, subcortical shape analysis and voxel based morphometry to evaluate longitudinal effects of treatment. These studies document the differential effects of both illness and treatment on brain anatomy. Dr. Deborah Yurgelun-Todd will present work applying fMRI to characterize alterations in connectivity and cerebral activity that are associated with affective and cognitive changes in bipolar disorder across the lifespan. Central to this work is emerging evidence for a failure of appropriate regulation of limbic structures by the prefrontal cortex. Dr. Stephen Dager will present work using multi-nuclear MRS to assess brain metabolic status in relationship to mood state and the effects of treatment. A growing literature that supports the presence of brain metabolic alterations in bipolar disorder has important treatment implications. These studies have led to the identification and evaluation of novel treatments for bipolar disorder.

Chairperson: P. Renshaw (USA) 83

8:30 GREY MATTER DENSITY AND STRUCTURAL CHANGES DURING TREATMENT IN MEDICATION-FREE BIPOLAR DISORDER PATIENTS 84

I.K. Lyoo, S.R. Dager, C.S. Jun, J.E. Kim, Y.J. Jun, P.F. Renshaw (Korea)

9:00 FUNCTIONAL MAGNETIC RESONANCE IMAGING BIPOLAR DISORDER 85

D. Yurgelun-todd, M.L. Lopez-Larson, E. McGlade (USA)

9:30 IMAGING BRAIN METABOLISM: EVIDENCE FOR ALTERED BRAIN BIOENERGETICS IN BIPOLAR DISORDER 86

S.R. Dager, N.M. Corrigan, T. Richards, D. Dunner, I.K. Lyoo, P.F. Renshaw (USA)


8:30 - 10:00 Hall F

RAPID COMMUNICATION SESSION: ORAL COMMUNICATIONS

Chairpersons: R. Belmaker (Israel) 87 H.S. Cho (Korea) 88

INDICATIONS OF A DOSE-RESPONSE RELATIONSHIP BETWEEN CANNABIS USE AND AGE AT ONSET IN BIPOLAR DISORDER 89

T.V. Lagerberg, L. Kvitland, S.R. Aminoff, M. Aas, P.A. Ringen, O.A. Andreassen, I. Melle (Norway)

MYOCARDIAL INFARCTION SURVIVAL IN PATIENTS WITH BIPOLAR DISORDER OR SCHIZOPHRENIA SPECTRUM DISORDERS- A NATIONWIDE COHORT STUDY 90

R. Bodén, E. Molin, T. Jernberg, H. Kieler, B. Lindahl, J. Sundström (Sweden)

SIMILAR WHITE MATTER CHANGES IN SCHIZOPHRENIA AND BIPOLAR DISORDER: A TBSS STUDY 91

L. Squarcina, M. Bellani, C. Perlini, G. Rambaldelli, V. Marinelli, N. Dusi, R. Cerini, R. Pozzi-Mucelli, M. Tansella, A. Bertoldo, P. Brambilla (Italy)

10:00 - 10:30

COFFEE BREAK


10:30 - 12:00 Hall A

KEYNOTE LECTURE

Chairpersons: S. Frangou (USA) 92 Y.H. Joo (Korea) 93

10:30 NEUROBIOLOGICAL BASIS OF BIPOLAR DISORDER 94

T. Kato (Japan)

11:15 EARLY INTERVENTION IN BIPOLAR DISORDER IN A MOOD DISORDER CLINIC 95

L. Vedel Kessing (Denmark)

12:00 - 13:30 Hall A



12:00 - 13:30

LUNCH BREAK


13:30 - 15:00 Hall A

SYMPOSIUM SESSION - TREATMENT: WHAT DO WE KNOW ABOUT LITHIUM’S ROLE IN MAINTENANCE TREATMENT OF BIPOLAR DISORDER, 60 YEARS AFTER ITS DISCOVERY?

Since its introduction into modern psychiatry in 1949, many new aspects of lithium’s use in psychiatry and the neurosciences have been discovered in basic and clinical research. More than 60 years from the breakthrough of identifying lithium salts to have antimanic and prophylactic activity, modern research serves to further substantiate lithium’s position at the front-line in the treatment of bipolar disorder. The drug continues to prove itself as an effective mood stabilizer, which also possesses unique anti-suicidal and antidepressant properties. Unfortunately, lithium is not widely used in clinical practice in many countries today. In this symposium, the latest research into the effects of lithium on different levels of clinical investigation, from placebo-controlled trials to naturalistic investigations will be covered by three prominent speakers in the respective field. This includes also data from a new meta-analysis on the reassessment of the evidence for lithium in relapse prevention of bipolar disorder. W. Nolen will discuss three recent studies: one proving lithium’s long-term efficacy, but only at plasma levels =0.6 mmol/l, and two (an effectiveness study and a pharmaco-epidemiological study) indicating lithiumís superiority over valproate. R. Licht will cover lithiumís position in international guidelines and discuss methodological considerations that have major clinical implications. Specifically, he will not only review the evidence for long-term treatment of lithium, stressing the distinction between evidence obtained from enriched and non-enriched trials, referring to the WFSBP guidelines approach, but will also discuss the implications in terms of generalizability. T. G. Schulze will present the latest findings from the international Consortium on Lithium Genetics (www.ConLiGen.org), the worldís largest effort to study the genomics and genotype-phenotype relationships of lithium response in bipolar disorder. The current sample size comprises close to 3000 bipolar individuals from 4 continents, rigorously phenoytped for lithium response and genotyped on a genome-wide level.

Chairpersons: M. Bauer (Germany) 96 J. Yi (Korea) 97

13:30 LITHIUM: STILL A CORNERSTONE IN THE LONG-TERM TREATMENT OF BIPOLAR DISORDER 98

W. Nolen (The Netherlands)

14:00 LITHIUM IN LONG-TERM TREATMENT OF BIPOLAR DISORDER: METHODOLOGICAL CONSIDERATIONS WITH MAJOR CLINICAL IMPLICATIONS. 99

R. Licht (Denmark)

14:30 GENOMIC AND PHENOMIC CORRELATES OF LITHIUM RESPONSE IN BIPOLAR DISORDER: A CONSORTIUM ON LITHIUM GENETICS (CONLIGEN) REPORT 100

T. Schulze (Germany)


13:30 - 15:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: THE BIPOLAR “PRODROME”: CAN WE IDENTIFY AT-RISK INDIVIDUALS?

Despite therapeutic advances, bipolar disorder remains one of the most severe and debilitating psychiatric disorders. Therefore, early identification and interventions during the prodromal (subsyndromal) stages of bipolar disorder have attracted increasing attention. This session aims at summarizing the knowledge about precursors, risk factors, terminology, specific instruments, emerging risk criteria and experience from a dedicated bipolar high-risk program helping clinicians and researchers to begin incorporating the concept of the bipolar prodrome into their respective practice. Dr. Anna Van Meter will review the evidence for precursors and risk factors for bipolar disorder. She will summarize information about the role of temperament, cyclothymic disorder, disruptive mood dysregulation disorder, and behavioral disorders as comorbidities or prodromal/subsyndromal manifestations. Attention will paid to the overlap between criteria and specificity as well as predictive validity of disorders or symptom constellation alone or in the context of familial high risk.Dr. Christoph Correll will summarize existing and emerging terminology, models and operational criteria for individuals considered at-risk for bipolar disorder and present data from an interview study of 205 youth aged 12-23 years and/or their caregivers that investigated the psychometric characteristics of the Bipolar Prodrome Symptom Scale-Prospective (BPSS-P), the first dedicated bipolar at-risk interview/rating scale. Dr. Andrea Pfennig will present data from their dedicated bipolar at-risk clinic, including a description of assessment instruments and data from the first 180 help-seeking persons who were assessed with a standardized diagnostic procedure. She will also present the frequency of at-risk status, using as risk factors for bipolar disorders familial risk, increasing mood swings, subsyndromal (hypo)manic symptoms, specific sleep and circadian rhythm disturbances, anxiety/fearfulness, affective disorder, decreased psychosocial functioning, increasing periodic substance use, and attention-deficit/hyperactivity disorder. Finally, treatment recommendations for at-risk subjects will be summarized.Data suggest that in a relevant subgroup, there is a clinically identifiable ìprodromalî symptom stage. While more phenomenological, pathophysiological and biomarker data are needed, early identification and interventions, following a staging paradigm, seem possible. To advance the field, common terminology, assessment instruments, outcomes and criteria need to be established and implemented. The ISBD Bipolar Prodromes Task Force is currently working toward these goals.

Chairpersons: B. Birmaher (USA) 101 Y.C. Chung (Korea) 102

13:30 PRECURSORS AND RISK FACTORS FOR BIPOLAR DISORDER: THE ROLE OF TEMPERAMENT, CYCLOTHYMIC DISORDER, DISRUPTIVE MOOD DYSREGULATION DISORDER, AND BEHAVIORAL DISORDERS 103

A. Van Meter, E. Youngstrom (USA)

14:00 CHARACTERIZING AND OPERATIONALIZING RISK FOR BIPOLAR DISORDER: TERMINOLOGY, TOOLS AND CRITERIA FOR THE MANIA-AT-RISK SYNDROME 104

B. Birmaher (USA)


14:30 IDENTIFICATION, CHARACTERISTICS AND NATURALISTIC TREATMENT OF INDIVIDUALS AT-RISK FOR BIPOLAR DISORDER: RESULTS FROM THE FIRST 3 YEARS OF THE DRESDEN HIGH-RISK PROGRAM 105

A. Pfennig, K. Leopold (Germany)


13:30 - 15:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: THE INVOLVEMENT OF MITOCHONDRIA IN BIPOLAR DISORDER AND ITS TREATMENT

Convergent data implicate mitochondrial dysfunction as an important component of the pathophysiology of bipolar disorder, possibly amended by mood stabilizers. Takaoki Kasahara’s group generated transgenic mice in which mutant POLG (mtDNA polymerase) was expressed in a neuron-specific manner. Dr Kasahara will elaborate on the phenotype of these mice, exhibiting forebrain-specific defects of mtDNA, altered monoaminergic functions in the brain, a distorted day-night rhythm and a robust periodic activity pattern associated with estrous cycle, behaviors resembling mood disorder worsened by tricyclic antidepressant treatment and improved by lithium. Dr Kasahara will suggest that accumulation of mtDNA defects in brain cause mood disorder-like mental symptoms responding to treatments of bipolar disorder. Galila Agam’s group performed a DNA-microarray study searching for pathways commonly affected by chronic lithium-treatment and by the knockout of each of two genes (IMPA1, Slc5a3) encoding for proteins related to inositol-metabolism which exhibit a lithium-like behavioral phenotype. All bioinformatics analyses revealed up-regulation of mitochondrial-function. Differential-expression of three gene members of the mitochondrial electron-transfer-chain commonly differentially-expressed in the three paradigms was verified by real-time PCR analysis. A further proteomics study indicated that the mitochondrial function-related process, autophagy, is enhanced. The result of the bioinformatics analysis was consistent with an observed interrelationship between treatment with lithium and rotenone, an inhibitor of mitochondrial-function, in the forced-swim test and the amphetamine-induced-hyperlocomotion paradigm. The results support the notion that the amelioration of aberrant mitochondrial function by lithium is mediated via the drug’s effect on inositol metabolism. Michael Berk will discuss the implication of the neuroprogressive nature of bipolar disorder’s clinical process as reflected by both progressive neuroanatomical changes and evidence of cognitive decline. The biochemical foundation of this process appears to incorporate changes in inflammatory cytokines, cortisone, neurotrophins and oxidative stress, some of which relate to mitochondrial function. He will provide evidence to suggest that these markers may differ between the early and late stages of the disorder and that most of the currently used mood stabilisers share effects on oxidative stress and neurotrophins. Dr Berk will suggest that the development of novel potentially neuroprotective agents currently under process need to be combined with service initiatives to maximise the opportunities for early diagnosis and intervention.

Chairperson: G. Agam (Israel) 106

13:30 MICE WITH NEURON-SPECIFIC ACCUMULATION OF MTDNA DELETIONS, THE DSM-5-VALIDATED ANIMAL MODEL FOR MOOD DISORDER 107

T. Kasahara, T. Kato (Japan)


14:00 A MICROARRAY AND PROTEOMICS STUDY OF LITHIUM-TREATED MICE AND KNOCKOUT MICE WITH LITHIUM-LIKE BEHAVIOR REVEALS A COMMON EFFECT ON MITOCHONDRIAL FUNCTION AND AUTOPHAGY 108

G. Agam, L. Toker, Y. Bersudsky, R.H. Belmaker, D. Moechars, G. Berry (Israel)

14:30 THE MITOCHONDRION AS A THERAPEUTIC TARGET IN BIPOLAR DISORDER. 109

G. Agam, M. Berk (Australia)


13:30 - 15:00 Hall D

SYMPOSIUM SESSION - IMAGING: THE POTENTIAL CLINICAL AND THERAPEUTIC RELEVANCE OF IMAGING AND COGNITIVE STUDIES IN BIPOLAR DISORDER

Bipolar disorder is a highly heritable disorder, the underlying neurobiology, cognition and aetiopathogenesis of which remains unclear. There is increasing neuroimaging and neuropsychological evidence that it is associated with subtle abnormal neural networks underlying cognitive function and mood regulation. In particular, there is evidence that disturbed structural integrity characterises both adult and pediatric bipolar disorder and potentially genetic liability for this illness. Also, it has become apparent that in addition to the discernible cognitive compromise patients with bipolar disorder experience when depressed or manic, their neurocognition is also impaired when euthymic, also present in subjects at risk to develop the disorder. Furthermore, recent bioinformatic techniques allow to automatically differentiate patients with bipolar based on imaging and cognitive data, which have potential translational clinical impact. Recognized scientists from USA and Italy will debate such issues.

Chairpersons: P. Brambilla (Italy) 110 J.J. Kim (Korea) 111

13:30 THE PREDICTIVE VALUE OF STRUCTURAL MAGNETIC RESONANCE SCANS IN BIPOLAR DISORDER USING PATTERN CLASSIFICATION APPROACHES 112

S. Frangou (USA)

14:00 A PROSPECTIVE COHORT STUDY OF COGNITION AND BRAIN MORPHOLOGY IN PATIENTS WITH FIRST EPISODE MANIA 113

L. Yatham (Canada)

14:30 CHANGES IN BRAIN MORPHOLOGY AND COGNITIVE OUTCOME IN JUVENILE PATIENTS WITH BIPOLAR DISORDER (FOR SYMPOSIUM SUBMISSION BY P. BRAMBILLA ET AL) 114

J.C. Soares (USA)


13:30 - 15:00 Hall F


Chairpersons: T. Kato (Japan) 115 K.S. Hong (Korea) 116

GENOME-WIDE ASSOCIATION STUDY OF LITHIUM RESPONSE IN A SWEDISH POPULATION 117

S. Bergen, J. Song, P. Lichtenstein, M. Landen (Sweden)

SINGLE INFUSION OF KETAMINE IN BIPOLAR DEPRESSION: EFFICACY AND RELATED FACTORS 118

J. Rybakowski, M. Skibinska, A. Bartkowska-Sniatkowska, A. Permoda-Osip (Poland)

THE OFFSPRING OF EXCELLENT LITHIUM RESPONDERS: NEUROBIOLOGICAL AND TEMPERAMENTAL FINDINGS 119

J. Rybakowski, E. Ferensztajn, M. Kaczmarek, J. Losy, M. Skibinska (Poland)

THE EFFICACY AND SAFETY OF QUETIAPINE EXTENDED RELEASE (XR) AS MONO-THERAPY IN THE TREATMENT OF CHINESE PATIENTS WITH BIPOLAR OR DEPRESSION 120

H.F. Li, N.F. Gu, H.Y. Zhang, G. Wang, Q.R. Tan, P.D. Yang, Y.P. Ning, H.G. Zhang, Z. Lu, X.F. Xu, J.G. Shi, C.G. Gao, L.J. Li, K.R. Zhang, H.J. Tian, X.P. Wang, K.Q. Li, H.C. Li, Y. Xu, X. Yu (China)

15:00 - 15:30

COFFEE BREAK


15:30 - 17:00 Hall A

SYMPOSIUM SESSION - TREATMENT: CLINICAL GUIDELINES FOR BIPOLAR DISORDER

Bipolar Disorders are common disorders, associated with significant personal and social burden. They have a chronic and relapsing course, and may present challenges in their management. There have been many attempts to streamline the approach and management of people with Bipolar Disorders, in order to improve outcomes. Several National and International organizations have published clinical guidelines ranging from consensus of expert opinions to evidence-based ones. CANMAT is a non-profit educational and research academic organization with a long history in the development of evidence-based guidelines. Following a major new edition of the CANMAT Guidelines in 2005, there have been frequent updates every few years with the more recent versions published in collaboration with the International Society for Bipolar Disorders (ISBD). The latest update was published in Bipolar Disorders in 2013. The objective of this symposium is to review the pros and cons of guidelines, examine the ways to make them more clinician friendly in order to increase the uptake of evidence based management, and review latest guidelines on management of patients with and without co-morbidities.

Chairpersons: L. Yatham (Canada) 121 J.S. Yoon (Korea) 122

15:30 FROM EVIDENCE TO TREATMENT GUIDELINES FOR BIPOLAR DISORDER: A BRIDGE TOO FAR? 123

R. Milev, K.N. Founoulakis (Greece)

16:00 CANMAT/ISBD GUIDELINES FOR BIPOLAR DISORDER: A CONSTANT EVOLUTION - 2013 UPDATE 124

R. Milev (Canada)

16:30 MANAGEMENT OF COMORBIDITIES IN BIPOLAR DISORDER PATIENTS - A CANMAT TASK FORCE 125

R. Milev, A. Schaffer (Canada)


15:30 - 17:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: UNIQUE FEATURES OF BIPOLAR DISORDER IN OLDER ADULTS

This symposium reflects the ongoing work of the ISBD Taskforce on bipolar disorders in older adults. The taskforce highlights those aspects of bipolar disorder that are unique to later life including late age of onset, medical and neurological comorbidities, cognition, and risk of dementia. The study of older adults presents the opportunity to identify subtypes and to learn more about the long term clinical course and neurobiological pathways central to bipolar disorder in mixed age patients. In this symposium, we will present data on ethnic and racial differences in medical comorbidities which are so prevalent in late-life mania, the relative risk of dementia and the double-edged sword of lithium therapy in older adults where toxicity and neuroprotection are both important considerations.

Chairpersons: K. Shulman (Canada) 126 H.Y. Jung (Korea) 127

15:30 BIPOLAR DISORDER IN OLD AGE AND THE RISK OF DEMENTIA 128

L. Vedel Kessing (Denmark)

16:00 SIMILARITIES AND DIFFERENCES IN MEDICAL MORBIDITY BETWEEN EASTERN AND WESTERN OLDER BIPOLAR PATIENTS 129

S. Tsai, K.H. Chung, S.H. Huang, P.H. Chen (Taiwan)

16:30 RISKS AND BENEFITS OF LITHIUM CARBONATE IN OLD AGE 130

K. Shulman (Canada)


15:30 - 17:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: DIET, EXERCISE, AND WEIGHT: MODIFIABLE DRIVERS OF DISEASE SEVERITY AND PROGRESSION IN PEOPLE WITH MOOD DISORDERS?

The last half-century has seen profound changes in dietary composition, physical activity, and rates of obesity in the Western world. Over that time, there has been a marked increase in the consumption of sugar-, fat-, and energy-dense foods, and a reduced intake of high-nutrient foods such as vegetables and fruits. Modern conveniences, the “built environment”, and new forms of recreation mean that people are far less physically active than previously. Currently, similar changes are happening in developing countries with growing middle classes, making this a truly global problem. As a result, worldwide obesity rates are skyrocketing. The World Health Organization has estimated that by 2015, 1.6 billion adults will be overweight, and an additional 700 million will be obese, and that, for the first time in human history, mortality attributable to obesity will outweigh that from malnutrition. As prevalent as these problems are in the general population, they disproportionately affect people with mood disorders, and their rise has coincided with a marked increase in the prevalence of mood illnesses. People with bipolar disorder (BD) are two-thirds again more likely to be obese than people without the illness. This symposium will provide an in-depth review of a number of relevant topics including 1) patterns of food intake, exercise, and obesity in people with mood disorders; 2) evidence that diet, physical activity, and weight are intimately related to important clinical outcomes, including the amount of time spent with mood symptoms, response rates to pharmacotherapy, inter-episode cognitive abilities, and overall psychosocial functioning; and 3) ground-breaking evidence that their impact on these outcomes is mediated by diet-, exercise- and obesity-related changes in neurobiological illness severity and progression. Particular attention will be paid to 1) the partly overlapping and partly distinct effects of nutrition, physical activity, and weight on key biological pathways implicated in mood illnesses, including inflammatory processes, synaptic plasticity, oxidative stress, and the impact of adipokines on brain structure and function; and 2) evidence that intervening to improve diet, increase physical activity, and reverse weight gain positively impacts on clinical and neurobiological outcomes in people with major depressive disorder and bipolar disorder.

Chairpersons: D. Bond (Canada) 131 Y.C. Park (Korea) 132

15:30 DIET AND NUTRITION: NEW OPPORTUNITIES FOR THE PREVENTION AND TREATMENT OF MOOD AND ANXIETY DISORDERS ACROSS THE LIFECOURSE 133

F. Jacka (Australia)

16:00 EXERCISE TREATMENT FOR MOOD DISORDERS: A NEUROBIOLOGICAL RATIONALE 134

M. Alsuwaidan (Kuwait)

16:30 THE IMPACT OF OBESITY ON CLINICAL AND NEUROBIOLOGICAL DISEASE PROGRESSION IN BIPOLAR DISORDER 135

D.J. Bond (Canada)


15:30 - 17:00 Hall D

SYMPOSIUM SESSION - IMAGING: CROSSING BORDERS IN COGNITIVE ASSESSMENT OF BIPOLAR DISORDERS

Assessing cognitive functioning in bipolar disorders has become one of the crucial steps for establishing prognosis and maximizing functional outcome and treatment response, particularly, but not only, in cases of late onset that can resemble other neurological disorders, such as dementias and Alzheimer’s Disease. Proper comorbidity among the aforementioned conditions, moreover, is not so infrequent to encounter in clinical practice. The present session is, therefore, specifically aimed to examine in detail prevalence, crossing borders, overlaps and peculiarities, as well as comorbidity patterns of bipolar disorder, dementias and Alzheimer’s Disease, after having provided a preliminary overview of main cognitive and neuroimaging findings related to bipolar disorders. Specific attention to genetic markers, functional neuroimaging data and implications for treatment will be paid by distinguished speakers with well-established expertise in these specific fields.

Chairpersons: C. Altamura (Italy) 136 T. Ketter (USA) 137

15:30 NEUROIMAGING AND COGNITIVE IMPAIRMENT IN BIPOLAR DISORDERS 138

P. Brambilla (Italy)

16:00 DIFFERENTIAL DIAGNOSIS AND COMORBIDITY BETWEEN FRONTOTEMPORAL DEMENTIA AND BIPOLAR DISORDER 139

S. Elio (Italy)

16:30 HOW CAN PHARMACOLOGICAL TREATMENT IMPROVE COGNITION IN MAJOR PSYCHOSES 140

T. Sumiyoshi (Japan)

17:00 - 18:30 Poster Area

POSTER SESSION I

18:00 - 19:00 Hall F

ISBD GENERAL MEMBERSHIP MEETING

For members only

SCIENTIFIC PROGRAMThursday, March 20, 2014

66 SCIENTIFIC PROGRAM THURSDAY, MARCH 20, 2014

SCIENTIFIC PROGRAM THURSDAY, MARCH 20, 2014

7:00 - 8:30 Hall C

BRAINSTORMING SESSION: NEW PSYCHOSOCIAL TREATMENTS FOR BIPOLAR DISORDER

Pharmacotherapy is the first line of treatment for patients with bipolar disorder. However, these treatments fail to bring most patients to sustained remission. Thus, despite advances in the pharmacologic treatment of bipolar disorder, it is clear that additional strategies are needed to provide patients with longer-term mood stability. The past two decades have witnessed the development of a number of psychosocial strategies for BP applied adjunctive to ongoing pharma¨cotherapy. This includes Interpersonal and Social Rhythm Therapy (IPSRT), Family-Focused Therapy (FFT) and cognitive behavioral approaches (CBT). Overall, these psychotherapies have documented efficacy for improving medication adherence, speeding up recovery from depressive episodes, reducing residual mood symptoms and improving psychosocial functioning. However, recent studies suggest these treatments are not consistently successful at preventing mood episode relapses, especially for patients with severe symptoms or a high number of previous episodes (Scott et al., 2006; Scott, Colom, & Vieta, 2007; Meyer & Hautzinger, 2012). Thus, there exists a need for adjunctive psychosocial interventions adapted for individuals who are less likely to benefit from existing interventions. This symposium focuses on the second wave of psychosocial treatments that have been designed for special subgroups of patients with bipolar disorder to better address their specific needs. We will present three new treatment approaches: (1) Cognitive remediation for bipolar disorder, (2) mindfulness-based cognitive therapy for bipolar disorder, and (3) an internet-based self-help program (MoodSwings.net.au). Amy Peters and Thilo Deckersbach, PhD will present a cognitive rehabilitation approach to for patients with bipolar disorder with cognitive and work functioning difficulties. They will also present a new mindfulness-based cognitive therapy developed for bipolar disorder with preliminary efficacy for patients with particularly severe bipolar disorder. The incorporation of psychosocial interventions into routine management plans is often confounded by cost and access constraints among individuals with bipolar disorder. Michael Berk, MD, PhD, will present an internet-adaptation of a validated, face-to-face group based psychosocial intervention for bipolar disorder. For each of these treatments we will present an overview of the treatment, critical treatment elements and how they are implemented for patients with bipolar disorder. In addition, preliminary feasibility and efficacy data for these new approaches will be presented as a basis for the discussion.

Chairperson: T. Deckersbach (USA) 141

67SCIENTIFIC PROGRAM THURSDAY, MARCH 20, 2014

7:00 COGNITIVE REMEDIATION AND MINDFULNESS-BASED COGNITIVE THERAPY FOR BIPOLAR DISORDER 142

A. Peters, L.G. Sylvia, A.A. Nierenberg, N. Hansen, J.P. Stange, A.D. Peckham, T. Deckersbach (USA)

7:45 A RANDOMIZED CONTROLLED TRIAL OF THE EFFICACY OF MOODSWINGS.NET.AU: AN INTERNET BASED SELF-HELP PROGRAM FOR BIPOLAR DISORDER 143

S. Lauder, A. Chester, D. Castle, S. Dodd, E. Gilddon, L. Berk, J. Chamberlain, B. Klein, M. Gilbert, D. Austin, M. Berk (Australia)

7:00 - 8:30 Hall D

BRAINSTORMING SESSION: HOW TO MANAGE BIPOLAR DISORDER IN PREGNANCY AND POSTPARTUM DISORDER

Treatment of women with bipolar disorder during pregnancy and in the postpartum period is a major challenge. Decisions must be made about whether or not to take psychiatric medication while pregnant and/or breastfeeding. It is important to weigh the risks for the mother and the (unborn) child with or without medication. Especially the postpartum period is associated with an increased risk for the onset or exacerbation of bipolar disorder and maternal death.Pregnant women and their partners have to face uncertainties about the course of the bipolar disorder during pregnancy and the postpartum period and uncertainties of the effect of the bipolar disorder en when used, medication, on their baby.When is medication necessary and if necessary, what medication should we give?

Chairperson: B. Geerling (The Netherlands) 144

7:00 WEIGHING THE RISKS 145

A. Stevens, B. Geerling, W. Bobo (The Netherlands)

7:45 MEDICATION DURING PREGNANCY AND BREASTFEEDING 146

W. Bobo, A. Stevens, B. Geerling (USA)


7:00 - 8:30 Hall F

BRAINSTORMING SESSION: STAGING AND PROFILING BIPOLAR DISORDER: CONCEPTUAL AND CLINICAL APPROACHES

Staging of psychiatric disorders is an evolving area that will add dimensional aspects to the current classification, leading to a better understanding of pathophysiology and treatment response. Several approached have been suggested for staging bipolar disorders, focussing more on illness progression or on interepisodic functioning. Bipolar disorder seems to progress in portion with the number of episodes in some bipolar patients. Thus, preventing episodes may be a means to avoid progression from early stage BD into more refractory and severe late-stage BD. Recent evidence suggests that apart from number of episodes, the level of funtioning during euthymia may have important clinical use. Next to defining the stage of illness progression, an individual profile of protective versus harmful factors may have prognostic value and help to choose effective interventions and avoid treatment reistance. The aim of this “brain storm” is to help investigators to establish a common language in terms of staging in order to plan future prospective studies.

Chairperson: R. Kupka (The Netherlands) 147

7:00 STAGING AND PROFILING: COMPLEMENTARY APPROACHES TO IMPROVE TREATMENT 148

F. Kapczinski (Brazil)

7:45 CLINICAL PROFILING AND STAGING 149

R. Kupka (The Netherlands)


8:30 - 10:00 Hall A

SYMPOSIUM SESSION - TREATMENT: THE CHALLENGE OF DESIGNING CLINICAL TRIALS: AN ISBD TASK FORCE REPORT

Bipolar disorder presents special challenges for researchers who conduct clinical trials. Because of the complexity of the disorder with multiple domains of symptoms (e.g. depression, mania, anxiety, psychosis) along with a chronic cycling course and polypharmacy, studies of interventions that inform clinical care have inherent strengths and limitations. Researchers must decide on who is most appropriate for the study using inclusion and exclusion criteria while trying to maximize generalizability, the duration of the study, and whether or not to include active comparators or placebo. Depending on the goals of the study, researchers must choose an efficacy or effectiveness study. This symposium will discuss the benefits and risks of different research designs of clinical trials.

Chairpersons: A. Nierenberg (USA) 150 C.H. Kim (Korea) 151

8:30 LONG-TERM TREATMENT OF MOOD DISORDERS: FOLLOW-UP OF ACUTE TREATMENT PHASE STUDIES VERSUS CONTINUATION AND MAINTENANCE PHASE STUDIES, AND ENRICHED VERSUS NON-ENRICHED DESIGNS 152

W. Nolen, H. Grunze (The Netherlands)

9:00 QUALITATIVE ANALYSES OF PATIENT EXPERIENCES IN CLINICAL TRIALS: A NAIL BITING ADVENTURE 153

M. Berk (Australia)

9:30 COMPARATIVE EFFECTIVENESS DESIGNS FOR BIPOLAR DISORDER: SIGNAL OR NOISE? 154

A. Nierenberg (USA)


8:30 - 10:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: NEUROENDOCRINE CHALLENGES AND GENDER DIFFERENCES IN BIPOLAR DISORDER: AN ISBD TASK FORCE REPORT

Metabolic syndrome is a cluster of interrelated metabolic dysfunctions which pose risk for the development of diabetes and cardiovascular disease. The prevalence of metabolic syndrome is 30°igher in bipolar patients compared to general population. Among several risk factors of metabolic syndrome, hyperlipidemia is a pronounced feature in mood disorders. Although some psychotropic drugs are known to cause an increase in serum lipid concentrations, a possible and primary link between dyslipidemia, insulin resistance and the mood disorder itself still remains to be elucidated. Among the wide range of biological and lifestyle related risk factors for the development of metabolic syndrome in mood disorders, specifically bipolar disorders, those that are related to HPA/HPG axis function are of critical importance. Disturbances of thyroid metabolism are known to cause mood and cognitive symptoms even in patients without underlying psychiatric disorders. Some thyroid disorders are present more frequently in females including those with unipolar depression and with rapid cycling bipolar disorder, and females with bipolar disorder respond better to thyroid hormone therapy than do males. In patients with mood disorders, the added burden of abnormal thyroid function as well as metabolic dysfunctions including those related to dyslipidemia and altered insulin resistance may have significant consequences that impact the course of illness, treatment selection and response, and the clinical monitoring requirements. In this symposia, data on lipid profiles and metabolic syndrome parameters of both treated and untreated depressed as well as euthymic bipolar patients will be presented. Inter-relation between these parameters and clinical features, specifically from treatment and gender difference point of view will be discussed. In addition to this, gender differences in thyroid system function in adults that are particularly relevant to the diagnosis and treatment of bipolar disorder will be reviewed. Taken together, the pathogenesis of bipolar disorder from the HPA/HPG/HPT axis window will be brought to the attention of the audience.

Chairpersons: A. Ozerdem (Turkey) 155 G. Malhi (Australia) 156

8:30 NEUROENDOCRINE AND METABOLIC CONTRIBUTIONS TO SEX-SPECIFIC PRESENTATIONS OF BIPOLAR DISORDER 157

N. Rasgon (USA)

9:00 GENDER VULNERABILITY FOR ADVERSE LIPID PROFILE IN BIPOLAR DISORDER 158

A. Ozerdem (Turkey)

9:30 GENDER DIFFERENCES IN THYROID SYSTEM FUNCTION: RELEVANCE TO MOOD DISORDER AND ITS TREATMENT 159

M. Bauer (Germany)


8:30 - 10:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: INVESTIGATIONS OF BIPOLAR DISORDERS WITH THE FOREFRONT NEUROPHYSIOLOGUCAL METHODS

Recent development of electrophysiological investigation includes neural oscillation, auditory steady state response, and feedback-related negativity with the use of multiple-channel EEG or magnetoencephalography (MEG). In this symposium, three speakers, as following, present forefront data of electrophysiological investigations which explore cognition, reward learning, and furthermore neurocircuitry in the cortex structures in bipolar disorders. These studies will deepen our understanding of neuronal basis of bipolar disorders. Also, these indices may be useful in differentiation between bipolar disorders and schizophrenia. Onitsuka et al. will show that in bipolar disorders abnormal neural oscillation measured by MEG may contribute to disturbances of cognitive and affective integration. In addition, an auditory steady state response (ASSR) in bipolar disorder is reduced in power and phase locking factors. These studies suggest that GABA inhibitory interneuronal activity in bipolar disorder is disturbed. Chang JS et al. will show that euthymic patients with BD I showed altered coordination between frontal alpha oscillation and neurocardiac activity. They speculate that the neuronal networks linking frontal activity to autonomic tone may be intact but their interactions are less efficient in patients with BD I, especially when under stress. Ryu V, in the probabilistic reward task, observed the reduced acquisition of the response bias toward rich rewarded stimuli and showed attenuated feedback-related negativity in the early phase of the task compared to controls. In ultimatum game, euthymic and manic patients rejected more than controls for unfair offers and showed larger (more negative) FRN amplitude than controls for unfair offers.

Chairpersons: S. Kanba (Japan) 160 S.H. Lee (Korea) 161

8:30 INTEGRATIVE ASSESSMENT OF NEURAL OSCILLATION AND CARDIAC AUTONOMIC REGULATION IN BIPOLAR PATIENTS 162

J.S. Chang, K. Ha, T. Ha (Korea)

9:00 ALTERED REWARD-RELATED NEUROPHYSIOLOGICAL PROCESSING IN PATIENTS WITH BIPOLAR I DISORDER 163

V. RYU (Korea)

9:30 AUDITORY STEADY STATE RESPONSE AND GAMMA OSCILLATION MEASURED BY MEG INBIPOLAR DISORDERS 164

T. Onitsuka (Japan)


8:30 - 10:00 Hall D

SYMPOSIUM SESSION - IMAGING: STRUCTURAL, FUNCTIONAL AND NEURORECEPTOR IMAGING IN AFFECTIVE DISORDERS

This symposium will provide new data using brain imaging technique in searaching biomarkers and exploring neurocircuitry in bipolar disorder and major depression. Dr. Ha from Korea, the first speaker, will present his study to differentiate bipolar I and II disorders using structural and functional MRI. Dr. Li, the second speaker from Taiwan, combined use of PET and MRI data obtained from patient with bipolar I and his unaffected siblings and normals to characterize their brain features focusing on the abnormal fronto-amygdala circuitry. The third speaker Dr. Yang from Taiwan used neuroreceptor SPECT imaging to illustrate dopamine transporter and serotonin transporter by Trodate and ADAM ligand separately in different kinds of depressed patients. These new data will inspire new thinking on the possible mechanisms of mood disorders.

Chairpersons: T. Su (Taiwan) 165 K.Y. Mak (Hong Kong, China) 166

8:30 SIMILARITIES AND DIFFERENCES IN BRAIN IMAGING FINDINGS BETWEEN BIPOLAR I AND II DISORDER 167

T.H. Ha, J.S. Kim, J.Y. Her, J.S. Chang, K. Ha (Korea)

9:00 ABNORMAL FRONTO-AMYGDALA CIRCUITRY IN BIPOLAR I DISORDERS AND THEIR UNAFFECTED SIBLINGS: A COMBINED RESTING-STATE FUNCTIONAL MRI AND PET STUDY 168

C.T. Li, T.P. Su, P.C. Tu (Taiwan)

9:30 MOLECULAR NEUROIMAGING STUDIES WITH DOPAMINERGIC AND SEROTONINERGIC SYSTEMS IN MOOD DISORDER 169

Y.K. Yang (Taiwan)


8:30 - 10:00 Hall F

SYMPOSIUM SESSION - CULTURAL: SOCIO-CULTURAL CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER

The current symposium will present new data from studies regarding patients with bipolar disorder in ethnic minorities and immigrants from the USA and Norway. In addition the first data from the ISBD transcultural task force ongoing research project will be presented. In this study experts in bipolar disorders from more than 20 ISBD countries have shared their insights into how bipolar disorder is managed in their particular country, culture or part of the world. The purpose of the Symposium is to engage the audience in a dialogue about culture, ethnicity and the practice of medicine related to bipolar patients and how this might be helpful in providing more effective healthcare.

Chairpersons: P. Mitchell (Australia) 170 T.Y. Hwang (Korea) 171

8:30 CULTURAL INFLUENCES ON ASSESSMENT, DIAGNOSIS, AND TREATMENT OF BIPOLAR DISORDER IN THE USA 172

E. Youngstrom, M.M. Jenkins, J.K. Youngstrom (USA)

9:00 COMPARING CLINICAL CHARACTERISTICS AND OUTCOME MEASURES IN A NATURALISTIC COHORT STUDY OF IMMIGRANT AND NON-IMMIGRANT BIPOLAR PATIENTS IN NORWAY 173

K.J. Oedegaard, L. Mellesdal, R. Gjestad, C.H. Oedegaard, O.B. Fasmer (Norway)

9:30 SOCIO- CULTURAL CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER: A TRANS- CULTURAL STUDY BY THE INTERNATIONAL SOCIETY OF BIPOLAR DISORDERS 174

K.J. Oedegaard, C.H. Oedegaard, M. Berk, L. Berk, K.M. Moland, O.B. Fasmer (Norway)

10:00 - 10:30

COFFEE BREAK


10:30 - 12:00 Hall A

KEYNOTE LECTURE

Chairpersons: L. Yatham (Canada) 175 S.H. Kim (Korea) 176

10:30 NOVEL THERAPIES: TRANSLATION, VALIDATION AND IMPLEMENTATION 177

M. Berk (Australia)

11:15 CLINICAL STAGING IN BIPOLAR DISORDER 178

F. Kapczinski (Brazil)

12:00 - 13:30 Hall A



12:00 - 13:30

LUNCH BREAK


13:30 - 15:00 Hall B

SYMPOSIUM SESSION - TREATMENT: NEW MEDICAL TREATMENTS TARGETING COGNITIVE DYSFUNTION IN BIPOLAR DISORDER

Bipolar disorder is associated with trait-related impairment of cognitive function in up to 50% of patients and this may be a key mediator of patientís psychosocial and occupational dysfunction. However, only few studies have investigated possible pharmacological treatments targeting cognitive dysfunction. Purpose: This session will aim to highlight and discuss pharmacological interventions with the potential to enhance cognitive function in bipolar patients with cognitive deficits. We will also outline the challenges in conducting cognitive trials in this heterogeneous sample and make preliminary recommendations for optimising future study design (e.g. how to deal with mood changes, concomitant medications etc.).Content: Methodological issues around study design will be discussed and three different pharmacological treatment targets will be presented. In the context of a recently published cognitive enhancement trial using the dopamine D2/D3 agonist, pramipexole, in bipolar patients, Dr. Burdick will present several pitfalls and challenges illustrated with concrete examples. Dr Miskowiak will describe novel results from a study evaluating the effect of Erythropoietin (Epo) on cognition, a study that included 44 bipolar patients in an 8-week, double blind, randomised design. Finally, Dr. Berk will focus on a RCT of lithium compared to quetiapine in the progression of cognition after first episode mania. Importance: New pharmacological treatment strategies are of major importance for advancing the current treatment of bipolar disorder to improve patientís prognosis. The field appears to be moving rapidly in this direction and this session will represent a timely summary of the findings to date.

Chairpersons: M. Vinberg (Denmark) 179 K.S. Oh (Korea) 180

13:30 METHODOLOGICAL CHALLENGES FOR COGNITIVE TRIALS IN BIPOLAR DISORDER: LESSONS LEARNED 181

K.E. Burdick, R.J. Braga, A.K. Malhotra (USA)

14:00 RECOMBINANT HUMAN ERYTHROPOIETIN TO TARGET COGNITIVE DYSFUNCTION IN BIPOLAR DISORDER: A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED PHASE 2 TRIAL 182

M. Kamilla (Denmark)

14:30 A RCT OF LITHIUM COMPARED TO QUETIAPINE IN THE PROGRESSION OF COGNITION AFTER FIRST EPISODE MANIA 183

M. Berk (Australia)


13:30 - 15:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: METABOLIC SYNDROME AND BIPOLAR DISORDER

High prevalence rate of metabolic syndrome (MetS) in Bipolar disorder (BD) has been recognized, but the prevalence of MetS across BP subtypes, the associated inflammatory reaction, and clinical outcomes were less investigated. Furthermore, genetic predisposition for MetS in those with BD has been suggested. Preclinical studies suggested that the circadian system can regulate gene transcription in glucose and lipid metabolism pathways and deletion of clock genes is associated with dysregulation of inflammatory cytokines. But clinical studies among BD patients are relatively limited. In this symposium, Prof. Chen will report a 12-week prospective study of 56 drug-naÔve bipolar II patients, the prevalence of MetS increased from 7*o 109Repeated measurements showed that the changes in metabolic indexes were not significant, with the exceptions of BMI, waist circumference, and buttock circumference. But the interaction between the improvement of hypomanic symptoms and BMI change was significant. Then Prof. Bai will report the comparison of pro-inflammatory cytokines among 130 patients with BD, 149 patients with depressive disorder and 130 age and gender matched normal controls. After adjusting the medical comorbidity and BMI, the BD patients had significantly higher levels of pro-inflammatory cytokines than the patients with depressive disorder. The prevalence of MetS among the BD patients was 29.49The patients with MetS were noted with more previous hospitalizations, more first mood episode with mania, more clinical side effects (extrapyrimal side effects and tardive dyskinesia), poorer global functioning and social function, poorer insight, more impairment of executive function by WCST, and higher levels of pro-inflammatory cytokines. Finally, Professor Eun Young Kim will reported the standardized prevalence ratio (95úI) of MetS in patients with BD was 1.54 (1.05ñ2.03) and 1.98 (1.36ñ2.60) in Korea, compared with general population, based on the criteria of ATPIII and IDF, respectively. They assessed the association of several genetic polymorphisms, related with the circadian system, with MetS risk in patients with BD. Period (Per2/Per3) genes were associated with levels of serum HDL cholesterols. Albumin D-element binding protein (Dbp), clock-controlled output genes, and casein kinase 1 epsilon (CSNK1E) gene were associated with waist circumference and the number of metabolic syndrome diagnostic criteria. Furthermore, the Akt/GSK-3þ genes were significantly associated with metabolic parameters in BD patients. They suggested the utility of circadian rhythm genes as a novel candidate genetic marker for metabolic risk in patients with bipolar disorder.

Chairpersons: Y.S. Kim (Korea) 184 Y.M. Mok (Singapore) 185


13:30 THE PREVALENCE OF METABOLIC SYNDROME IN DRUG-NAÏVE BIPOLAR II DISORDER PATIENTS 186

P. Chen, R. Lu, Y. Yang (Taiwan)

14:00 METABOLIC SYNDROME, INFLAMMATORY CYTOKINES, COGNITIVE FUNCTION AND CLINICAL OUTCOMES IN BIPOLAR DISORDER 187

Y.M. Bai (Taiwan)

14:30 ASSOCIATION BETWEEN CIRCARDIAN RHYTHM GENES AND METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER 188

E.Y. Kim, Y.M. Ahn (Korea)


13:30 - 15:00 Hall D

SYMPOSIUM SESSION - IMAGING: BIPOLAR DISORDER AND NEUROINFLAMMATION: WHAT CAN WE SEE?

The pathophysiology of bipolar disorder (BD) is complex. Both genetic and environmental factors likely interact to predispose to the disorder, but the specific nature of the gene-environment interactions shaping the neurobiology of BD remains unclear. The “monocyte-T-cell theory of mood disorders” considers an activated inflammatory response system to be a driving force behind mood disorders. In BD this hypothesis is supported by many studies showing altered concentrations of immune-related peripheral biomarkers, specifically elevated levels of pro-inflammatory cytokines, aberrant expression of pro-inflammatory genes, alterations in the kynurenine pathway, and immune modulating effect of several psychotropic drugs found to be effective in BD. Several recent studies have examined the relationship between peripheral immune markers and neuroimaging-derived measures of brain structure and brain function in the context of BD. The first speaker will detail the relationship between serum concentrations of kynurenine-pathway metabolites and gray matter volume of the hippocampus and amygdala in healthy controls and unmedicated subjects with mood disorders. The second speaker will present the association of cytokines with the serotonin transporter in different brain regions in patients with BD-I in euthymic state. The third speaker will present the results of a [11C]PK11195 PET study measuring microglia activation in naturalistic treated euthymic BD-I patients compared to healthy controls.

Chairpersons: W. Nolen (The Netherlands) 189 Y. Chou (Taiwan) 190

8:30 NEUROPROTECTIVE AND NEUROTOXIC KYNURENINE PATHWAY METABOLITES ARE ASSOCIATED WITH HIPPOCAMPAL AND AMYGDALAR VOLUMES IN DEPRESSION 191

J. Savitz, W.C. Drevets, T.A. Victor, J. Bodurka, T.K. Teague, R. Dantzer (USA)

9:00 INTERACTION OF CYTOKINES AND SEROTONIN TRANSPORTER IN BIPOLAR I DISORDER 192

Y. Chou (Taiwan)

9:30 NEUROINFLAMMATION IN BIPOLAR DISORDER? AN [11C]PK11195 PET STUDY IN EUTHYMIC PATIENTS 193

B. Haarman, J. Doorduin, R.F. Riemersma - van der Lek, T.E. Zandstra, H.A. Drexhage, W.A. Nolen (The Netherlands)


13:30 - 15:00 Hall F

SYMPOSIUM SESSION - CULTURAL: IDENTIFYING MOOD DISORDER AND CORRELATES IN YOUTH FROM DIFFERENT CULTURES

This symposium investigates similarities and differences in the assessment and expression of pathological mood among youth in the US and Korea.Recent epidemiological and clinical studies have drawn attention to the prevalence of serious mood disorders worldwide. Although pediatric mood disorders can cause significant impairment, it often takes many years before an accurate mood disorder diagnosis is made, leading to a worse prognosis over time.Research into the evidence-based assessment of mood disorders, and into risk factors related to psychopathology, aims to improve early identification and intervention. Pediatric bipolar disorder (PBD) has been a controversial diagnosis. Though there are tools that reliably distinguish PBD from other childhood disorders in American youth, not all work equally well. Even less is known about how these tools perform in other cultures, where semantic differences and variability in the subjective experience of mood could render even well-established methods ineffective.This symposium examines the discriminative validity of parent, child, and teacher checklists for assessing PBD in the US, and compares these results to effect sizes from a Korean youth sample (Youngstrom et al.). Next, we will compare youth and parent report on a diagnostic checklist for PBD, elaborating on the different validity of parent report in the Korean sample (Kim et al.). Finally, we will investigate the prevalence of traits associated with PBD among American and Korean college students, and assess the relation between these measurable risk factors and negative outcomes including suicidal ideation, self-injury, and suicide attempt (Van Meter et al.).

Chairpersons: S.C. Cho (Korea) 194 E. Youngstrom (USA) 195

13:30 ADOLESCENTS-PARENTS AGREEMENT ON MOOD SYMPTOMS IN KOREAN ADOLESCENTS 196

H.W. Kim, H.J. Lee, Y. Joo, E.A. Youngstrom, S.Y. Yum (Korea)

14:00 TEMPERAMENT AND BIS-BAS: CROSS-CULTURAL INDICATORS OF SUICIDALITY AND SELF-INJURY IN YOUNG ADULTS 197

A. Van Meter, J. Genzlinger, E.A. Youngstrom (USA)

14:30 BENCHMARKING KOREAN DATA AGAINST A META-ANALYSIS OF THE DISCRIMINATIVE VALIDITY OF CAREGIVER, TEACHER, AND YOUTH CHECKLISTS FOR ASSESSING PEDIATRIC BIPOLAR DISORDER 198

E. Youngstrom, A. Van Meter, J. Genzlinger, G. Egerton, C. Sowder, E. McKinney, H.W. Kim (USA)

15:00 - 15:30

COFFEE BREAK


15:30 - 17:00 Hall A

SYMPOSIUM SESSION - TREATMENT: PREDICTORS AND MODERATORS OF PSYCHOSOCIAL TREATMENT OUTCOME FOR BIPOLAR DEPRESSION: RESULTS FROM THE SYSTEMATIC TREATMENT ENHANCEMENT PROGRAM FOR BIPOLAR DISORDER (STEP-BD)

Bipolar disorder is characterized by recurrent manic and/or depressive episodes that affect approximately 5.7 million (2.6Èadult Americans. Pharmacotherapy is the first line of treatment, but unfortunately, these treatments fail to bring many patients with bipolar disorder to sustained symptomatic and functional remission. Empirically tested adjunctive psychosocial treatments for bipolar disorder have demonstrated efficacy for increasing medication adherence, preventing relapse, enhancing family functioning and shortening the length of depressive episodes. Yet, despite these advancements, many individuals with bipolar disorder continue to show impairments in psychosocial functioning and overall quality of life. Clinically, depression is the biggest unresolved problem for patients with bipolar disorder both in terms of recurrence as well as response to pharmacotherapy or psychosocial treatment. This symposium focuses on moderators of response to psychosocial treatment for acute depression in patients with bipolar disorder using data from the Systematic Enhancement Program for Bipolar Disorder (STEP-BD). STEP-BD is the largest multi-site longitudinal study of bipolar disorder to date, enrolling 4361 participants across 21 sites. Embedded within STEP-BD was a randomized controlled trial of psychotherapy for bipolar depression (n=293 patients) comparing intensive psychotherapy (cognitive-behavior therapy [CBT], family-focused therapy [FFT], or interpersonal and social rhythm therapy [IPSRT]) with a brief intervention drawing on the most common psychosocial strategies shown to offer benefit for bipolar disorder (collaborative care). Overall, results indicated that adjunctive intensive psychotherapy was more beneficial in achieving and reducing time to recovery from a depressive episode than collaborative care. No differences were found among the 3 intensive psychosocial treatments in their capacity to aid and sustain recovery. In this symposium we will review predictors and moderators of treatment response for this STEP-BD randomized controlled trial. Andrew Nierenberg, MD will provide a brief overview of the STEP-BD study and present findings that patients with anxiety disorders benefit more from psychotherapy for depression than patients without anxiety disorders. Amy Peters will review the role of age of onset, chronicity (previous mood episodes), and illness duration in predicting and moderating treatment response. David Miklowitz, PhD will provide new findings on the role of extreme attributions as a predictor of response to psychotherapy and transition to mania after a depressive episode. The talks will be integrated and discussed by Thilo Deckersbach, PhD.

Chairpersons: T. Deckersbach (USA) 199 M.S. Lee (Korea) 200


15:30 CO-MORBID ANXIETY MODERATES PSYCHOSOCIAL TREATMENT OUTCOME FOR BIPOLAR DEPRESSION 201

A. Nierenberg, N. Hansen, A. Peters, L.G. Sylvia, P.V. Magalhaes, M. Berk, M. Otto, D. Miklowitz, E. Frank, T. Deckersbach (USA)

16:00 AGE OF ONSET, COURSE OF ILLNESS, AND RESPONSE TO PSYCHOTHERAPY FOR BIPOLAR DEPRESSION 202

A. Peters, L.G. Sylvia, P.V. Magalhaes, D. Miklowitz, E. Frank, M. Otto, M. Berk, A. Nierenberg, T. Deckersbach (USA)

16:30 EXTREME ATTRIBUTIONS PREDICT THE COURSE OF BIPOLAR DISORDER FOLLOWING PSYCHOTHERAPY TREATMENT FOR DEPRESSION 203

D. Miklowitz, J. Stange, L.G. Sylvia, P.V. Magalhaes, M. Otto, E. Frank, A. Peters, M. Berk, A. Nierenberg, T. Deckersbach (Australia)


15:30 - 17:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: SUICIDE IN BIPOLAR DISORDER: AN ISBD TASK FORCE REPORT

Objectives: Bipolar disorder (BD) is associated with an elevated risk of suicide and suicide attempts. The goals of the International Society for Bipolar Disorders Task Force on Suicide were to identify and quantity the risks, characteristics, and neurobiological correlates of suicide and suicide attempts in BD, and to examine treatment interventions for suicide prevention in this patient population. Methods: The task force was comprised of 21 international experts in the areas of BD and/or suicide. Four working groups were organized to focus on: 1) Prevalence and characterization of suicide and suicide attempts in BD; 2) Risk stratification to identify high risk groups; 3) Neurobiological aspects of suicide in BD, and 4) Clinical interventions for suicide prevention in BD. Each working group completed a comprehensive literature review of papers published since 1980 on suicide or suicide attempts in BD among people age 15 or older, and meta-analyses were conducted for variables with sufficient data. Results: A summary of the key findings from three of these groups will be presented in this symposium. Most of the literature to date has focused on suicide attempts rather than completed suicide in BD, yet there are several large recent studies of suicide in BD that have found high rates compared to other psychiatric conditions. There are numerous studies that have focused on identifying high risk BD groups, based on sex, age of illness onset, polarity of 1st episode, polarity of recent episode, psychosis, substance use, anxiety, personality, bipolar subtype, and family history. Meta-analyses confirmed the associations of a number of these sociodemographic and clinical variables. Conclusions: There is a growing body of literature that provides key insights into the rates of suicide and suicide attempts in BD and is beginning to replicate data on specific high risk groups. There is a paucity of data on neurobiology of suicide specific to BD or on effective diagnosis-specific treatment interventions. Impact: Understanding the current state of knowledge on suicide and suicide attempts in BD can inform clinical, research, and educational needs in this critical, but understudied area.

Chairpersons: A. Schaffer (Canada) 204 Y. Lee (Korea) 205

15:30 PREVALENCE AND CHARACTERISTICS OF SUICIDE IN BIPOLAR DISORDER 206

D. Moreno (Brazil)

16:00 FACTORS THAT INFLUENCE THE RISK OF SUICIDE ATTEMPTS OR SUICIDE IN BIPOLAR DISORDER 207

A. Schaffer (Canada)

16:30 CLINICAL INTERVENTIONS FOR SUICIDE PREVENTION IN BIPOLAR DISORDER 208

L. Yatham (Canada)


15:30 - 17:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: GLUTAMATERGIC SYSTEM IN BIPOLAR DISORDERS: FROM ETIOLOGY TO TREATMENT

Glutamate (Glu) is the most abundant neurotransmitter in the brain and glutamatergic neurotransmission plays a key role in brain function. Abnormalities in glutamatergic neurotransmission are also implicated in mood disorders. Neuroimaging studies indicated an elevated glutamine/glutamate ratio (Gln/Glu) in bipolar mania and with antidepressant treatment in bipolar depression, and a reduced Gln/Glu in major depression. In line with the findings from neuroimaging studies, genetic studies supported the importance of glutamate metabolism in mood and psychotic disorders. It was reported that variation in GLS1 (the gene encoding the brain isoform of glutaminase, which catalyzes Gln-to-Glu conversion) is associated with Gln/Glu measured in vivo in two brain regions. These findings suggest that genetic variation in a key component of glutamatergic machinery is associated with a putative in vivo index of glutamatergic neurotransmission. Genetic findings also led to the development of novel therapeutic agents that modulate the glutamate system. For instance, the NMDA antagonist ketamine is effective not only in unipolar but also bipolar depression and lithium has been shown to increase the synaptic uptake of glutamate ñ possibly the mechanism responsible for its neuroprotective effect. Recently, methylene blue (MB) which is known to inhibit nitric oxide synthase, one of downstream targets of glutamate signaling, was found to have a robust effect on symptoms of depression and anxiety among thirty-seven bipolar patients in a study by Alda and colleagues. Under the lights of these evidence role of glutamate in bipolar disorders(BD) from etiology to treatment will be discussed. Firstly, Dr. ÷ng¸r will overview neuroimaging studies of glutamate in BD and later on Dr. Altinbas will present the data from genetic studies on glutamate in BD. Lastly, Dr. Alda will discuss the current and future upcoming glutamatergic treatments.

Chairpersons: K. Altinbas (Turkey) 209 J. Rybakowski (Poland) 210

15:30 NEUROIMAGING STUDIES OF GLUTAMATE ABNORMALITIES IN BIPOLAR DISORDER 211

D. Ongur (USA)

16:00 GENETICS OF GLUTAMATERGIC SYSTEM IN BIPOLAR DISORDERS 212

K. Altinbas (Turkey)

16:30 GLUTAMATE AND TREATMENT OF BIPOLAR DISORDER 213

M. Alda (Canada)


15:30 - 17:00 Hall D

SAMUEL GERSHON AWARD: AWARD WINNERS ORAL PRESENTATIONS

The International Society for Bipolar Disorders (ISBD) recognizes the vital role of developing the next generation of leaders in the field of bipolar disorders and will offer 4 awards for original research publication submissions. In order to promote research interest in bipolar disorders in developing countries, two of the awards will be reserved for those from low and middle-income countries, as defined by the 2013 World Bank Classification. The award recipients will present their abstracts in this session.

Chairperson: G. Malhi (Australia) 214

15:30 EXOME SEQUENCING IN BIPOLAR DISORDER: FAMILY AND CASE-CONTROL RESULTS IMPLICATE A SET OF TEN INTERACTING GENES 215

F. Goes, J. Parla, M. Pirooznia, M. Kramer, P. Zandi, W.R. McCombie, J. Potash (USA)

15:50 EARLY SIGNS OF ANOMALOUS NEURAL FUNCTIONAL CONNECTIVITY IN HEALTHY OFFSPRING OF PARENTS WITH BIPOLAR DISORDER 216

M. Singh, K.D. Chang, R.G. Kelley, M. Saggar, A. Reiss, I.H. Gotlib (USA)

16:10 KETAMINE MODULATES BEHAVIORAL AND NEUROCHEMICAL ALTERATIONS INDUCED BY STRESS:NOVEL EVIDENCE FOR TREATMENT OF MOOD DISORDERS 217

G. Reus, M.P. Nacif, H. Abelaira, F. Dal Pizzol, E. Streck, J. Quevedo (Brazil)

16:30 LATE-ONSET MANIA: WHITE MATTER INTEGRITY AND COGNITIVE IMPLICATIONS. 218

J. Ramírez-Bermúdez, C. Berlanga, A. Guadamuz, O. Marrufo-Melendez, P. Alvarado, C. Atriano, R. Favila, J. Taboada, R. Carrillo-Meza (Mexico)


15:30 - 17:00 Hall F

SYMPOSIUM SESSION - CULTURAL: CULTURAL ISSUES AND BIPOLAR DISORDER IN CHINA

Bipolar Diagnosis and Management in Chinese Context

Chairpersons: Z. Jingping (China) 219 S.J. Kim (Korea) 220

15:30 BIPOLARITY INDEX AS AN ASSESSMENT INSTRUMENT IN THE DIAGNOSIS AND ONE YEAR OUTCOME OF BIPOLAR DISORDERS 221

X. Yu, Y. Ma, T. Si, J.I.N.G. Li, Z. Liu, G.A.N.G. Wang, J.I.N.G. Sun, Y.I.R.U. Fang, H. Yang, Y. Zhang, X. Wang, S. Gary (China)

16:00 MICROAARAY-BASED ANALYSIS OF MICRO-RIBONUCLEIC ACID EXPRESSION IN AN ANIMAL MODEL OF MANIA 222

H. Rong, T.B. Liu, H.C. Yang, J. Zhang, H.Z. Yang, J.Q. Bi, Q.J. Shen (China)

16:30 CHARACTERISTICS OF UNRECOGNIZED BIPOLAR DISORDER IN PATIENTS TREATED FOR MAJOR DEPRESSIVE DISORDER IN CHINA: GENERAL VS. PSYCHIATRIC HOSPITALS 223

G. Wang, Y. Xiang, F. Chen (China)


POSTER SESSION II


SCIENTIFIC PROGRAMFriday, March 21, 2014

88 SCIENTIFIC PROGRAM FRIDAY, MARCH 21, 2014

SCIENTIFIC PROGRAM FRIDAY, MARCH 21, 2014

7:00 - 8:30 Hall D

BRAINSTORMING SESSION: TRANSCRANIAL MAGNETIC STIMULATION BIOMARKER AND THERAPEUTIC STUIDES IN BIPOLAR DISORDER

This session will review current investigations employing transcranial magnetic stimulation (TMS) to study the neurophysiology of psychiatric illnesses and its application as a treatment modality. There is a critical need for biomarkers in bipolar disorder to assist with early identification, treatment selection, and monitoring illness progression. Further, bipolar depression is a devastating condition with suboptimal treatments. Brain stimulation modalities such as TMS may play a role in addressing biomarker development and providing additional treatment options. Work with bipolar disorder is nascent, but presenters will focus on existing literature as a basis for interactive discussions. This dialogue will explore options for integrating TMS into future research protocols and clinical practice for patients with bipolar disorders. TMS non-invasively stimulates cortical neurons with rapidly oscillating magnetic fields which thereby induce electrical currents in the brain. Three types of delivery include single-pulse, paired-pulse, and repetitive stimulation (rTMS). Protocols often combine TMS stimulation with electromyography (EMG), electroencephalography (EEG), or neuroimaging to study brain functions. For example, existing paradigms examine motor evoked potentials or cortical oscillations as indirect measures of gamma-aminobutyric acid (GABA) and glutamatergic functioning. Prior rTMS research has examined its effects in the treatment of anxiety disorders, mood disorders, and psychotic disorders. Dr. Chae will give an overview of rTMS and discuss its applications in depression and anxiety disorders. Dr. Daskalakis will discuss prior neurophysiologic research and potential future directions in bipolar disorder. Ongoing rTMS work targeting working memory deficits in schizophrenia will serve as one model of how meaningful research and clinical applications could address neurocognitive deficits in bipolar disorder. The session chair, Dr. Croarkin has prior experience in TMS research with special populations such as children and adolescents. This will be integrated into the ongoing dialogue of the session to examine opportunities across the lifespan. The presenters will maximize opportunities for interactive discussions with attendees, with the goal of forming effective international collaborations that will maximize the clinical and research applications of TMS for bipolar disorders.

Chairperson: P. Croarkin (USA) 224

7:00 REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION TREATMENT STUDIES IN DEPRESSION AND ANXIETY DISORDERS 225

J.H. Chae (Korea)

7:45 TRANSCRANIAL MAGNETIC STIMULATION AS A NEUROPHYSIOLOGIC AND THERAPEUTIC TOOL IN BIPOLAR DISORDERS 226

Z.J. Daskalakis (Canada)

89SCIENTIFIC PROGRAM FRIDAY, MARCH 21, 2014

7:00 - 8:30 Hall F

BRAINSTORMING SESSION: STIGMA AS PERCEIVED BY PATIENTS WITH BIPOLAR DISORDER. CULTURAL DIFFERENCES BETWEEN THE NETHERLANDS AND JAPAN

An unfortunate reality is that nine out of ten patients with mental illnesses experience stigmatization. Often a distinction is made between us, the normal people and them, the people with mental illnesses. In literature, different types of stigma are described. Public stigma is the negative reaction that the general population has to people with mental illness. Self-stigma is when a patient internalize public stigma and experience diminished self-esteem and self-efficacy Structural stigma is when the policies of private and governmental institutions intentionally restrict the opportunities of people with mental illness. And associative stigma is when stigmatization not only affects people with mental illnesses, but their families as well. The effects of stigma on patients with mental illnesses are; diminished self-esteem and self-efficacy; isolation from others; not taking part in everyday activities; difficulties in finding or holding a job; avoid seeking help because they fear being labeled as crazy, dangerous, unreliable, or even contagious and negative health outcomes. Beside these personal effects, stigmatization causes financial burden on families and society. Culture shapes how individuals perceive and respond to others with mental illness. Studies have suggested that Asians and Asian Americans typically endorse greater stigma of mental illness compared to Westerners (White Europeans and Americans).In this brainstorm session we will give an overview of the different kinds of stigma perceived by patients with a bipolar disorder from The Netherlands and from Japan. We interviewed patients to collect their stories on how they encounter stigmatization, how it affects them, and how they coped with it. We will discuss with the audience which strategies they know and use to help their patients dealing with the consequences of perceived stigma or self-stigma. We will give an overview of facts that might have influenced the general populations attitudes towards people with mental illnesses. We will give examples of anti-stigma campaigns from Westerners and Asian countries and discuss with the audience if they think these campaigns could be carried out in their home country or why they could not.

Chairperson: A. Stevens (The Netherlands) 227

7:00 HOW DO PATIENTS WITH BIPOLAR DISORDER IN THE NETHERLANDS PERCEIVE STIGMATIZATION 228

P. Goossens (The Netherlands)

7:45 HOW ATTITUDES OF THE GENERAL POPULATION AND A CULTURAL PERSPECTIVE AFFECT LIVES OF THE PEOPLE WITH BIPOLAR DISORDER IN JAPAN 229

Y. Omori (Japan)


8:30 - 10:00 Hall A

SYMPOSIUM SESSION - ADVOCACY: THE FUTURE CARE OF BIPOLAR DISORDER: TRIALOGICAL APPROACHES

Outcome criteria for the treatment of patients with bipolar disorder has changed in the last couple of decades. While immediate treatment response to pharmacotherapy was the main focus, good quality of life and psychosocial functioning, as well as absence of cognitive disturbances, are now important goals for remission and recovery for both the patients and their relatives. Bifocal psychoeducation, for example, tries to establish more shared decision-making within the doctor-patient relationship. This approach attempted to actively integrate patients and relatives in the treatment process in order to reach the goals in a joint process. However, experiences have revealed that organizational forms of a trialogical approach improve effectiveness on all levels in balancing the relationships between professionals, patients and relatives. Furthermore, integration of the patient and relative into developing guidelines or research programs produce even more efficacy. Anti- stigma campaigns and public education contribute to the trialogical approach. Ultimately, these initiatives will change the atmosphere between patients with bipolar disorder and the mental health system in which their services are rendered. This symposium will present trialogical approaches and perspectives from Germany as well as from the US.

Chairpersons: M. Bauer (Germany) 230 L. Vedel Kessing (Denmark) 231

8:30 THE TRIALOGICAL GERMAN ASSOCIATION FOR BIPOLAR DISORDER AND ITS DEVELOPMENT OF NATIONAL TREATMENT GUIDELINES 232

M. Bauer (Germany)

9:00 LIVING TRIALOGUE AS A PATIENT’S SPEAKER 233

M.K. Kolbe (Switzerland)

9:30 ADVOCACY AS PART OF THE TREATMENT PLAN 234

M. Walker (USA)


8:30 - 10:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: BIPOLAR DEPRESSION: PHENOMENOLOGY, BRAIN IMAGING AND PREDICTORS OF TREATMENT RESPONSE

Bipolar depression is a topic arousing considerable controversy, particularly with regard to its recognition and treatment. This symposium will address three main areas: phenomenology / clinical recognition; brain imaging; and predictors of response to treatment. Recent phenomenological data from Australia and China will be presented, focusing on the distinctions between bipolar and unipolar depression, and bipolar I and bipolar II depression. Data on using factor analyses to identify potential predictors of response to pharmacological treatment in bipolar depression will be outlined. fMRI data from China on bipolar depression will also be discussed.Furthermore, recent US MR spectroscopy data will address the issue of understanding drug mechanism of action. The resonance frequency of several metabolites on the 1H-MRS spectrum can be reliably quantified and can be used to probe drug mechanism of action in bipolar disorder. This presentation will review key clinical treatment intervention studies evaluating change in N-acetylaspartate (NAA), glutamate / glutamine, choline and myoinositol focusing on how MR imaging can delineate either therapeutic drug mechanism of action or disease burden of illness.

Chairperson: P. Mitchell (Australia) 235

8:30 PHENOMENOLOGY OF BIPOLAR I AND II DEPRESSION COMPARED TO UNIPOLAR DEPRESSION, AND PREDICTORS OF RESPONSE TO TREATMENT. 236

P. Mitchell, A. Frankland, G. Roberts (Australia)

9:00 ON THE FEATURES OF BIPOLAR COMPARED TO UNIPOLAR DEPRESSION IN CHINA 237

T. Si (China)

9:30 MR SPECTROSCOPY TO STUDY DRUG MECHANISM OF ACTION IN BIPOLAR DISORDER 238

M. Frye (USA)


8:30 - 10:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: INFLAMMATORY MARKERS AND NEW THERAPEUTIC CHALLENGE IN BIPOLAR DISORDER

Bipolar disorder has been reconceptualized as a multisystem disease associated with mood, cognitive, metabolic, immunomodulatory, and autonomic dysfunctions. However, there are currently no biological tests that differentiate patients with bipolar disorder from major depression or schizophrenia. Accordingly, recent studies have focused on the identification of biomarkers related to the pathophysiological mechanisms underlying the development, clinical presentation, and course of bipolar disorder. The existing evidence suggests that a single biomarker will not be able to cover the biological and clinical complexity of bipolar disorder. Alternatively, a composite of biomarkers, including inflammatory parameters, neurotrophic factors, and oxidative stress molecules, may be promising to identify altered mood states and neuroprogression in bipolar disorder. It is well known that the involvement of immune system dysfunction is possibly related to disease activity. However, results in individual studies remain inconsistent and clinical studies examining longitudinal changes within individuals are recommended. Vitamin D receptors and vitamin D metabolizing enzymes are present in the central nervous system. Calcitriol (the active vitamin D hormone) affects numerous neurotransmitters and neurotrophic factors, relevant for mental disorders. In the case of depressive disorders, considerable evidence supports a role of suboptimal vitamin D levels. Therefore, repurposed drugs, which are approved for other medical conditions, represent an underutilized therapeutic resource for patients who have not responded to mood-stabilizing drugs. Treatment outcome of bipolar disorder may be improved by additional use of certain nutraceuticals with conventional pharmacotherapies. Biomarker studies should also be carried out to identify subgroups of patients who do respond to these drugs. This symposium will focus on the current evidence in these areas, particularly inflammatory marker, and providing a critical look at use of neutraceuticals to provide a new perspective for treatment of bipolar disorder. Three speakersí topics will cover: (1) the various alternations of inflammatory markers in bipolar depression and mania from acute episode to full remission compared with healthy controls, (2) vitamin D deficiency or insufficiency in bipolar disorder as schizophrenia and major depression compared to healthy controls, and (3) the potentiality of biologically active form of folate correcting mood stabilizer-associated functional folate deficiency and aiding in improving treatment outcomes, particularly bipolar depression.

Chairpersons: A. Nierenberg (USA) 239 F. Kapczinski (Brazil) 240

8:30 THE DIFFERENCE IN ALTERED INFLAMMATORY MARKERS THROUGHOUT ACUTE EPISODE BETWEEN BIPOLAR MANIA AND DEPRESSION 241

S. Tsai, K.H. Chung, S.H. Huang, P.H. Chen (Taiwan)

9:00 ONE CARBON METABOLISM AND BIPOLAR DISORDER 242

J.H. Baek, E.E. Bernstein, A.A. Nierenberg (USA)

9:30 VITAMIN D DEFICIENCY IN BIPOLAR DISORDER 243

B. Cha (Korea)


8:30 - 10:00 Hall F


Chairpersons: Y. Chou (Taiwan) 244 P. Udomratn (Thailand) 245

CORRELATION OF SERUM BDNF LEVEL WITH CLINICAL SYMPTOM DOMAINS IN BIPOLAR DISORDER-I 246

B. Chatterjee, R. Sagar, S. Vivekanandan, A. Sahu (India)

SIMILARITIES AND DIFFERENCES IN BRAIN IMAGING FINDINGS BETWEEN BIPOLAR I AND II DISORDERS 247

T. Ha, J. Kim, J. Her, J. Chang, K. Ha (Korea)

SURVEY OF THE PSYCHOTROPIC DRUGS IN OUTPATIENTS WITH BIPOLAR DISORDER IN JAPAN: PRELIMINARY CROSS-SECTIONAL STUDY 248

T. Hashimoto, M. Koseki, D. Sakurai, T. Hasegawa, N. Kanahara, I. Masaomi (Japan)

DIAGNOSTIC STABILITY AND INTERCHANGE OF SCHIZOPHRENIC AND BIPOLAR DISORDERS 249

S.K. Lin, Y.N. Hung, S.Y. Yang (Taiwan)

THOUGHT DISORDER IN MANIC PATIENTS: WHERE’S THE IMPAIRMENT? 250

D. Raucher-Chéné, S. Terrien, F. Gierski, S. Caillies, C. Besche-Richard, A. Kaladjian (France)

10:00 - 10:30

COFFEE BREAK


10:30 - 12:00 Hall A

KEYNOTE LECTURE

Chairpersons: M. Sanchez de Carmona (Mexico) 251 K. Ha (Korea) 252

10:30 PSYCHOEDUCATION AND OTHER PSYCHOLOGICAL INTERVENTIONS: CLASS EFFECT OR SPECIFIC TREATMENT MODALITIES? 253

F. Colom (Spain)

11:15 GRASSROOTS ADVOCACY; HOPE, RESOURCES, SUPPORT 254

M. Walker (USA)

12:00 - 13:30 Hall A



12:00 - 13:30

LUNCH BREAK


13:30 - 15:00 Hall A

SYMPOSIUM SESSION - ADVOCACY: SELF-MANAGEMENT IN BIPOLAR DISORDER

The dynamic and continuous process of self-monitoring and regulation of symptoms, treatment, and life style changes inherent in living with a chronic disease is called ëself-managementí. Teaching patients and informal caregivers to recognize and respond to signs of recurrence is a goal in todayís treatment. Although self-management is a desirable outcome of patient education, studies have found a varying success rates. No figures predict a sustainable long-term positive effect on health. During this symposium we will explore the concept of ëself-managementí from different perspectives. Firstly results of a phenomenological study of clinical experiences and tacit knowledge of patients, caregivers and professionals about self-management strategies will be presented. Secondly we will discussed specific challenges of self-management during pregnancy and in the postpartum period where there is an increased risk for recurrence and maternal death. It is important to give the woman and her partner tools to manage this period in such a way that they can manage problems that they will probably face. Psycho education and the development of a specific pregnancy related relapse prevention plan for the different periods will be discussed. Thirdly the development and testing of Care Indicator will be presented. Care Indicator is an E-Health tool that monitors the mental disposition of a patient based on observations of the patient, the professional caregiver and a support group. If there are critical changes in the mental state of the patient, Care Indicator gives a signal to the patient, the professional caregiver and (selected) members of the support group.

Chairpersons: P. Goossens (The Netherlands) 255 M. Walker (USA) 256

13:30 TRIANGULATING PERSPECTIVES ON SELF-MANAGEMENT OF BIPOLAR DISORDER: A PHENOMENOLOGICAL STUDY OF PATIENTS, CAREGIVERS AND PROFESSIONALS 257

S. Van den Heuvel, P. Goossens, C. Terlouw, T. Van Achterberg (The Netherlands)

14:00 SELFMANAGEMENT IN PREGNANCY AND POSTPARTUM PERIOD 258

A. Stevens, S. Van de Heuvel, P. Goossens, B. Geerling (The Netherlands)

14:30 CAREINDICATOR, A SELF-MANAGEMENT E-TOOL FOR EARLY SIGNALING AND INTERVENTION IN BIPOLAR DISORDER 259

B. Geerling, P. Goossens, A. Stevens, S. Van den Heuvel (The Netherlands)


13:30 - 15:00 Hall B

SYMPOSIUM SESSION - CLINICAL MANIFESTATION: DIFFERENT ASPECTS OF MIXED DEPRESSION

Placement of mixed features specifier in the case of major depression in the latest version of diagnostic and statistical manual for mental disorders (DSM 5) has the potential of revitalizing the already existing challenge on the “mixed phenomenon”. The controverises related to the pathophysological and clinical properties of the mixed states in the broad sense reflect on the treatment practice,in particular, use of antidepressants, treatment response, , occurrence of manic switch and transition from unipolar (UP) to bipolar disorders (BD). Gender is one of the factors that is considered to impact the clinical representation of depression. Most of the studies on mixed depression indicated that it is more common among females. Syndromes arising from sudden dopamine depletion such as neuroleptic dysphoria or withdrawal syndromes from dopaminergic drugs, bear remarkable clinical similarities with mixed depression. These syndromes are subject to further research and may thus provide a model for the pathophysiology of mixed states. Based on the paucity of data on the etiopathogenesis a better comprehension of the biological basis of mixed phenomenology is needed. In this symposia, the first speaker will review the current data on mixed depression and present the interpretations for the clinical practice. The second speaker will present a data driven discussion on the influence of gender on the representation of mixed features in depression. Lastly, the third speaker will argue a novel etiological hypothesis for mixed depression.

Chairpersons: K. Altinbas (Turkey) 260 M. Frye (USA) 261

13:30 UNIPOLAR VERSUS BIPOLAR MIXED DEPRESSION: INTERPRETATIONS FOR THE CLINICAL PRACTICE 262

K. Altinbas (Turkey)

14:30 DOPAMINE DYSREGULATION AS A NEUROBIOLOGICAL HYPOTHESIS FOR MIXED DEPRESSION 263

D. Quiroz, S. Strejilevich (Chile)

14:00 FEMALE GENDER AND THE CO-OCCURING MANIC SYMPTOMS IN DEPRESSION 264

A. Ozerdem (Turkey)


13:30 - 15:00 Hall C

SYMPOSIUM SESSION - NEUROBIOLOGY: GENETIC STUDIES ON BIPOLAR DISORDERS

In this session, I invited 3 speakers, from mainland China, Taiwan, and Korea, to introduce their researches and findings that focus on the genetic studies of mechanism and etiology in bipolar disorders.

Chairperson: Y. Fang (China) 265

13:30 ASSOCIATION STUDY OF 43 CANDIDATE GENES WITH BIPOLAR I AND II DISORDER IN THE KOREAN POPULATION 266

S. Ryu, I. Huh, J. Baek, E. Cho, T. Park, J. Kim, K. Lee, K. Ha, K. Hong (Korea)

14:30 BRAIN-DERIVED NEUROTROPHIC FACTOR LEVELS PREDICT BIPOLAR DISORDERS IN THEIR FIRST DEPRESSIVE EPISODE: RESULT OF A LONGITUDINAL STUDY 267

C. Zhang, Z. Li, Y. Fang (China)

14:00 GENETIC PROFILES IN DISTINGUISHING BIPOLAR SUBTYPE I AND II DISORDER 268

P. Kuo, C.f. Kao, H.c. Chen, Y.h. Chiu, M.c. Huang, R.b. Lu (Taiwain)

13:30 - 15:00 Hall F


Chairperson: M.C.M. Wong (Hong Kong, China) 269

NEUROPSYCHOLOGICAL PERFORMANCE IN PATIENTS WITH SOFT BIPOLAR SPECTRUM DURING A MAJOR DEPRESSIVE EPISODE 270

K. Lin, G. Xu, W. Lu, H. Ouyang, Y. Dang, K. So, T. Lee (Hong Kong China)

BIPOLARITY INDEX AS AN ASSESSMENT INSTRUMENT IN THE DIAGNOSIS AND ONE YEAR OUTCOME OF BIPOLAR DISORDERS 271

Y. Ma, X.I.N. Yu, T. Si, J.I.N.G. Li, Z. Liu, G.A.N.G. Wang, J.I.N.G. Sun, Y.I.R.U. Fang, H. Yang, Y. Zhang, X. Wang, S. Gary (China)

COMPARING COGNITIVE DEFICITS IN PATIENT WITH SOFT BIPOLAR DISORDER WITH THOSE WITH BIPOLAR I DISORDER 272

G. Xu, W. Lu, H. Ouyang, Y. Dang, Y. Guo, K. Lin (China)


13:30 - 16:30 Hall D

KOREAN ADVOCACY MEETING (IN KOREAN)


Chairperson: K. Ha (Korea) 273

13:30 INTRODUCTION 274K. Ha (Korea)

13:50 SHARING EXPERIENCE: LIVING WITH BIPOLAR DISORDER

14:30 BIPOLAR DISORDER: AN OVERVIEW 275Y.H. Joo (Korea)

15:00 HOW TO TREAT BIPOLAR DISORDER: UPDATE 276H.S. Cho (Korea)

15:30 MANAGEMENT OF EVERYDAY LIFE OF BIPOLAR PATIENTS 277H.J. Lee (Korea)

16:00 HOW TO HELP BIPOLAR PATIENTS: CAREGIVERS’ UNDERSTANDING AND ROLE 278S. Oh (Korea)

REGIONAL POSTER SESSIONTuesday, March 18, 2014

100

BOARD N°

REGIONAL POSTER SESSION TUESDAY, MARCH 18, 2014


REGIONAL POSTER SESSION

P-001 OLANZAPINE-INDUCED DIABETIC KETOACIDOSIS IN A SAUDI FEMALE 279

H. Al Amri (Saudi Arabia)

P-002 THE ASSOCIATION BETWEEN THYROID STIMULATING HORMONE (TSH) AND BRAIN-DERIVED NEUROTROPHIC FACTORS (BDNF) IN MAJOR DEPRESSIVE DISORDER 280

J.H. Baek, E.S. Kang, M. Fava, D. Mischoulon, B.H. Yu, D. Lee, H.D. Park, H.J. Jeon (USA)

P-003 NEUROCOGNITIVE IMPAIRMENTS IN INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS: WHO WILL REALLY CONVERT? 281

M.J. Bang, K.R. Kim, Y.Y. Song, J.Y. Park, S.Y. Baek, E. Lee, S.K. An (Korea)

P-004 STABILITY OF A DIAGNOSIS OF DEPRESSION IN ADMISSIONS TO A SPECIALIST MOOD DISORDERS UNIT IN SINGAPORE 282

N. Chandwani (Singapore)

P-005 CLINICAL FACTORS ASSOCIATED WITH COMORBID MAJOR DEPRESSIVE DISORDER IN PATIENTS WITH PANIC DISORDER 283

H.C. Chang, S.W. Lim, K.S. Oh (Korea)

P-006 EFFECTS OF GENETIC VARIATIONS IN NRG1 ON COGNITIVE DOMAINS IN PATIENTS WITH SCHIZOPHRENIA AND HEALTHY SUBJECTS 284

Y. Cho, S.H. Ryu, I.S. Huh, E.Y. Cho, H.J. Oh, Y.S. Lee, T.S. Park, K.S. Hong (Korea)

P-007 MENTAL DISORDERS IN OFFSPRING OF PARENTS WITH BIPOLAR DISORDERS IN KOREA 285

Y. Cho, S. Shim, Y. Kwon, H. Lee (Korea)

P-008 A CORRELATIONAL STUDY BETWEEN SOCIAL WITHDRAWAL AND PSYCHOPATHOLOGY AMONG KOREAN ADOLESCENT 286

T.Y. Choi, Y.J. Lee (Korea)

101REGIONAL POSTER SESSION TUESDAY, MARCH 18, 2014

BOARD N°

P-009 RELATIONSHIP BETWEEN EMOTIONAL DISTRESS, HEALTH RELATED QUALITY OF LIFE, AND GENETIC POLYMORPHISM IN THE KOREAN HEMODIALYSIS PATIENTS 287

W.J. Choi, J.H. Sohn, H.C. Park, J.H. Seok (Korea)

P-010 IMPROVEMENT IN OBJECTIVE AND SUBJECTIVE NEUROCOGNITIVE FUNCTION IN MELANCHOLIC AND NON-MELANCHOLIC SUBTYPES OF MAJOR DEPRESSIVE DISORDER AFTER 12-WEEK SELECTIVE SEROTONIN REUPTAKE ENHANCER(SSRE; TIANEPTINE) TREATMENT 288

J.Y. Heo, I.K. Yu, B.H. Yu (Korea)

P-011 THE RELATIONS AMONG QUALITY OF LIFE, NEUROCOGNITION AND PSYCHOPATHOLOGY OF ELDERLY SCHIZOPHRENIA 289

K.K. Hong, J.N. Lee, S.J. Yim, J.M. Kim, E.H. Na (Korea)

P-012 THE EFFECT OF PHYSICAL AND PSYCHO-SOCIAL STRESSORS ON MOOD CHANGES OF WOMEN REFERRING TO THE HEALTH CLINICS, SHIRAZ-IRAN 290

I. Jahanbin, G. Yadollahikhales (Iran)

P-013 DIFFERENCES IN DEPRESSIVE SYMPTOMS BETWEEN KOREAN AND AMERICAN OUTPATIENTS WITH MAJOR DEPRESSIVE DISORDER 291

H. Jeon, R.S. Walker, A. Inamori, J.P. Hong, M.J. Cho, L. Baer, A. Clain, M. Fava, D. Mischoulon (Korea)

P-014 KOREAN MEDICATION ALGORITHM PROJECT FOR BIPOLAR DISORDER 2014: RAPID CYCLING 292

J. Jeong, D.I. Jon, J.S. Seo, J.G. Lee, Y.S. Woo, M.D. Kim, I.G. Son, S.H. Shim, K.J. Min, Y.C. Shin, W.M. Bahk (Korea)

P-015 PREVALENCE STUDY OF SENILE DEMENTIA IN A RURAL AREA OF MINIA DISTRICT 293

N. Kamal, R. Sadek, M. El Sherif, F. Mosalem (Egypt)

P-016 FUNCTIONAL CONNECTIVITY MRI EVIDENCE OF THE EFFECT OF A 2-WEEK REPETITIVE TRANSCRANIAL MAGNETIC STIMULATION TREATMENT IN MAJOR DEPRESSION; A DOUBLE-BLIND SHAM CONTROLLED STUDY 294

J.I. Kang, H.L. Lee, J.M. Kim, K. Namkoong, E. Lee (Korea)

102

BOARD N°


P-017 CIRCADIAN PREFERENCE AND IMPULSIVITY: HIGH IMPULSIVITY IS RELATED TO EVENING TYPES 295

J.I. Kang, K.A. Cheon, H.W. Kim, C.I. Park, Y.Y. Nam, S.J. Kim (Korea)

P-018 SIMPLE SNORING SUBJECTS SHOWED MORE PSYCHIATRIC SYMPTOMS THAN OBSTRUCTIVE SLEEP APNEA PATIENTS IN SCL-90-R SCALE: PRELIMINARY DATA 296

S.G. Kang, H.J. Lee, K.S. Na, J.M. Kang, S.T. Kim, K.H. Park (Korea)

P-019 METABOLIC DISTURBANCES INDEPENDENT OF BODY MASS IN PATIENTS WITH SCHIZOPHRENIA TAKING ATYPICAL ANTIPSYCHOTICS 297

S. Kang, J.I. Lee (Korea)

P-020 TYPE OF PSYCHIATRIC WARD ON DEPRESSION PREVALENCE IN PSYCHIATRIC NURSE WHO WORKS IN RAZI HOSPITAL 298

S.H. Kavari, K. Nourozi (Iran)

P-021 COMPARISON STUDY OF THE PREVALENCE OF DEPRESSION IN WIDOW ELDERLY WHO LIVE IN NURSING HOME AND THE ELDERLY REMARRIAGE USE OF DAY CARE 299


P-022 SURVEY OF IMPACT RELIGIOUS PRETENTIOUSENESS AND HEDONISITIC IN RUNAWAY AND NON - RUNAWAY GRILS IN SHIRAZ 300

S.H. Kavari (Iran)

P-023 ASSESS TO THE EFFECTS OF TAI CHI CHUAN ON REDUCE IN WOMEN WITH ACUTE STRESS REACTION 301


P-024 SERIOUSNESS OF FIRST SUICIDE ATTEMPTER IS EQUIVALENT AS MULTIPLE SUICIDE ATTEMPTER: A PRELIMINARY ANALYSIS FROM KOREA NATIONAL SUICIDE SURVEY IN 2010 AND 2012 302

B. KIM, E.Y. KIM, K.S. HA, Y.M. Ahn (Korea)

P-025 DIAGNOSTIC UTILITY OF QUANTITATIVE EEG IN UN-MEDICATED SCHIZOPHRENIA 303

J. Kim (Korea)


BOARD N°

P-026 THE EFFECT OF ALPHA-LIPOIC ACID ON ATYPICAL ANTIPSYCHOTICS INDUCED WEIGHT GAIN AND METABOLIC ABNORMALITIES OF SCHIZOPHRENIA PATIENTS: A DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED TRIAL 304

N. Kim, Y. Song, E. Kim, H. Cho, S. Kim, J. Park (Korea)

P-027 EMOTIONAL DYSREGULATION, ATTRIBUTIONAL BIAS, NEUROCOGNITIVE IMPAIRMENT IN ULTRA-HIGH RISK FOR PSYCHOSIS AND SCHIZOPHRENIA: ITS ASSOCIATION WITH PARANOIA 305

N. Kim, Y. Song, J. Park, S. Baek, J. Kang, E. Lee, S. An (Korea)

P-028 THE ASSOCIATION BETWEEN THE COMT VAL158MET POLYMORPHISM AND ALEXITHYMIA IN OBSESSIVE-COMPULSIVE DISORDER 306

M.J. Koh, J.I. Kang, H.W. Kim, K. Namkoong, S.J. Kim (Korea)

P-029 UPPER AIRWAY RESISTANCE SYNDROME PATIENTS TEND TO BE MORE NEUROTIC, ANXIOUS AND SENSITIVE THAN OBSTRUCTIVE SLEEP APNEA SYNDROME 307

S.J. So, H.J. Lee, S.G. Kang, C.H. Cho, H.K. Yoon, K.Y. Jung, C.S. Han, L. Kim (Korea)

P-030 ASSOCIATION OF THE RORA GENE POLYMORPHISM AND SEASONAL VARIATIONS IN MOOD AND BEHAVIOR 308

H.I. KIm, S.J. So, H.J. Yang, H.M. Song, J.H. Moon, H.K. Yoon, S.G. Kang, Y.M. Park, S.H. Lee, H.G. Jeong, L. Kim, H.J. Lee (Korea)

P-031 HIGH ALTITUDE REMAINS ASSOCIATED WITH ELEVATED SUICIDE RATES AFTER ADJUSTING FOR SOCIOECONOMIC STATUS: A STUDY FROM SOUTH KOREA 309

J. Kim, N. Choi, Y.J. Lee, H. An, N. Kim, M.S. Lee, E.S. Won, H.J. Lee (Korea)

P-032 ASSOCIATION OF SLEEP IRREGULARITY WITH ‘FIRST-NIGHT EFFECT’ IN YOUNG ADULT MALE SUBJECTS 310

D.H. Lee, C.H. Cho, H.K. Yoon, S.G. Kang, S.H. Son, Y.K. Kim, S.H. Kim, K.N. Bok, E.I. Lee, H.J. Lee, L. Kim (Korea)

P-033 IMPROVEMENT ON DYSLIPIDEMIA AND NEGATIVE SYMPTOMS BY ZIPRASIDONE AUGMENTATION IN CLOZAPINE-RESISTANT PATIENTS WITH SCHIZOPHRENIA 311

H.B. Lee, S.J. Yim, M. Sim (Korea)

104

BOARD N°


P-034 SUBJECTIVE DEPRESSIVE SYMPTOMS AND METABOLIC SYNDROME IN GENERAL POPULATION 312

S.J. Rhee, E.Y. Kim, S.H. Kim, H.J. Lee, B. Kim, D.H. Yoon, Y.M. Ahn (Korea)

P-035 A STUDY ON CHANGE OF METABOLIC PARAMETERS WITH ANTIPSYCHOTIC TREATMENT IN SCHIZOPHRENIC PATIENTS: 12-MONTH PROSPECTIVE NATUALISTIC STUDY 313

I.S. Hwang, J. Lee (Korea)

P-036 RISK FACTOR FOR EXECUTIVE COGNITIVE DYSFUNCTION IN ALCOHOLICS 314

K.S. LEE (Korea)

P-037 COMPARING STRESS PERCEPTION AND LEISURE TYPE PREFERENCE BETWEEN SMOKING AND NONSMOKING CASINO EMPLOYEES 315

T. LEE, C.K. LEE, H.M. LEE, H.J. Shaffer (Korea)

P-038 THE DIFFERENCES BETWEEN IMPULSIVE SUICIDE ATTEMPTS AND NON-IMPULSIVE SUICIDE ATTEMPTS 316

M. Lim, S.W. Kim, Y.Y. Nam, E. Moon, J. Yu, S. Lee, J.S. Chang, J.H. Jhoo, B. Cha, J.S. Choi, J.I. Park (Korea)

P-039 VARIABLES INFLUENCING SUBJECTIVE WELL-BEING IN PATIENTS WITH SCHIZOPHRENIA 317

J.S. Oh, Y.H. Ko, J.W. Paik, M.S. Lee, C.S. Han, H.G. Jeong, S.H. Kim (Korea)

P-040 CHANGES OF PLASMA CATECHOLAMINE LEVELS AFTER PAROXETINE TREATMENT IN PANIC DISORDER PATIENTS 318

J.Y. Oh, J.Y. Heo, B.H. Yu (Korea)

P-041 CLINICAL DETERMINANTS AND COGNITIVE EFFECTS OF ANTIPSYCHOTIC POLYPHARMACY FOR KOREAN PATIENTS WITH SCHIZOPHRENIA AND SCHIZOAFFECTIVE DISORDER 319

J. Choi, S. Kang, J. Lee, Y. Ha, H. Yoon, E. Park, D. Park (Korea)

P-042 A STUDY ON RELIABILITY AND VALIDITY OF THE KOREAN VERSION OF IMPACT OF FUTURE EVENTS SCALE 320

E. Park, S. Choi, I.C. Jung (Korea)


BOARD N°

P-043 NEURAL NETWORKS INVOLVED IN SELF-REFERENTIAL PROCESSING AND PERSPECTIVE TAKING IN HEALTHY PEOPLE: ITS ASSOCIATION WITH THEORY OF MIND ABILITY AND ANOMALOUS SELF EXPERIENCE 321

K. Park, H.Y. Park, M. Bang, S.K. An (Korea)

P-044 NEURAL NETWORKS INVOLVED IN SELF-REFERENTIAL PROCESSING AND PERSPECTIVE TAKING IN HEALTHY PEOPLE: ITS ASSOCIATION WITH THEORY OF MIND ABILITY AND ANOMALOUS SELF EXPERIENCE 322

K. Park, H.Y. Park, M. Bang, S.K. An (Korea)

P-045 MULTIPLE OSCILLATORS ASSURE SOFT MARGIN OF DIURNAL FUNCTION AND ARE THE RESULT OF ALTERNATE SPLICING AND LATER GENETIC REARRANGEMENT: POSSIBLE ROLE IN BIPOLAR DISORDER 323

K. Pirkalani, Z. Talaeerad, H. Bigdeli (Iran)

P-046 BIPOLAR MOOD DISORDER (BMD) IS THE RESULT OF AMBIGUITY BETWEEN MASTER AND SLAVE CIRCADIAN OSCILLATOR 324

K. Pirkalani, Z. Talaeerad (Iran)

P-047 GENERAL RESULTS OF PERSONALITY SCORES OF BIPOLAR PATIENTS STUDIED BY MCMI-III DURING INTER-ATTACK PERIODS AND RELEVANCE TO CLINICAL COURSE 325

K. Pirkalani, Z. Talaeerad, H. Bigdeli, M. Nazari, R. Khodabakhsh Pirkalani (Iran)

P-048 BIPOLAR MOOD DISORDER BMD CAN BE CLASSIFIED INTO 4-5 BROAD MOLECULAR CATEGORIES BASED ON PARAMETRIC OSCILLATION THEORY AND SIGNS AND SYMPTOMS 326

K. Pirkalani, Z. Talaeerad, M. Mehdizadeh, M. Saghaei, M. Nazari (Iran)

P-049 DESCRIPTION OF DEPRESSION’S LEVEL IN STUDENTS OF MEDICAL FACULTY UNIVERSITY OF MUHAMMADIYAH JAKARTA 2013 327

R. Rifa Imaroh, I.N.G.E. Inge Dackrisna Daud, I.R.F.A. Irfa Irawati (Indonesia)

P-050 PREVALENCE AND CORRELATES OF SUICIDAL BEHAVIOR: A NATIONWIDE STUDY OF KOREAN MEDICAL STUDENTS 328

M. Roh, H. Lee, M.J. Cho, B.J. Hahm (Korea)

106

BOARD N°


P-051 SOCIO-DEMOGRAPHIC FACTORS ASSOCIATED WITH THE USE OF MENTAL HEALTH SERVICES IN DEPRESSED ADULTS: RESULTS FROM THE KOREA NATIONAL HEALTH AND NUTRITION EXAMINATION SURVEY (KNHANES) 329

S. Roh, M. Soh, S.J. Park, H.J. Jeon, J.Y. Kim, S. Kim (Korea)

P-052 DIAGNOSING BIPOLAR DISORDER IN SEVERELY INTELLECTUALLY DISABLED PATIENTS- A CHALLENGE WORTH TAKING! 330

S. Sajith, A. Su (Singapore)

P-053 ASSESSMENT OF RISK TAKING AND IMPULSIVE BEHAVIORS IN OBSESSIVE-COMPULSIVE DISORDER 331

S.J. Kim, S.Y. Sohn, D.H. Song, H.W. Kim, J.I. Kang, C.I. Park (Korea)

P-054 IMPACT OF HIV/AIDS ON THE ELDERLY: A CASE STUDY OF CHIRADZULU DISTRICT IN MALAWI 332

A. Sefasi, A.P. Sefasi (Malawi)

P-055 A PILOT STUDY OF THE EFFECTIVENESS OF ISLAMIC COGNITIVE THERAPY (ICT) THERAPY IN MANAGING DEPRESSION AND CONTROLLING SMOKING 333

T. Seghatoleslam, H. Habil (Malaysia)

P-056 KOREAN MEDICATION ALGORITHM FOR BIPOLAR DISORDER 2014: DEPRESSIVE EPISODE 334

J. SEO, W.M. Bahk, J.G. Lee, Y.S. Woo, J.H. Joeng, M.D. Kim, I.G. Son, Y.J. Min, D.I. Jon, Y.C. Shin, B.H. Yoon (Korea)

P-057 ASSOCIATIONS OF DEPRESSION AND EMOTIONAL EATING IN BARIATRIC SURGERY PATIENTS 335

G. Sevincer, N. Konuk (Turkey)

P-058 INFLUENCE OF POSITIVE THINKING IN DEPRESSIVE SYMPTOMS IN MAJOR DEPRESSIVE DISORDER 336

E. Shin, K.S. Oh (Korea)


BOARD N°

P-059 THE RELATIONSHIPS BETWEEN POST-TRAUMATIC STRESS SYMPTOMS, DEPRESSIVE SYMPTOMS, AND STRESS COPING STRATEGIES IN CIVIL AFFAIRS OFFICIALS 337

J.A. Kim, M. SIm, K.A. Jeong, D.S. Yong, H.B. Lee, I.Y. Kang, J.I. Yang, O.J. Kim, Y.R. Lee (Korea)

P-060 THE EFFECTS OF EXPOSURE TO TRAUMATIC EVENTS AND PERSONALITY DIMENSIONS ON POST-TRAUMATIC STRESS SYMPTOMS IN POLICE OFFICERS 338

O.J. Kim, M. Sim, J.I. Yang, I.Y. Kang, H.B. Lee, K.A. Jeong, J.A. Kim, D.S. Yong, Y.R. Lee (Korea)

P-061 SELF-REPORTED EMPATHIC ABILITIES IN SCHIZOPHRENIA AND ULTRA-HIGH RISK FOR PSYCHOSIS 339

Y. Song, K. Jhung, Y. Nam, S. An (Korea)

P-062 LONG-TERM USE OF RISPERIDONE IN KOREAN CHILDREN AND ADOLESCENTS WITH AUTISM SPECTRUM DISORDERS 340

E. Won, J. Park, J. Choi, H. Min, Y. Kim (Korea)

P-063 KOREAN MEDICATION ALGORITHM FOR BIPOLAR DISORDER 2014: MANIC EPISODE 341

Y.S. Woo, W.M. Bahk, D.I. Jon, J.S. Seo, J.G. Lee, J.H. Jeong, M.D. Kim, I.G. Son, S.H. Shim, K.J. Min, B.H. Yoon, Y.C. Shin (Korea)

P-064 RELATIONS OF SELF-ESTEEM WITH PARANOIA IN HEALTHY CONTROLS, INDIVIDUALS AT ULTRA-HIGH RISK FOR PSYCHOSIS AND WITH RECENT ONSET SCHIZOPHRENIA 342

H. Yoon, Y.Y. Song, J.I. Kang, S.K. An (Korea)

P-065 THE RELATION BETWEEN DEPRESSION AND DOODLES 343

M. Zokaee (Iran)

108

BOARD N°


POSTER SESSION IWednesday, March 19, 2014

110

BOARD N°

POSTER SESSION 1 WEDNESDAY, MARCH 19, 2014


SESSION I

P-001 LATERAL HYPOTHALAMIC KINDLING INDUCES MANIC-LIKE BEHAVIOR IN RATS: A NOVEL ANIMAL MODEL 344

O. Abulseoud, U.M. Camsari, C.L. Ruby, K. Mohamed, N. Abdel Gawad, A. Kasabeh, M.Y. Yuksel, D.S. Choi (USA)

P-002 NEUROMODULATION OF THE DLPFC INDUCED BY RTMS ASSESSED WITH OCULOMOTRICITY AND CORTICAL EXCITABILITY IN BIPOLAR DISORDER 345

L. Beynel, A. Chauvin, N. Guyader, S. Harquel, T. Bougerol, C. Marendaz (France)

P-003 SACCADIC INHIBITION - A TRAIT BIOMARKER OF BIPOLAR DISORDER 346

A. Chauvin, N. Guyader, L. Beynel, S. Harquel, B. Fredembach, T. Bougerol, C. Marendaz, M. Polosan (France)

P-004 EPIGENETIC REGULATION OF EAAT2 (SLC1A2) IN BIPOLAR DISORDER PATIENTS 347

J. Ayers Ringler, N. Kang, Y. Choi, D. Choi, M. Veldic (USA)

P-005 SERUM MYELIN OLIGODENDROCYTE GLYCOPROTEIN LEVELS ARE STABLE IN DEPRESSED FEMALES WITH BIPOLAR DISORDER 348

M. Sehmbi, L. Cudney, R.B. Sassi, M. Steiner, B.N. Frey (Canada)

P-006 MOOD AND COGNITION IN BIPOLAR DISORDER - THE ASSOCIATION WITH GLYCOGEN SYNTHASE KINASE-3 BETA 349

A.S. Jacoby, M. Vinberg, K. Munkholm, L. Kessing (Denmark)

P-007 STRONG EVIDENCE FOR AN ASSOCIATION BETWEEN ELECTRODERMAL HYPOREACTIVITY AND SUICIDE PROPENSITY IN BIPOLAR DISORDER 350

W. Kaschka, L.H. Thorell, S. Hodgkinson, J. Steyer, R. Straub, M. Wolfersdorf, M. Jandl (Germany)

P-008 METABOLIC PARAMETERS IN FIRST EPISODE MANIA 351

S. Kesebir, E. Tatlidil Yaylaci, N. Atgüden, M. Altintas (Turkey)

111 POSTER SESSION 1 WEDNESDAY, MARCH 19, 2014

BOARD N°

P-009 THYROID FUNCTIONING IN FIRST EPISODE MANIA 352

S. Kesebir, E. Tatlidil Yaylaci, N. Atgüden, M. Altintas (Turkey)

P-010 ARE ICAM, VCAM AND E-SELECTIN LEVELS DIFFERENT IN FIRST MANIC EPISODE AND SUBSEQUENT REMISSION? 353

S. Kesebir, C. Turan (Turkey)

P-011 SEROTONERGIC DYSFUNCTION IN PATIENTS WITH BIPOLAR DISORDER ASSESSED BY THE LOUDNESS DEPENDENCE OF THE AUDITORY EVOKED POTENTIAL (LDAEP) 354

S. Lee (Korea)

P-012 INFLUENCE OF AHI1 VARIANTS ON DIAGNOSIS AND TREATMENT OUTCOME IN MOOD DISORDERS 355

C. Pae, S. Porcelli, B. Balzarro, O. Bianchini, C. Han, S. Lee, S. Lee, P.S. Masand, A. Serretti (Korea)

P-013 QUANTITATIVE ELECTROENCEPHALOGRAM (QEEG) FINDINGS SUGGESTING BIPOLARITY IN PATIENTS WITH DEPRESSIVE EPISODE: A PRELIMINARY REPORT 356

S. Ryu, H. Jeon, B. Lee, Y. Cho, Y. Kim, E. Lee, S. Yoon, K. Hong, B. Yu (Korea)

P-014 LITHIUM AMELIORATES ROTENONE-INDUCED METHYLATION AND HYDROXYMETHYLATION OF DNA IN CORTICAL PRIMARY NEURONS 357

G. Scola, H.H. Kim, M. Salvador, L.T. Young, A.C. Andreazza (Canada)

P-015 CORRELATION BETWEEN PERIPHERAL BDNF LEVELS AND HIPPOCAMPUS VOLUME IN CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER 358

T.L. Peruzzolo, M. Anes, G.L.C.L. Motta, L.S. Motta, A.C. Louredo, J.B. Brun, R. Rodrigues, F. Kapczinski, S. Tramontina, C.P. Zeni (Brazil)

P-016 AMYGDALAR VOLUMETRIC CORRELATES OF SOCIAL ANXIETY IN BIPOLAR OFFSPRING WITH SUBTHRESHOLD MOOD SYMPTOMS AND HIGH SOCIAL ANXIETY 359

M.H. Park, A. Garrett, S. Boucher, M. Howe, E.M. Sanders, J.G. Pearlstein, M.K. Singh, K.D. Chang (USA)

P-017 LAMOTRIGINE TREATMENT OF ADOLESCENTS WITH UNIPOLAR AND BIPOLAR DEPRESSION: A RETROSPECTIVE CHART REVIEW 360

S.H. Shon, H.W. Kim, Y.H. Joo, J.S. Lee (Korea)

112

BOARD N°


P-018 CIRCADIAN RHYTHM DISRUPTION IN WOMEN WITH BIPOLAR AND PREMENSTRUAL DYSPHORIC DISORDER DURING REMISSION: PRELIMINARY RESULTS 361

S.K. Syan, M. Smith, N. Snelgrove, M. Sehmbi, O. Allega, L. Minuzzi, B.N. Frey (Canada)

P-019 DOES PREGNANCY AFFECT CIRCADIAN RHYTHMS IN WOMEN WITH MOOD DISORDERS DURING REMISSION? 362

E. Krawczak, M. Sehmbi, B.N. Frey (Canada)

P-020 IRREGULARITY IN SLEEP AND MEALTIME IN THE PATIENTS WITH BIPOLAR DISORDERS: A PRELIMINARY STUDY 363

E. Joo, E. Kim, K. Lee, C.W. Yeom (Korea)

P-021 SEASONALITY AND ITS DISTINCT CLINICAL CORRELATES IN BIPOLAR II DISORDER: A COMPARISON STUDY WITH BIPOLAR I DISORDER AND MAJOR DEPRESSIVE DISORDER 364

J. Kim, T.H. Ha, Y.S. Park, J.S. Chang, J. Kim, K.S. Hong, K.S. Ha (Korea)

P-022 CHANGES IN SLEEP ARCHITECTURE AND QUALITY IN MINIMAL HEPATIC ENCEPHALOPATHY PATIENTS AND RELATIONSHIP TO PSYCHOLOGICAL DYSFUNCTION 365

C. Liu, J. Zhou (China)

P-023 ULTRA-BRIEF RIGHT UNILATERAL ECT IS RAPIDLY EFFECTIVE IN AMELIORATING SEVERE MANIA-A CASE SERIES 366

P. Mayur, A. Sidorov, A. Harris (Australia)

P-024 OSTEOPOROSIS: A NEGLECTED MEDICAL CO-MORBIDITY IN MOOD DISORDERS 367

M. Berk, J.A. Pasco, F.N. Jacka, J.M. Hodge, A. Stuart, A. Torpy, S. Dodd, L. Williams, Y. Gilbert (Australia)

P-025 CIRCADIAN GENES AND RISK OF THE METABOLIC SYNDROME IN PATIENT WITH BIPOLAR DISORDERS 368

E.Y. Kim, Y.M. Ahn, S.H. Kim (Korea)

P-026 COULD METABOLIC SYNDROME COMORBIDITY IN BIPOLAR DISORDER BE OVERRATED?: A STUDY OF METABOLIC SYNDROME IN YOUNG SUBPOPULATION OF BIPOLAR DISORDER PATIENTS 369

N. Yalin, O.U. Agdanli, G. Ergör, Z. Tunca, S. Vitoratou, A. Ozerdem (Turkey)


BOARD N°

P-027 ARE EEG SPECTRAL POWER DENSITY OF BD I AND II DIFFERENT? 370

S. Kesebir, S. Sayakçi Gürdal, R.M. Demirer (Turkey)

P-028 CANNABIS USE IN FIRST EPISODE BIPOLAR DISORDER IS ASSOCIATED WITH ELEVATED MOOD AFTER ONE YEAR 371

L. Kvitland, P.A. Ringen, S.R. Aminoff, O.A. Andreassen, C. Demmo, T.V. Lagerberg, I.S. Melle (Norway)

P-029 CLINICAL AND BIOLOGICAL CHARACTERISATION OF YOUNGPEOPLE AT HIGH GENETIC RISK FOR BIPOLAR DISORDER 372

P. Mitchell (Australia)

P-030 LONGITUDINAL CHANGE OF THE STATE OF METABOLIC SYNDROME IN PATIENTS WITH BIPOLAR DISORDER 373

N.Y. Lee, S.H. Kim, Y.S. Kim, Y.M. Ahn (Korea)

P-031 ASSOCIATION OF SERUM BDNF WITH VERBAL AND VISUAL MEMORY DEFICIT IN SUBJECTS WITH BIPOLAR DISORDER-I 374

B. Chatterjee, A. Sahu, R. Sagar, S. Vivekanandan (India)

P-032 STUDY TO DETERMINE APPROPRIATE TIME FOR SERUM LEVEL ESTIMATION FOR ONCE A DAY ADMINISTRATION OF DIVALPROEX SODIUM EXTENDED RELEASE PREPARATIONS 375

S. Damegunta, M. S Reddy (India)

P-033 STUDY TO DETERMINE APPROPRIATE TIME FOR SERUM LEVEL ESTIMATION FOR ONCE A DAY ADMINISTRATION OF LITHIUM 376

S. Damegunta, M. S Reddy (India)

P-034 ANTIPSYCHOTIC USE AND DIFFERENTIAL MONITORING OF CARDIOMETABOLIC HEALTH IN PATIENTS WITH BIPOLAR DISORDER COMPARED TO PATIENTS WITH PRIMARY PSYCHOTIC DISORDERS 377

J. Kamath, R. Singh (USA)

P-035 EFFECT OF MEDITATION ON REDUCE IN GIRLS WITH ACUTE STRESS REACTION IN TEHRAN MEDITATION SOCIETY IN 2013 378


P-036 MAINTENANCE ECT FOR BIPOLAR DISORDER 379

O. Koh, H. Habil (Malaysia)

114

BOARD N°


P-037 COMPARISON OF BRAIN WHITE MATTER CONNECTIVITY BETWEEN PANIC DISORDER WITH AND WITHOUT COMORBID BIPOLAR DISORDER 380

S. Kim, M.K. Kim, B. Kim, S.H. Lee (Korea)

P-038 MIRROR NEURON ACTIVITY AND SYMPTOM DIMENSIONS IN DRUG-NAÏVE MANIA- A TRANSCRANIAL MAGNETIC STIMULATION STUDY 381

R. Basavaraju, U.M. Mehta, J. Thirthalli (India)

P-039 MATERNAL OXYTOCIN TO INDUCE LABOR INCREASES THE RISK FOR OFFSPRING BIPOLAR DISORDER AND IMPAIRED COGNITION 382

D. Freedman, Y. Bao, L. Shen, C.A. Schaefer, A.S. Brown (USA)

P-040 A GENOME-WIDE ASSOCIATION STUDY OF BIPOLAR DISORDER USING A SUBPHENOTYPE: SLEEPLESSNESS BIPOLAR MANIA 383

H. Lee, C. Cho, H. Woo, T. Greenwood, D. Kripke, J. Kelsoe (Korea)

P-041 CROSS-DISORDER GWAS OF ADHD AND BIPOLAR DISORDER 384

A. Reif, K. Van Hulzen, C.J. Scholz, A. Arias-Vasquez, K.P. Lesch, S.V. Faraone, B. Franke (Germany)

P-042 SOCIOECONOMIC DECISION MAKING IN MANIC AND EUTHYMIC PATIENTS WITH BIPOLAR DISORDER: THE FEEDBACK-RELATED NEGATIVITY STUDY 385

R.Y. Ha, V. RYU, S.J. Lee, H.S. Ryu, H.S. Cho (Korea)

P-043 ELECTROPHYSIOLOGICAL FINDING OF SYNTACTIC ANOMALIES IN PATIENTS WITH BIPOLAR DISORDER AND SCHIZOPHRENIA: A P600 STUDY 386

C.W. Lee, V. RYU, R.Y. Ha, S.J. Lee, H.S. Ryu, H.S. Cho (Korea)

P-044 EFFECTS OF ANTIPSYCHOTIC DRUGS ON THE EXPRESSION OF SYNAPSE-ASSOCIATED PROTEINS IN THE FRONTAL CORTEX OF RATS SUBJECTED TO IMMOBILIZATION STRESS 387

C.H. Lee, M.K. Seo, H.Y. Cho, J.G. Lee, B.J. Lee, S.W. Park, Y.H. Kim (Korea)

P-045 EFFECTS OF MOOD-STABILIZING DRUGS ON DENDRITIC OUTGROWTH AND SYNAPTIC PROTEINS LEVELS IN THE PRIMARY HIPPOCAMPAL NEURONS 388

C.H. Lee, M.K. Seo, J.G. Lee, B.J. Lee, S.W. Park, Y.H. Kim (Korea)


BOARD N°

P-046 EFFECTS OF TIANEPTINE ON MTOR SIGNALING IN RAT HIPPOCAMPAL NEURONS 389

M.K. Seo, C.H. Lee, H.Y. Cho, S.W. Park, B.J. Lee, W.G. Seol, J.G. Lee, H.Y. Kim (Korea)

P-047 DNA METHYLATION ANALYSIS OF QUETIAPINE: POSSIBLE ROLE AS A MOOD STABILIZER 390

H. Sugawara, M.B. Bundo, T.A. Asai, F.S. Sunaga, J.U. Ueda, J.I. Ishigooka, K.K. Kasai, T.K. Kato, K.I. Iwamoto (Japan)

P-048 THE EFFECT OF VITAMIN D TREATMENT ON GLIA DERIVED NEUROTROPHIC FACTOR IN CORTICAL NEURONS 391

S. Yilmazer, T. Ulutin, E. Dursun, D. Gezen-Ak (Turkey)

P-049 NEUROANATOMICAL PREDICTORS OF PSYCHOEDUCATION RESPONSE IN EUTHYMIC BIPOLAR PATIENTS: A VOXEL-BASED MORPHOMETRIC STUDY 392

P. Favre, M. Baciu, A. Perrin, C. Pichat, T. Bougerol, M. Polosan (France)

P-050 HIPPOCAMPAL VOLUMES ARE CORRELATED TO INFLAMMATORY MARKERS IN EARLY STAGE BIPOLAR DISORDER 393

M. Vianna-Sulzbach, P.D. Goi, R. Massuda, M. Vasconcelos-Moreno, B. Panizzutti, G. Colpo, R. Reckziegel, M. Costanzi, B.T. Dos Santos, M.D. Curra, S.L. Polita, J.A. Duarte, A.L. Teixeira, F. Kapczinski, C.S. Gama (Brazil)

P-051 REGIONAL GRAY MATTER VOLUME ABNORMALITIES RELATED TO CYCLOTHYMIA IN FEMALE SUBJECTS WITH BIPOLAR II DISORDER 394

T.H. Ha, J.S. Kim, J.Y. Her, J.H. Kim, J.S. Chang, D.Y. Lee, K. Ha (Korea)

P-052 THE EFFECT OF CORTISOL AND BDNF ON SEROTONIN TRANSPORTER IN BIPOLAR I DISORDER 395

W.C. Hsieh, Y.T. Jou, J.L. Lin, S.J. Wang, Y.H. Chou (Taiwan)

P-053 NEUROANATOMICAL CORRELATES OF INHIBITED TEMPERAMENT IN OFFSPRING OF PARENTS WITH BIPOLAR DISORDER 396

E.J. Kim, A. Garrett, S. Boucher, M. Howe, E. Sanders, A. Reiss, M. Singh, K.D. Chang (USA)

116

BOARD N°


P-054 REGIONAL GRAY MATTER VOLUME ALTERATIONS RELATED TO PREDOMINANT POLARITY IN BIPOLAR I DISORDER 397

J. Kim, T.H. Ha, J.Y. Her, J. Kim, J.S. Chang, K. Ha (Korea)

P-055 CORRELATION BETWEEN NEUROFUNCTIONAL AND NEUROCOGNITIVE PERFORMANCE OF BD I EUTHYMIC PATIENTS 398

C. Lopez Jaramillo, C. Vargas, M. Valencia-Escobar, A. Vanegas, S. Rascovsky (Colombia)

P-056 THE EFFECTS OF LITHIUM ON BRAIN FUNCTION: PRELIMINARY NEURAL NETWORK CHANGES 399

G. Curran, P. Das, K. Fritz, G.S. Malhi (Australia)

P-057 BIPOLAR AND BORDERLINE PATIENTS DISPLAY DIFFERENTIAL PATTERNS OF FUNCTIONAL CONNECTIVITY AMONG RESTING STATE NETWORKS 400

P. Das, V. Calhoun, G.S. Malhi (Australia)

P-058 ALTERED AUDITORY STEADY-STATE MAGNETIC FIELDS IN BIPOLAR DISORDERS: A SOURCE LOCALIZATION STUDY 401

Y. Oda, N. Hironaga, S. Hirano, R. Tsuchimoto, T. Maekawa, T. Onitsuka, S. Tobimatsu, S. Kanba (Japan)

P-059 REDUCED ACTIVATION OF THE TEMPORAL CORTEX IN PATIENTS WITH EUTHYMIC BIPOLAR DISORDER DURING A VERBAL FLUENCY TASK: A MULTI-CHANNEL NEAR-INFRARED SPECTROSCOPY STUDY 402

N. Tsujii, W. Mikawa, H. Akashi, E. Tsujimoto, E. Kirime, T. Adachi, M. Takaya, H. Ono, M. Yanagi, O. Shirakawa (Japan)

P-060 REDUCTION OF LEFT TEMPORAL CORTEX ACTIVATION IN SUICIDE ATTEMPTERS WITH BIPOLAR DISORDER AFTER A VERBAL FLUENCY TASK: A MULTI-CHANNEL NEAR-INFRARED SPECTROSCOPY STUDY 403

N. Tsujii, W. Mikawa, E. Tsujimoto, E. Kirime, H. Akashi, M. Takaya, M. Yanagi, T. Adachi, H. Ono, O. Shirakawa (Japan)

P-061 DENSE CRANIAL ELECTROACUPUNCTURE STIMULATION, A NOVEL BRAIN STIMULATION THERAPY FOR MOOD DISORDERS: RATIONALE AND CLINICAL TRIALS 404

Z. Zhang (Hong Kong China)


BOARD N°

P-062 EFFICACY OF CARIPRAZINE IN PATIENTS WITH ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER: RESULTS FROM 2 PHASE III, PLACEBO-CONTROLLED TRIALS 405

J. Calabrese, K. Lu, I. Laszlovszky, M. Debelle, W. Earley, S. Durgam (USA)

P-063 SAFETY AND TOLERABILITY OF CARIPRAZINE IN PATIENTS WITH ACUTE MANIC OR MIXED EPISODES ASSOCIATED WITH BIPOLAR I DISORDER: RESULTS FROM 2 PHASE III PLACEBO-CONTROLLED TRIALS 406

T. Ketter, K. Lu, M. Debelle, I. Laszlovszky, S. Durgam, W. Earley (USA)

P-064 OLANZAPINE INDUCED PROLONGED THROMBOCYTOPENIA 407

N. Kathirvel, J. Xiao, C. Ankur, S. Naik (Singapore)

P-065 CLINICAL SATISFACTION AND PREFERENCE BETWEEN ORAL AND LONG-ACTING INJECTABLE MEDICATION: VIEWS FROM PSYCHIATRISTS 408

J. Lee (Taiwan)

P-066 EFFECT OF LURASIDONE MONOTHERAPY OR ADJUNCTIVE THERAPY ON ANXIETY SYMPTOMS IN PATIENTS WITH BIPOLAR I DEPRESSION 409

J. Cucchiaro, A. Pikalov, J. Hsu, H. Kroger, A. Loebel (USA)

P-067 SHORT- AND LONGER-TERM TREATMENT WITH LURASIDONE IN PATIENTS WITH BIPOLAR I DEPRESSION: EFFECT ON METABOLIC SYNDROME 410

S. McElroy, A. Pikalov, J. Cucchiaro, J. Hsu, H. Kroger, D. Phillips, A. Loebel (USA)

P-068 EFFICACY AND SAFETY OF TREATMENT WITH LURASIDONE ADJUNCTIVE WITH LITHIUM OR VALPROATE IN BIPOLAR I DEPRESSION: RESULTS OF TWO 6-WEEK STUDIES 411

J. Calabrese, T. Suppes, K. Sarma, R. Silva, H. Kroger, J. Cucchiaro, A. Pikalov, A. Loebel (USA)

P-069 MOOD-STABILIZING MEDICATION AFTER HOSPITALIZATION FOR BIPOLAR DISORDER IN SWEDEN: A REGISTER-BASED COHORT STUDY 412

J. Reutfors, L. Scheen, L. Brandt, R. Bodén, A. Tanskanen, M. Andersen, J. Tiihonen (Sweden)

P-070 EFFICACY OF LITHIUM IN THE LONG-TERM TREATMENT OF BIPOLAR DISORDERS: A NEW META-ANALYSIS 413

E. Severus, M. Taylor, C. Sauer, A. Pfennig, M. Bauer, J. Geddes (Germany)

118

BOARD N°


P-071 A PROSPECTIVE 4 YEARS NATURALISTIC FOLLOW UP OF 300 BIPOLAR I & BIPOLAR II PATIENTS 414

C. Simhandl, B. König, B. Amann (Austria)

P-072 PREDICTORS OF ADHERENCE TO PSYCHOPHARMACOLOGICAL AND PSYCHOSOCIAL TREATMENT IN BIPOLAR I OR II DISORDERS - AN 18-MONTH PROSPECTIVE STUDY 415

K. Suominen, P. Arvilommi, O. Mantere, S. Leppämäki, H.V. Valtonen, E. Isometsä (Finland)

P-073 MAINTENANCE TREATMENT IN PATIENTS WITH BDII MISDIAGNOSED AS RDD IN RUSSIA 416

S.N. Mosolov, A.V. Ushkalova, E.G. Kostukova, A.A. Shafarenko (Russia)

P-074 GUIDELINES CONCORDANCE FOR ACUTE BIPOLAR DEPRESSION IN MAINLAND CHINA 417

Z. Wang, W. Hong, M. Xing, Z. Wu, J. Chen, Y. Fang (China)

P-075 GUIDELINES CONCORDANCE FOR ACUTE MANIC AND MIXED EPISODES IN MAINLAND CHINA 418

Z. Wang, W. Hong, M. Xing, Z. Wu, J. Chen, Y. Fang (China)

P-076 EFFECTIVENESS OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS IN PATIENTS WITH BIPOLAR I DISORDER 419

Y.C. Yen, C.Y. Huang (Taiwan)

P-077 PSYCHOPHARMACOLOGICAL TREATMENT OF BIPOLAR DISORDER IN PREGNANCY: RECOMMENDATIONS AND CLINICAL MONITORING SYSTEMS 420

M. Snellen, M. Assoc. Prof. Galbally (Australia)

P-078 LURASIDONE IN BIPOLAR I DEPRESSION: A 24 WEEK, OPEN-LABEL EXTENSION STUDY 505

T.A. Ketter, A. Pikalov, K. Sarma, R. Silva, H. Kroger, J. Cucchiaro, A. Loebel (USA)

P-079 EFFICACY AND SAFETY OF LURASIDONE IN BIPOLAR DEPRESSION: RESULTS FROM TWO, DOUBLE BLIND, PLACEBO-CONTROLLED STUDIES 506

A. Loebel, A. Pikalov, J. Cucchiaro, R. Silva, K. Sarma, H. Kroger, J. Calabrese, G. Sachs (USA)

POSTER SESSION IIThursday, March 20, 2014

120

BOARD N°

POSTER SESSION 2 THURSDAY, MARCH 20, 2014


SESSION II

P-001 SMOKING DURING PREGNANCY AND THE RISK OF BIPOLAR DISORDER 421

R. Chudal, M. Gissler, A. Suominen, A.S. Brown, A. Sourander (Finland)

P-002 STANDARDIZATION OF BIPOLAR DEPRESSION RATING SCALE (BDRS) IN KOREAN CHILDREN AND ADOLESCENTS WITH BIPOLAR DISORDER: PRELIMINARY ANALYSIS 422

D.Y. Lee, E.K. Won, J.W. Choi, H.J. Min, K.S. Ha, J.S. Chang, Y. Kim (Korea)

P-003 OPPORTUNITIES AND CHALLENGES IN ESTABLISHING THE EMORY LONGITUDINAL COHORT OF OFFSPRING OF MOTHERS WITH BIPOLAR DISORDER (ELCOM-BD) 423

D.I. Simeonova, T. Nguyen, H.C. Hsu, S. Juul, J. Mast, T. Goldsmith, E. Craighead, K. Ressler (USA)

P-004 ADOLESCENCE AND IMPULSIVITYEVOLUTION AND TREATMENT OF ONE ADOLESCENT WITH COMORBIDITY BETWEEN BULIMIA NERVOSA, BIPOLAR DISORDER, AND ADHD 424

J.A. Vargas Castro, A. Canudas, T. Grau, G. Faus, M. Sánchez Povedano (Spain)

P-005 BIPOLAR DISORDER VS DISRUPTIVE MOOD DYSREGULATION DISORDER: MRI STUDIES 425

C.P. Zeni, S. Tramontina, M. Anes, T. Peruzzolo, G. Motta, J. Brun, F.P. Kapczinski, L.A. Rohde (Brazil)

P-006 PREDICTORS OF TRANSITION INTO BIPOLAR DISORDER AFTER THE FIRST LIFETIME DEPRESSIVE EPISODE 426

J.D. Bukh, L.V. Kessing (Denmark)

P-007 LIFETIME EXPERIENCES OF HYPOMANIC SYMPTOMS ARE ASSOCIATED WITH DELAYED AND IRREGULAR SLEEP-WAKE CYCLE AND SEASONALITY IN NON-CLINICAL ADULT SAMPLES 427

M. Bae, K. Lee, J.S. Kim, Y. Cho, S. Ryu, J.H. Baek, K. Ha, K.S. Hong (Korea)

P-008 CLINICAL CORRELATES OF RESILIENCE IN EUTHYMIC PATIENTS WITH BIPOLAR DISORDER 428

B. CHA, J.W. Choi, I.Y. Ahn, J.H. Jang, S.Y. Lee, C.S. Park, B.J. Kim, C.S. Lee, S.J. Lee (Korea)

121 POSTER SESSION 2 THURSDAY, MARCH 20, 2014

BOARD N°

P-009 FIVE-YEAR OUTCOME OF BIPOLAR I AND II DISORDERS: FINDINGS FROM THE JORVI BIPOLAR STUDY (JOBS) 429

E. Isometsa, S. Pallaskorpi, K. Suominen, O. Mantere, H. Valtonen, P. Arvilommi, S. Leppamaki (Finland)

P-010 EFFECTS OF BIPOLARITY ON DRINKING BEHAVIOR ACCORDING TO AGE AND GENDER 430

J. Lee (Korea)

P-011 LATENT BIPOLAR DISORDER (2 CASE REPORTS) 431

K. Nikaido (Japan)

P-012 PERSONALITY TRAITS DEPENDING ON MOOD STATE IN PATIENTS WITH BIPOLAR DISORDER 432

S. Park, S.J. LEE, U. Yoon, Y. Joo (Korea)

P-013 INFORMING INTERVENTION STRATEGIES FOR BIPOLAR BISORDER USING DYNAMIC TREATMENT REGIMES 433

F. Wu, E. Laber, I. Lipkovich, E. Severus (Germany)

P-014 SEMANTIC PRIMING AND HYPOMANIC PERSONALITY: AN ELECTROPHYSIOLOGICAL STUDY 434

S. Terrien, G. Iakimova, C. Besche-Richard (France)

P-015 EMOTIONAL MEANING IN CONTEXT IN RELATION TO HYPOMANIC TRAITS: AN ERP STUDY 435

C. Besche-Richard, S. Terrien, G. Iakimova, P. Mazzola-Pomietto, V. Baltazart, A. Kaladjian (France)

P-016 IMPLICIT MOTOR LEARNING IN BIPOLAR DISORDER AND SCHIZOPHRENIA 436

A. Chrobak, K. Siuda, G. Siwek, M. Siwek, M. Pilecki, D. Dudek (Poland)

P-017 CARE-ORIENTED MORAL REASONING AMONG PATIENTS WITH BIPOLAR DISORDER 437

N. Czyzowska, R. Epa, M. Siwek, D. Dudek, J.K. Gierowski (Poland)

P-018 EFFECTS OF COGNITIVE REMEDIATION ON COGNITIVE DYSFUNCTION IN PARTIALLY OR FULLY REMITTED PATIENTS WITH BIPOLAR DISORDER: A RANDOMISED CONTROLLED TRIAL 438

K.M. Demant, M. Vinberg, L.V. Kessing, K.W. Miskowiak (Denmark)

122

BOARD N°


P-019 NEUROCOGNITIVE PERFORMANCE IN FIRST EPISODE BIPOLAR I DISORDER COMPARED TO FIRST EPISODE SCHIZOPHRENIA AND HEALTHY CONTROLS 439

C. Demmo, I.M. Melle, L.K. Kvitland, O.A.A. Andreassen, T.V.L. Vik Lagerberg, T.U. Ueland (Norway)

P-020 TREATMENT NONADHERENCE IS NOT ASSOCIATED WITH COGNITIVE IMPAIRMENT IN EUTHYMIC BIPOLAR DISORDER 440

R. Ekinci, E. Ozalp, E. Karakurt, E. Karslioglu, A. Caykoylu (Turkey)

P-021 THE RELATIONS BETWEEN THE BIPOLAR AFFECTIVE DISORDER AND THE DEVELOPMENT OF JUSTICE-ORIENTED MORAL REASONING 441

R. Epa, N. Czyzowska, M. Siwek, J.K. Gierowski, D. Dudek (Poland)

P-022 IMPLICIT PROCESSING OF NEGATIVE EMOTION IMPAIRS SACCADIC CONTROL IN EUTHYMIC BIPOLAR DISORDER 442

N. Guyader, A. Chauvin, L. Beynel, S. Harquel, B. Fredembach, T. Bougerol, C. Marendaz, M. Polosan (France)

P-023 COMPARISON OF NEUROCOGNITIVE DEFICITS IN PATIENTS WITH SCHIZOPHRENIA,BIPOLAR I DISORDER AND THEIR UNAFFECTED FIRST-DEGREE RELATIVES 443

D.H. Kim, J.W. Kim, T.H. Koo, S.H. Won (Korea)

P-024 MENTAL ROTATION AND WORKING MEMORY IN EUTHYMIC PATIENTS WITH BIPOLAR I DISORDER 444

J.Y. Kim, S.J. Lee, H.S. Ryu, V. Ryu, S.H. Lee, H.S. Cho (Korea)

P-025 PERCEPTUAL-ORGANIZATIONAL CHARACTERISTICS OF THE RORSCHACH TASK IN PATIENTS WITH BIPOLAR MANIA WITH OR WITHOUT PSYCHOTIC FEATURES: COMPARISON TO SCHIZOPHRENIA PATIENTS 445

S.H. Kim, E. Lee, S.J. Lee, H.S. Ryu, R.Y. Ha, H.S. Cho (Korea)

P-026 AUTOBIOGRAPHICAL MEMORY AND ITS ASSOCIATION WITH NEUROPSYCHOLOGICAL FUNCTION IN BIPOLAR DISORDER 446

W.J. Kim, R.Y. Ha, J.Y. Sun, V. Ryu, S.J. Lee, K. Ha, S.J. Kim, H.S. Cho (Korea)

P-027 RELATIONS OF EXECUTIVE COGNITIVE FUNCTIONS WITH RORSCHACH VARIABLES IN PATIENTS WITH BIPOLAR MANIA 447

C.W. Lee, S.J. Lee, H.S. Ryu, R.Y. Ha, J.I. Kang, K.S. Ha, H.S. Cho (Korea)


BOARD N°

P-028 MENTAL IMAGERY AND ITS RELATIONS WITH CLINICAL CHARACTERISTICS IN EUTHYMIC PATIENTS WITH BIPOLAR I DISORDER 448

D.H. Oh, J.H. Seok, K.H. Huh, S.J. Lee, H.S. Ryu, H.S. Cho (Korea)

P-029 WORKING MEMORY CAPACITY AND EMOTIONAL REGULATION IN EUTHYMIC PATIENTS WITH BIPOLAR I DISORDER 449

H.S. Cho, D.H. Oh, T.Y. Kim, S.J. Kim, R.Y. Ha, S.J. Lee, H.S. Ryu (Korea)

P-030 IMPLICIT SELF-ESTEEM IN BIPOLAR MANIC AND EUTHYMIC PATIENTS 450

J.Y. Park, V. Ryu, R.Y. Ha, S.J. Lee, W.J. Choi, K. Ha, H.S. Cho (Korea)

P-031 NEUROCOGNITIVE IMPAIRMENTS IN EUTHYMIC PATIENTS WITH BIPOLAR DISORDER 451

S. Shimano, T. Miura, T. Onitsuka, Y. Kaneda, I. Sora, S. Kanba (Japan)

P-032 EVIDENCE FOR COGNITIVE SUBGROUPS IN BIPOLAR DISORDER AND THE INFLUENCE OF SUBCLINICAL DEPRESSION 452

J. Volkert, J. Kopf, J. Kazmaier, F. Glaser, S. Kittel-Schneider, A. Reif (Germany)

P-033 MAY A SEVERE COURSE OF ILLNESS CONTRIBUTE TO COGNITIVE IMPAIRMENT IN BIPOLAR DISORDER? 453

M. Vrabie, V. Marinescu, A. Talasman, I. Miclutia (Romania)

P-034 VALUABLE INTERVENTION AGAINST THE EXCESS MORTALITY OF PSYCHIATRIC PATIENTS 454

J. Aagaard, F. Nissen, A. Wernlund, L. Foldager, L.A.R.S. Merinder (Denmark)

P-035 PREVALENCE OF SUBSTANCE USE DISORDER IN THAI PATIENTS WITH BIPOLAR DISORDERS 455

S. Arunpongpaisal, S. Maneeganondh, N. Jarassaeng, V. Pimpanit, K. Boontooch (Thailand)

P-036 EFFECTS OF CHILDHOOD TRAUMA ON CLINICAL PRESENTATION AND PROGNOSIS OF BIPOLAR DISORDERS 456

S. Cakir, R. Tasdelen, I. Ozyildirim (Turkey)

P-037 A CROSS SECTIONAL STUDY TO ESTIMATE CARDIOVASCULAR AND METABOLIC RISK FACTORS IN PATIENTS WITH BIPOLAR DISORDER 457

S. Damegunta, G. Prasad Rao (India)

124

BOARD N°


P-038 MDQ SCORE AS A PREDICTOR OF 6 MONTH OUTCOMES AMONG PATIENTS WITH DEPRESSION MANAGED UNDER COLLABORATIVE CARE 458

R. DeJesus, M. Williams, K. Angstman (USA)

P-039 ANXIETY DISORDERS COMORBIDITY IN BIPOLAR PATIENTS IN TURKEY 459

N. Dilbaz, A. Darcin Enez (Turkey)

P-040 NICOTINE DEPENDENCE AND BIPOLAR DISORDERS 460

L. Gutiérrez-Rojas, J.M. Martínez-Ortega, G.I. Goldstein (Spain)

P-041 COMPARISON OF CLINICAL CHARACTERISTICS BETWEEN PANIC DISORDER WITH AND WITHOUT COMORBID BIPOLAR DISORDER 461

K. Kim, M.K. Kim, B. Kim, S.H. Lee (Korea)

P-042 INFLUENCE OF BIPOLARITY ON PROBLEMATIC DRINKING IN DEPRESSIVE PATIENTS 462

E. Moon, J.M. Park, B.D. Lee, Y.M. Lee, H.J. Jeong, J.J. Lee, Y. Choi, Y.I. Chung (Korea)

P-043 EVOLUTION TO BIPOLAR DISORDER FROM UNIPOLAR FIRST DEPRESSIVE EPISODE IN A COHORT OF PATIENTS WITH SUBSTANCE USE DISORDER COMORBIDITY. A THREE YEAR FOLLOW UP PROSPECTIVE STUDY 463

A. Nieto (Mexico)

P-044 PSYCHOMETRIC PROPERTIES OF THE CHINESE VERSION OF THE BIPOLAR SPECTRUM DIAGNOSTIC SCALE 464

K. Chou (Taiwan)

P-045 BIPOLARITY IN MEDICAL STUDENTS AT A PRIVATE UNIVERSITY IN LIMA - PERU 465

E. Galli (Peru)

P-046 LIFETIME MOOD SPECTRUM SYMPTOMS AMONG BIPOLAR PATIENTS AND HEALTHY CONTROLS 466

A. Ghouse, M. Sanches, Z. Soares, J.C. Soares (USA)

P-047 THE RELATIONSHIP BETWEEN TEMPERAMENT AND RESIDUAL AFFECTIVE SYMPTOMS IN CLINICALLY STABLE PATIENTS WITH BIPOLAR DISORDERS 467

D. Lee, J.S. Jang, J.Y. Kim, T.H. Ha, M. Lim, K. Ha (Korea)


BOARD N°

P-048 VERIFICATION OF USABILITY OF THE HYPOMANIA CHECKLIST 32 (HCL-32) FOR THE SCREENING OF BIPOLAR DISORDER IN NON-CLINICAL ADULT SAMPLES 468

K. Lee, H. Oh, E.H. Lee, J.H. Kim, J.H. Kim, K.S. Hong (Korea)

P-049 CLINICAL CHARACTERISTICS OF PATIENTS WITH RECURRENT MANIA 469

S. Lee, Y. Joo, H. Kim, S. Park (Korea)

P-050 A TALE OF TWO DIATHESES: TEMPERAMENT, BIS, AND BAS AS RISK FACTORS FOR MOOD DISORDER 470

A. Van Meter, E. Youngstrom (USA)

P-051 BIPOLAR AFFECTIVE DISORDER: CONSTITUTIONAL-BIOLOGICAL, CLINICAL-DYNAMIC AND CLINICAL-PROGNOSTIC REGULARITIES 471

I. Zrazhevskaya, A. Israelyan (Russia)

P-052 QUALITATIVE STUDY ON CHARACTERISTICS OF BIPOLAR DISORDER AND DEPRESSION IN JAPAN 472

K. Koganei, H. Fujiu (Japan)

P-053 A COMPARISON OF PREDICTIVE PROPERTIES OF RISK MEASURES FOR BIPOLAR DISORDER AMONG HELP-SEEKING YOUTH 473

A. Ratheesh, S.M. Cotton, B.N. Nelson, J.K. Betts, A. Chanen, P.D. McGorry, M. Berk, A. Bechdolf (Australia)

P-054 THE BURDEN OF RECURRENT MOOD EPISODES IN BIPOLAR I DISORDER: RESULTS FROM THE NATIONAL EPIDEMIOLOGICAL SURVEY ON ALCOHOL AND RELATED CONDITIONS (NESARC) 474

A. Peters, A. West, L. Eisner, T. Deckersbach (USA)

P-055 THE RELATIONSHIP BETWEEN QUALITY OF LIFE IN ELDERLY PATIENTS WITH BIPOLAR DISORDER AND LIVING IN REHABILITATION CENTERS OR OWN HOME 475


P-056 THE PSYCHOLOGICAL EFFECTS OF DRAMA ACTIVITY ON DEPRESSED OLDER PEOPLE: A LITERATURE REVIEW 476

W.C. Wong (Hong Kong China)

126

BOARD N°


P-057 THE RELATIONSHIP OF IMPULSIVITY AND LIPID LEVELS IN BIPOLAR PATIENTS: GENDER EFFECT 477

S. Kesebir, E. Tatlidil Yaylaci, A. Demirkan, M. Altintas (Turkey)

P-058 CURRENT PERSPECTIVES OF BIPOLAR DISORDER IN WOMEN: GENDER DIFFERENCES OR GENDER BIAS? 478

D. Ray, V.G. Jhanwar, M.S. Reddy, R. Nagpal (India)

P-059 AN EXPLORATORY FACTOR ANALYSIS OF COPING INVENTORY FOR STRESSFUL SITUATIONS (CISS) IN KOREAN ADULTS 479

Y.M. Choi, E.S. Moon, J.M. Park, B.D. Lee, Y.M. Lee, H.J. Jeong, Y.I. Chung (Korea)

P-060 CONVERGENCE INSUFFICIENCY SYMPTOM IN BIPOLAR DISORDER AND SCHIZOPHRENIA AND ITS ASSOCIATION WITH NES AND ICARS 480

A. Chrobak, K. Siuda, A. Arciszewska, M. Siwek, M. Pilecki, D. Dudek (Poland)

P-061 BIPOLAR II DISORDER IN TAIWAN: HIGHLY PREVALENT IN OUTPATIENTS PRESENTING WITH DEPRESSION? 481

K. Chung, S.Y. Tsai, S.H. Huang, P.H. Chen (Taiwan)

P-062 DIFFERENCE IN PSYCHOLOGICAL RESILIENCE BETWEEN BPD I AND BPD II: A PRELIMINARY STUDY 482

E. Joo, K. Lee, E. Kim, J. Yi (Korea)

P-063 POOLING CHILDHOOD & ADOLESCENT ONSET ATTENUATES EARLY ONSET CLINICAL RELEVANCE IN BIPOLAR DISORDER 483

T.A. Ketter, J. Holtzman, S. Miller, F. Hooshmand, P.W. Wang, S.J. Hill (USA)

P-064 MORE LIBERAL ‘WITH MIXED FEATURES’ THRESHOLD FOR BIPOLAR DEPRESSION MAY BE NOT ONLY MORE INCLUSIVE, BUT ALSO MORE CLINICALLY RELEVANT 484

W. Kim, S. Miller, F. Hooshmand, P.W. Wang, S.J. Hill, T.A. Ketter (USA)

P-065 EDUCATION ON BIPOLAR AFFECTIVE DISORDER IN HONG KONG 485

S. Law (Hong Kong China)

P-066 THE PRESTIGE MODEL OF SPECTRUM BIPOLARITY 486

J. Le Bas, R. Newton, D. O’Loughlin, R. Sore, D. Castle (Australia)


BOARD N°

P-067 CHARACTERISTICS OF COPING STYLE IN BIPOLAR PATIENTS 487

E. Moon, J.M. Park, B.D. Lee, Y.M. Lee, H.J. Jeong, J.J. Lee, Y. Choi, Y.I. Chung (Korea)

P-068 EVOLUTIONARY ANTHROPOLOGICAL HYPOTHESES OF BIPOLAR DISORDER 488

H. Park, J. Choi, E. Woo, S. Park (Korea)

P-069 CLINICAL PROFILE OF PEOPLE WITH BIPOLAR DISORDER WHO DIE BY SELF-POISONING 489

A. Schaffer, L. Weinstock, M. Sinyor, B.I. Goldstein, A.J. Levitt (Canada)

P-070 SUICIDE IN BIPOLAR DISORDER: CHARACTERISTICS AND SUBGROUPS 490

A. Schaffer, M. Sinyor, C. Reis, B.I. Goldstein, A.J. Levitt (Canada)

P-071 SOCIO-DEMOGRAPHIC CHARACTERISTICS OF ADMITTED MANIC EPISODE OF BIPOLAR MOOD DISORDER PATIENTS IN A TERTIARY PSYCHIATRIC HOSPITAL IN BANGLADESH 491

M.M.J. Uddin, H.U. Ahmed, M.T. Alam, M.F. Alam, M.A. Hamid, W.A. Chowdhury, M.G. Rabbani (Bangladesh)

P-072 ELEVATED LEVELS OF URINARY MARKERS OF OXIDATIVELY GENERATED DNA AND RNA DAMAGE IN BIPOLAR DISORDER 492

K. Munkholm, H.E. Poulsen, L.V. Kessing, M. Vinberg (Denmark)

P-073 COMPARISON OF DIFFERENT CREATIVITY BETWEEN BIPOLAR DISORDERS AND NORMAL CONTROL AND CORRELATE WITH FUNCTIONAL CONNECTIVITY IN THE BRAIN: PRELIMINARY FINDINGS 493

T. Su, Y. Kuan (Taiwan)

P-074 THE MONARCA PROJECT- ELECTRONIC DAILY SELF-MONITORING OF SUBJECTIVE AND OBJECTIVE SYMPTOMS IN BIPOLAR DISORDER 494

M. Faurholt-Jepsen, M.V. Vinberg, A.S. Jacoby, E.M. Christensen, M. Frost, J. Bardram, L.V. Kessing (Denmark)

P-075 THE EFFECTS OF DISTANCE LEARNING (BY MOBILE) ON THE ANXIETY & DEPRESSION LEVEL OF NURSING CARE PATIENTS WITH BIPOLAR DISORDER 495


128

BOARD N°


P-076 EFFECTS OF ASSERTIVE COMMUNITY TREATMENT AFTER TWO YEARS OF TREATMENT OF PATIENTS WITH SEVERE MENTAL ILLNESS 496

J. Aagaard, S. Skadhede, J. Achton Nielsen (Denmark)

P-077 NEEDS ASSESSMENT OF COMMUNITY FAMILIES TO PATIENTS WITH SEVERE MENTAL ILLNESS (SMI) 497

J. Aagaard, P. Kølbæk, U.L.L.A. Væggemose, P.I.A. Vedel Ankersen (Denmark)

P-078 THE EFFICACY OF PSYCHOEDUCATION WITH HOME VISIT IN PATIENTS WITH BIPOLAR AFFECTIVE DISORDER 498

T.A. Batista, C. Baes, M.F. Juruena (Brazil)

P-079 NURSING CARE FOR HOSPITALISED PATIENTS WITH ACUTE MANIA: A DESCRIPTIVE STUDY 499

T.H. Daggenvoorde, B. Geerling, P.J.J. Goossens (The Netherlands)

P-080 ADDRESSING SUICIDE AND SELF-HARM IN YOUNG PEOPLE WITH BIPOLAR DISORDER 500

M.L. Inder, M.T. Crowe, S. Moor, P.R. Joyce, J. Carter (New Zealand)

P-081 THE INTERNALIZED STIGMA AND ITS CORRELATES IN PATIENTS WITH BIPOLAR I DISORDER IN KOREA 501

W.J. Kim, Y.J. Song, V. Ryu, J.M. Kim, R.Y. Ha, S.J. Lee, K.R. Kim, H.S. Cho (Korea)

P-082 COMPREHENSIVE REHABILITATION PROGRAM IN BIPOLAR DISORDER(PRISMA): A MULTIMODAL APPROACH 502

C. Lopez Jaramillo, C. Vargas, S. Saldarriaga-Gomez, J.D. Palacio, J. Ospina-Duque, S. Ospina (Colombia)

P-083 OVERCOMING STIGMA: A NEW PSYCHOEDUCATIONAL AND BEHAVIOR MODIFICATION COURSE 503

R. Milev, H. Stuart, C. Petznick (Canada)

P-084 A NEW CBT-TREATMENT FOR BIPOLAR DISORDER - RESULTS FROM A PILOT-STUDY AND PLAN FOR FURTHER TESTING OF THE MODEL INCLUDING AN INTERNET-MEDIATED SUPPORT SYSTEM 504

S.V. Pankowski, C. Svanborg, M. Adler, G. Andersson, N. Lindefors (Sweden)


BOARD N°

P-085 SIMPLE PSYCHOEDUCATION CONDUCTED IN A CLINIC FOR PATIENTS WITH BIPOLAR II DISORDER 505

Y. Saito-Tanji, A. Nishikawa, E. Tsujimoto, R. Taketani, A. Maruyama, H. Ono (Japan)

P-086 GROUP PSYCHOEDUCATION TO BIPOLAR PATIENTS FROM SOUTH KOREA 506

S. Won, T. Koo, J. Kim, D. Kim (Korea)

P-087 RELATIONSHIP MANAGEMENT FUNCTIONALITY SUBTHRESHOLD DEPRESSIVE SYMPTOMS IN BIPOLAR DISORDER 507

B. Erkek, E. Ozalp, E.H. Karslioglu, S. Peker, N. Sevil (Turkey)

P-088 CLINICAL AND NEUROCOGNITIVE PREDICTORS OF PSYCHOSOCIAL FUNCTIONING IN EUTHYMIC BIPOLAR II PATIENTS 508

R. Ilhan, V. Senturk Cankorur (Turkey)

P-089 RELATIONSHIP BETWEEN PERCEIVED CRITICISM AND EMOTIONAL SOCIAL SUPPORT TO DEPRESSIVE SYMPTOMS, AND SOCIAL FUNCTIONING IN JAPANESE PATIENTS WITH BIPOLAR DISORDER: A PRELIMINARY STUDY 509

M. Naruse, S. Horiuchi, Y. Sakano (Japan)

P-090 RELATION BETWEEN DEPRESSION, ANXIETY, SELF-ESTEEM, DEMOGRAPHICAL FACTOR AND MATERNAL COMPLICATIONS WITH FEAR OF CHILDBIRTH IN MARITAL SATISFACTION, NULLIPAROUS WOMEN 510

F. Akhlaghi, N. Mokhber, F. Shamsa (Iran)

130

BOARD N°


INDEX OF AUTHORS

132

Aagaard, J. 454, 496, 497Aas, M. 89Abdel Gawad, N. 344Abelaira, H. 217Abulseoud, O. 344Achton Nielsen, J. 496Adachi, T. 402, 403Adler, M. 504Agam, G. 106, 108, 109Agdanli, O.U. 369Ahmed, H.U. 491Ahn, I.Y. 428Ahn, Y.M. 80, 188, 302, 312, 368, 373Akashi, H. 402, 403Akdeniz, F. 45Akhlaghi, F. 510Al Amri, H. 279Alam, M.F. 491Alam, M.T. 491Alda, M. 213Allega, O. 361Alsuwaidan, M. 134Altamura, C. 136Altinbas, K. 209, 212, 260, 262Altintas, M. 351, 352, 477Alvarado, P. 218Amann, B. 414Aminoff, S.R. 89, 371An, H. 309An, S. 305, 339An, S.K. 281, 321, 322, 342Andersen, M. 412Andersson, G. 504Andreassen, O.A. 89, 371Andreassen, O.A.A. 439Andreazza, A.C. 357Anes, M. 358, 425Angstman, K. 458Ankur, C. 407Arciszewska, A. 480Arias-Vasquez, A. 384Arunpongpaisal, S. 455Arvilommi, P. 415, 429Asai, T.A. 390Atgüden, N. 351, 352Atriano, C. 218Austin, D. 143Ayers Ringler, J. 347Baciu, M. 392Bae, M. 427Baek, J. 266Baek, J.H. 5, 242, 280, 427Baek, S. 305Baek, S.Y. 281Baer, L. 291Baes, C. 498Bahk, W.M. 292, 334, 341Bai, Y.M. 187Balanzá-Martínez, V. 66

Baltazart, V. 435Balzarro, B. 355Bang, M. 321, 322Bang, M.J. 281Bao, Y. 382Bardram, J. 494Bartkowska-Sniatkowska, A. 118Basavaraju, R. 381Batista, T.A. 498Bauer, M. 42, 72, 96, 159, 230, 232, 413Bechdolf, A. 473Bellani, M. 91Belmaker, R.H. 87, 108Benjamin, G. 77Bergen, S. 117Berk, L. 143, 174Berk, M. 109, 143, 153, 174, 177, 183, 201, 202, 203, 367, 473Berlanga, C. 218Bernstein, E.E. 242Berry, G. 108Bersudsky, Y. 108Bertoldo, A. 91Besche-Richard, C. 250, 434, 435Betts, J.K. 473Beynel, L. 345, 346, 442Bi, J.Q. 222Bianchini, O. 355Bigdeli, H. 323, 325Birmaher, B. 29, 76, 101Bobo, W. 46, 145, 146Bodén, R. 90, 412Bodurka, J. 191Bok, K.N. 310Bond, D. 131, 135Boontooch, K. 455Boucher, S. 359, 396Bougerol, T. 345, 346, 392, 442Braga, R.J. 181Brambilla, P. 91, 110, 138Brandt, L. 412Brown, A.S. 382, 421Brun, J. 425Brun, J.B. 358Bukh, J.D. 426Bundo, M.B. 390Burdick, K.E. 181Caillies, S. 250Cakir, S. 456Calabrese, J. 37, 39, 405, 411Calhoun, V. 400Camsari, U.M. 344Canudas, A. 424Carrillo-Meza, R. 218Carter, J. 500Castle, D. 143, 486Caykoylu, A. 440Cerini, R. 91Cha, B. 243, 428, 316

133

Chae, J.H. 225Chamberlain, J. 143Chandwani, N. 282Chanen, A. 473Chang, H.C. 283Chang, J. 162Chang, J. 247Chang, J.S. 167, 316, 364, 394, 397, 422Chang, K. 22, 25Chang, K.D. 216, 359, 396Chatterjee, B. 246, 374Chauvin, A. 345, 346, 442Chen, F. 223Chen, H.C. 268Chen, J. 417, 418Chen, P. 186Chen, P.H. 129, 241, 481Cheon, K.A. 295Chester, A. 143Cheung, Y.W.E. 7, 70Chiu, Y.H. 268Cho, C. 383Cho, C.H. 307, 310Cho, E. 266Cho, E.Y. 284Cho, H. 88, 276, 304Cho, H.S. 385, 386, 444, 445, 446, 447, 448, 449, 450, 501Cho, H.Y. 387, 389Cho, M.J. 291, 328Cho, S. 194Cho, S.C. 26Cho, Y. 284, 356, 427, 285Choi, D. 347Choi, D.S. 344Choi, J. 319, 340, 488Choi, J.S. 316Choi, J.W. 422, 428Choi, N. 309Choi, S. 320Choi, T.Y. 286Choi, W.J. 287, 450Choi, Y. 347, 462, 487Choi, Y.M. 479Chou, K. 464Chou, Y. 190, 192, 244Chou, Y.H. 395Chowdhury, W.A. 491Christensen, E.M. 494Chrobak, A. 436, 480Chudal, R. 421Chung, K. 481Chung, K.H. 129, 241Chung, Y.C. 102Chung, Y.I. 462, 479, 487Clain, A. 291Colom, F. 34, 35, 253Colpo, G. 393Correll, C. 104

Corrigan, N. 86Costanzi, M. 393Cotton, S.M. 473Craighead, E. 423Croarkin, P. 224Crowe, M.T. 500Cucchiaro, J. 409, 410, 411, 505, 506Cudney, L. 348Curra, M.D. 393Curran, G. 399Czyzowska, N. 437, 441Dager, S.R. 86Dager, S.R.D. 84Daggenvoorde, T.H. 499Dal Pizzol, F. 217Damegunta, S. 375, 376, 457Dang, Y. 270, 272Danilo, Q. 16Dantzer, R. 191Darcin Enez, A. 459Das, P. 399, 400Daskalakis, Z.J. 226Debelle, M. 405, 406Deckersbach, T. 141, 142, 199, 201, 202, 203, 474DeJesus, R. 458Demant, K.M. 438Demirer, R.M. 370Demirkan, A. 477Demmo, C. 371, 439Dilbaz, N. 459Dodd, S. 143, 367Doorduin, J. 193dos Santos, B.T. 393Drevets, W.C. 191Drexhage, H.A. 193Duarte, J.A. 393Dudek, D. 436, 437, 441, 480Dunner, D. 86Durgam, S. 405, 406Dursun, E. 391Dusi, N. 91Earley, W. 405, 406Egerton, G. 198Eisner, L. 474Ekinci, R. 440El Sherif, M. 293Epa, R. 437, 441Ergör, G. 369Erkek, B. 507Fang, Y. 6, 265, 267, 417, 418Fang, Y.R. 221, 271Faraone, S.V. 384Fasmer, O.B. 173, 174Faurholt-Jepsen, M. 494Faus, G. 424Fava, M. 280, 291Favila, R. 218Favre, P. 392Ferensztajn, E. 119

134

Foldager, L. 454Founoulakis, K.N. 123Frangou, S. 92, 112Frank, E. 201, 202, 203Franke, B. 384Frankland, A. 236Fredembach, B. 346, 442Freedman, D. 382Frey, B. 44Frey, B.N. 348, 361, 362Fritz, K. 399Frost, M. 494Frye, M. 238, 261Fujiu, H. 472Galbally, M. 420Galli, E. 465Gama, C.S. 393Gao, C.G. 120Garrett, A. 359, 396Gary, S. 221, 271Geddes, J. 413Geerling, B. 48, 144, 145, 146, 259, 499, 258Genzlinger, J. 197, 198Gezen-Ak, D. 391Ghouse, A. 466Gierowski, J.K. 437, 441Gierski, F. 250Gilbert, M. 143Gilbert, Y. 367Gilddon, E. 143Gissler, M. 421Gitlin, M. 41Gjestad, R. 173Glaser, F. 452Goel, D. 62Goes, F. 215Goi, P.D. 393Goikolea, J. 67Goldsmith, T. 423Goldstein, B. 31, 75, 76Goldstein, B.I. 489, 490Goldstein, G.I. 460Goossens, P. 228, 255Goossens, P.J.J. 257, 259, 499, 258Gotlib, I.H. 216Grau, T. 424Greenwood, T. 383Grunze, H. 152Gu, N.F. 120Guadamuz, A. 218Guo, Y. 272Gutiérrez-Rojas, L. 460Guyader, N. 345, 346, 442Ha, K. 53, 162, 167, 247, 252, 266, 273, 274, 394, 397, 427, 446, 450, 467HA, K.S. 302, 364, 422, 447Ha, R.Y. 385, 386, 445, 446, 447, 449, 450, 501Ha, T 247Ha, T. 162

Ha, T.H. 167, 364, 394, 397, 467Ha, Y. 319Haarman, B. 193Habil, H. 333, 379Hahm, B.J. 328Hamid, M.A. 491Han, C. 355Han, C.S. 307, 317Hansen, N. 142, 201Harquel, S. 345, 346, 442Harris, A. 366Hasegawa, T. 248Hashimoto, T. 248Heo, J.Y. 288, 318Her, J 247Her, J.Y. 167, 394, 397Heuvel, S.C.G.H. 259Hill, S.J. 483, 484Hirano, S. 401Hironaga, N. 401Hodge, J.M. 367Hodgkinson, S. 350Holtzman, J. 483Hong, J.P. 291Hong, K. 266, 356Hong, K.K. 289Hong, K.S. 116, 284, 364, 427, 468Hong, W. 417, 418Honma, K. 81Honma, S. 81Hooshmand, F. 483, 484Horiuchi, S. 509Howe, M. 359, 396Hsieh, W.C. 395Hsu, H.C. 423Hsu, J. 409, 410Huang, C.Y. 419Huang, M.C. 268Huang, S.H. 129, 241, 481Huh, I. 266Huh, I.S. 284Huh, K.H. 448Hung, Y.N. 249Hwang, I.S. 313Hwang, T. 171Iakimova, G. 434, 435ilhan, R. 508Imaroh, R. 327Inamori, A. 291Inder, M.L. 500Inge Dackrisna Daud, I.N.G.E. 327Inoue, T. 81Irawati, I.R.F.A. 327Isaac, M. 64Ishigooka, J.I. 390Isometsa, E. 429, 415Israelyan, A. 471Iwamoto, K.I. 390Jacka, F. 133

135

Jacka, F.N. 367Jacoby, A.S. 349, 494Jahanbin, I. 290Jandl, M. 350Jang, J.H. 428Jang, J.S. 467Jarassaeng, N. 455Jenkins, M.M. 172Jeon, H. 291, 356Jeon, H.J. 280, 329Jeong, H.G. 308, 317Jeong, H.J. 462, 479, 487Jeong, J. 292Jeong, J.H. 341Jeong, K.A. 337, 338Jernberg, T. 90Jhanwar, V.G. 478Jhoo, J.H. 316Jhung, K. 339Jingping, Z. 219Joeng, J.H. 334Jon, D.I. 292, 334, 341Joo, E. 79, 363, 482Joo, Y. 196, 432, 469Joo, Y.H. 20, 52, 93, 275, 360Jou, Y.T. 395Joung, Y.S. 24Joyce, P.R. 500Jun, C.S.J. 84Jun, Y.J.J. 84Jung, H.Y. 127Jung, I.C. 320Jung, K.Y. 307Juruena, M.F. 498Juul, S. 423Kaczmarek, M. 119Kaladjian, A. 250, 435Kamal, N. 293Kamath, J. 377Kamilla, M. 182Kanahara, N. 248Kanba, S. 3, 160, 401, 451Kaneda, Y. 451Kang, E.S. 280Kang, I.Y. 337, 338Kang, J. 305Kang, J.I. 294, 295, 306, 331, 342, 447Kang, J.M. 296Kang, N. 347Kang, S. 297, 319Kang, S.G. 296, 307, 308, 310Kao, C.F. 268Kapczinski, F. 18, 82, 148, 178, 240, 358, 393Kapczinski, F.P. 425Karakurt, E. 440Karslioglu, E. 440Karslioglu, E.H. 507Kasabeh, A. 344Kasahara, T. 107

Kasai, K.K. 390Kaschka, W. 350Kathirvel, N. 407Kato, T. 78, 94, 107, 115, 390Kavari, S.H. 298, 299, 300, 495, 301, 378, 475Kazmaier, J. 452Kelley, R.G. 216Kelsoe, J. 383Kesebir, S. 351, 352, 353, 370, 477Kessing, L.V. 95, 128, 231, 349, 426, 438, 492, 494Ketter, T. 137, 406, 483, 484, 505Khodabakhsh Pirkalani, R. 325Kieler, H. 90KIM, B. 302, 312, 380, 461Kim, B.J. 428Kim, B.N. 28Kim, C. 151Kim, C.Y. 69Kim, D. 506kim, D.H. 443Kim, E. 304, 363, 482Kim, E.J. 396KIM, E.Y. 302, 188, 312, 368Kim, H. 469Kim, H.H. 357KIm, H.I. 308Kim, H.W. 23, 196, 198, 295, 306, 331, 360Kim, H.Y. 389Kim, J 247Kim, J. 111, 266, 303, 309, 364, 364, 397, 397, 506Kim, J.A. 337, 338Kim, J.E.K. 84Kim, J.H. 394, 468, 468Kim, J.M. 289, 294, 501Kim, J.S. 167, 394, 427Kim, J.W. 443Kim, J.Y. 329, 444, 467kim, K. 461Kim, K.R. 281, 501Kim, L. 307, 308, 310Kim, M.D. 292, 334, 341Kim, M.K. 380, 461Kim, N. 304, 305, 309Kim, O.J. 337, 338Kim, S. 80, 176, 304, 329, 380Kim, S.H. 310, 312, 317, 368, 373, 445Kim, S.J. 295, 306, 331, 446, 449Kim, S.T. 296Kim, S.W. 316Kim, T.Y. 449Kim, W. 484Kim, W.J. 446, 501Kim, Y. 51, 59, 340, 356, 422Kim, Y.H. 387, 388Kim, Y.K. 310Kim, Y.S. 80, 184, 373Kirime, E. 402, 403Kittel-Schneider, S. 452Klein, B. 143

136

Ko, Y.H. 317Koganei, K. 472Koh, M.J. 306Koh, O. 379Koh, O.H. 13Kølbæk, P. 497Kolbe, M.K. 233König, B. 414Konuk, N. 335Koo, T. 506Koo, T.H. 443Kopf, J. 452Koseki, M. 248Kostukova, E.G. 416Kramer, M. 215Krawczak, E. 362Kripke, D. 383Kroger, H. 409, 410, 411, 505, 506Kuan, Y. 493Kumar, S. 63Kuo, P. 268Kupka, R. 32, 40, 71, 147, 149Kvitland, L. 89, 371Kvitland, L.K. 439Kwak, Y.S. 74Kwon, J. 61Kwon, Y. 285Laber, E. 433Lagerberg, T.V. 89, 371Landen, M. 117Laszlovszky, I. 405, 406Lauder, S. 143Law, S. 485Le Bas, J. 486Lee, B. 356Lee, B.D. 462, 479, 487Lee, B.J. 387, 388, 389Lee, C.H. 387, 388, 389Lee, C.K. 315Lee, C.S. 428Lee, C.W. 386, 447Lee, D. 280, 467Lee, D.H. 310Lee, D.Y. 394, 422Lee, E. 281, 294, 305, 356, 445Lee, E.H. 468Lee, E.I. 310Lee, H. 277, 285, 328, 383Lee, H.B. 311, 337, 338Lee, H.J. 196, 296, 307, 308, 309, 310, 312Lee, H.L. 294Lee, H.M. 315Lee, J. 19, 313, 319, 408, 430Lee, J.G. 292, 334, 341, 387, 388, 389Lee, J.I. 297Lee, J.J. 462, 487Lee, J.N. 289Lee, J.S. 360Lee, K. 266, 363, 427, 468, 482

Lee, K.S. 314Lee, M. 200Lee, M.S. 309, 317Lee, N.Y. 373Lee, S. 316, 354, 355, 355, 469Lee, S.H. 161, 308, 380, 444, 461Lee, S.J. 432, 385, 386, 428, 444, 445, 446, 447, 448, 449, 450, 501Lee, S.Y. 428Lee, T. 315, 270Lee, Y. 205Lee, Y.J. 286, 309Lee, Y.M. 462, 479, 487Lee, Y.R. 337, 338Lee, Y.S. 284Leopold, K. 105Leppamaki, S. 429, 415Lesch, K.P. 384Levitt, A.J. 489, 490Li, C.T. 168Li, H.C. 120Li, H.F. 120Li, J.I.N.G. 221, 271Li, K.Q. 120Li, L.J. 120Li, Z. 267Licht, R. 99Lichtenstein, P. 117Lim, M. 316, 467Lim, S.W. 283Lin, J.L. 395Lin, K. 270, 272Lin, S.K. 249Lindahl, B. 90Lindefors, N. 504Lipkovich, I. 433liu, C. 365Liu, T.B. 222Liu, Z. 221, 271Loebel, A. 409, 410, 411, 505, 506Lopez Jaramillo, C. 398, 502Lopez-Larson, M. 85Losy, J. 119Louredo, A.C. 358Lu, K. 405, 406Lu, R. 186Lu, R.B. 268Lu, W. 270, 272Lu, Z. 120Lyoo, I.K 84, 86Ma, Y. 221, 271Maekawa, T. 401Magalhaes, P.V. 201, 202, 203Mak, K. 166Malhi, G. 54, 156, 214, 399, 400Malhotra, A.K. 181Maneeganondh, S. 455Mantere, O. 415, 429Marendaz, C. 345, 346, 442

137

Marinelli, V. 91Marinescu, V. 453Marrufo-Melendez, O. 218Martínez-Ortega, J.M. 460Maruyama, A. 505Masand, P.S. 355Masaomi, I. 248Massuda, R. 393Mast, J. 423Mayur, P. 366Mazzola-Pomietto, P. 435McCombie, W.R. 215McElroy, S. 410McGlade, E.M. 85McGorry, P.D. 473McKinney, E. 198Mehdizadeh, M. 326Mehta, U.M. 381Melle, I. 89Melle, I.M. 439Melle, I.S. 371Mellesdal, L. 173Merinder, L.A.R.S. 454Miclutia, I. 453Mikawa, W. 402, 403Miklowitz, D. 201, 202, 203Milev, R. 123, 124, 125, 503Miller, S. 483, 484Min, H. 340Min, H.J. 422Min, K.J. 292, 341Min, Y.J. 334Minuzzi, L. 361Mischoulon, D. 280, 291Miskowiak, K.W. 438Mitchell, P. 170, 235, 236, 372Miura, T. 451Moechars, D. 108Mohamed, K. 344Mok, Y.M. 12, 185Mokhber, N. 510Moland, K.M. 174Molin, E. 90Montes, J.M. 65Moon, E. 316, 462, 487Moon, E.S. 479Moon, J.H. 308Moor, S. 500Moreno, D. 206Mosalem, F. 293Mosolov, S.N. 416Motta, G. 425Motta, G.L.C.L. 358Motta, L.S. 358Munkholm, K. 349, 492Na, E.H. 289Na, K.S. 296Nacif, M.P. 217Nagpal, R. 478

Naik, S. 407Nam, Y. 339Nam, Y.Y. 295, 316Namkoong, K. 294, 306Naruse, M. 509Natsubori, A. 81Nazari, M. 325, 326Nelson, B.N. 473Newton, R. 486Nguyen, T. 423Nierenberg, A. 142, 150, 154, 201, 202, 203, 239, 242Nieto, A. 463Nikaido, K. 431Ning, Y.P. 120Nishikawa, A. 505Nissen, F. 454Nolen, W. 2, 36, 38, 50, 56, 58, 71, 98, 152, 189, 193Nourozi, K. 298, 299, 301, 378, 475, 495Oda, Y. 401Oedegaard, C.H. 173, 174Oedegaard, K.J. 173, 174Oh, D.H. 448, 449Oh, H. 468Oh, H.J. 284Oh, J.S. 317Oh, J.Y. 318Oh, K.S. 180, 283, 336Oh, S. 278O’Loughlin, D. 486Omori, Y. 229Ongur, D. 211Onitsuka, T. 164, 401, 451Ono, H. 402, 403, 505Ospina, S. 502Ospina-Duque, J. 502Otto, M. 201, 202, 203Ouyang, H. 270, 272Ozalp, E. 440, 507Ozerdem, A. 43, 155, 158, 264, 369Ozyildirim, I. 456Pae, C. 355Paik, J.W. 317Palacio, J.D. 502Pallaskorpi, S. 429Panizzutti, B. 393Pankowski, S.V. 504Park, C.I. 295, 331Park, C.S. 428Park, D. 319Park, E. 319, 320Park, H. 488Park, H.C. 287Park, H.D. 280Park, H.Y. 321, 322Park, J. 304, 305, 340Park, J.I. 316Park, J.M. 462, 479, 487

138

Park, J.Y. 281, 450Park, K. 321, 322Park, K.H. 296Park, M.H. 359Park, S. 432, 469, 488Park, S.J. 329Park, S.W. 387, 388, 389Park, T. 266Park, T.S. 284Park, T.W. 21Park, Y.C. 132Park, Y.M. 308Park, Y.S. 364Parla, J. 215Pasco, J.A. 367Pearlstein, J.G. 359Peckham, A.D. 142Peker, S. 507Perlini, C. 91Permoda-Osip, A. 118Perrin, A. 392Peruzzolo, T. 425Peruzzolo, T.L. 358Peters, A. 142, 201, 202, 203, 474Petznick, C. 503Pfennig, A. 105, 413Phillips, D. 410Pichat, C. 392Pikalov, A. 409, 410, 411, 505, 506Pilecki, M. 436, 480Pimpanit, V. 455Pirkalani, K. 323, 324, 325, 326Pirooznia, M. 215Polita, S.L. 393Polosan, M. 346, 392, 442Porcelli, S. 355Post, R. 73Potash, J. 215Poulsen, H.E. 492Pozzi-Mucelli, R. 91Prasad Rao, G. 457Quevedo, J. 217Quiroz, D. 263Rabbani, M.G. 491Rambaldelli, G. 91Ramírez-Bermúdez, J. 218Rascovsky, S. 398Rasgon, N. 49, 157Ratheesh, A. 473Raucher-Chéné, D. 250Ray, D. 478Reckziegel, R. 393Reddy, M.S. 9, 11, 375, 376, 478Regeer, E.J. 71Reif, A. 384, 452Reis, C. 490Reiss, A. 216, 396Renes, J.W. 71Renshaw, P. 83, 84, 86

Ressler, K. 423Reus, G. 217Reutfors, J. 412Rhee, S.J. 312Richards, T. 86Riemersma - van der Lek, R.F. 193Ringen, P.A. 89, 371Roberts, G. 236Rodrigues, R. 358Roh, M. 328Roh, S. 329Rohde, L.A. 425Rong, H. 222Ruby, C.L. 344Rybakowski, J. 118, 119, 210Ryu, H.S. 385, 386, 444, 445, 447, 448, 449Ryu, S. 266, 356, 427Ryu, S.H. 284Ryu, V. 163, 385, 386, 444, 446, 450, 501Sadek, R. 293Sagar, R. 246, 374Saggar, M. 216Saghaei, M. 326Sahu, A. 246, 374Saito-Tanji, Y. 505sajith, S. 330Sakano, Y. 509Sakurai, D. 248Saldarriaga-Gomez, S. 502Salvador, M. 357Sanches, M. 466Sanchez de Carmona, M. 14, 15, 55, 251Sánchez Povedano, M. 424Sachs, G. 506Sanders, E. 396Sanders, E.M. 359Sarma, K. 411, 505, 506Sassi, R.B. 348Sauer, C. 413Savitz, J. 191Sayakçi Gürdal, S. 370Scarpini, E. 139Schaefer, C.A. 382Schaffer, A. 125, 204, 207, 489, 490Scheen, L. 412Scholz, C.J. 384Schulze, T. 100Scola, G. 357Se Joo, K. 220Sefasi, A. 332Sefasi, A.P. 332Seghatoleslam, T. 333Sehmbi, M. 348, 361, 362Senturk Cankorur, V. 508Seo, J. 334Seo, J.S. 292, 341Seo, M.K. 387, 388, 389Seok, J.H. 287, 448Seol, W.G. 389

139

Serretti, A. 355Severus, E. 413, 433Sevil, N. 507Sevincer, G. 335Shafarenko, A.A. 416Shaffer, H.J. 315Shamsa, F. 510Shen, L. 382Shen, Q.J. 222Shi, J.G. 120Shim, S. 285Shim, S.H. 292, 341Shimano, S. 451Shin, E. 336Shin, Y.C. 292, 334, 341Shirakawa, O. 402, 403Shon, S.H. 360Shulman, K. 126, 130Si, T. 221, 237, 271Sidorov, A. 366Silva, R. 411, 505, 506Sim, K. 10SIm, M. 337, 311, 338Simeonova, D.I. 423Simhandl, C. 414Singh, M. 30, 216, 396Singh, M.K. 359Singh, R. 377Sinyor, M. 489, 490Siuda, K. 436, 480Siwek, G. 436Siwek, M. 436, 437, 441, 480Skadhede, S. 496Skibinska, M. 118, 119Smith, M. 361Snelgrove, N. 361Snellen, M. 420So, K. 270So, S.J. 307, 308Soares, J.C. 114, 466Soares, Z. 466Soh, M. 329Sohn, J.H. 287Sohn, S.Y. 331Son, I.G. 292, 334, 341Son, S.H. 310Song, D.H. 331Song, H.M. 308Song, J. 117Song, Y. 304, 305, 339Song, Y.J. 501Song, Y.Y. 281, 342Sora, I. 451Sore, R. 486Sourander, A. 421Sowder, C. 198Squarcina, L. 91Stange, J. 203Stange, J.P. 142

Steiner, M. 348Stevens, A. 47, 145, 146, 227, 258Stevens, A.W.M.M. 259Steyer, J. 350Straub, R. 350Streck, E. 217Strejilevich, S. 17, 263Stuart, A. 367Stuart, H. 503Su, A. 330Su, T. 165, 493Su, T.P. 168Sugawara, H. 390Sumiyoshi, T. 140Sun, J.I.N.G. 221, 271Sun, J.Y. 446Sunaga, F.S. 390Sundström, J. 90Suominen, A. 421Suominen, K. 429Suppes, T. 411Svanborg, C. 504Syan, S.K. 361Sylvia, L.G. 142, 201, 202, 203Taboada, J. 218Takaya, M. 402, 403Taketani, R. 505Talaeerad, Z. 323, 324, 325, 326Talasman, A. 453Tan, Q.R. 120Tansella, M. 91Tanskanen, A. 412Tasdelen, R. 456Tatlidil Yaylaci, E. 351, 352, 477Taylor, M. 413Teague, T.K. 191Teixeira, A.L. 393Terlouw, C. 257Terrien, S. 250, 434, 435Thirthalli, J. 381Thorell, L.H. 350Tian, H.J. 120Tiihonen, J. 412Tobimatsu, S. 401Toker, L. 108Torpy, A. 367Toyomaki, A. 81Tramontina, S. 358, 425Tsai, S. 129Tsai, S.Y. 481Tsuchimoto, R. 401Tsujii, N. 402, 403Tsujimoto, E. 402, 403, 505Tu, P.C. 168Tunca, Z. 369Turan, C. 353Uddin, M.M.J. 491Udomratn, P. 1, 8, 57, 245Ueda, J.U. 390

140

Ueland, T.U. 439Ulutin, T. 391Ushkalova, A.V. 416Væggemose, U.L.L.A. 497Valencia-Escobar, M. 398Valtonen, H. 429Valtonen, H.V. 415van Achterberg, T. 257van de Heuvel, S. 258van den Heuvel, S.C.G.H. 257van Hulzen, K. 384Van Meter, A. 103, 197, 198, 470Vanegas, A. 398Vargas Castro, J.A. 424Vargas, C. 398, 502Vasconcelos-Moreno, M. 393Vedel Ankersen, P.I.A. 497Veldic, M. 347Vianna-Sulzbach, M. 393Victor, T.A. 191Vik Lagerberg, T.V.L. 439Vinberg, M. 179, 349, 438, 492Vinberg, M.V. 494Vitoratou, S. 369Vivekanandan, S. 246, 374Volkert, J. 452Vrabie, M. 453Walker, M. 234, 254, 256Walker, R.S. 291Wang, G. 120, 223Wang, G. 221, 271Wang, P.W. 483, 484Wang, S.J. 395Wang, X. 221, 271Wang, X.P. 120Wang, Z. 417, 418Weinstock, L. 489Wernlund, A. 454West, A. 474Williams, L. 367Williams, M. 458Wolfersdorf, M. 350Won, E. 340Won, E.K. 422Won, E.S. 309Won, S. 506Won, S.H. 443Wong, M. 4Wong, M. 70Wong, M.C.M. 68, 269Wong, W.C. 476Woo, E. 488Woo, H. 383Woo, Y.S. 292, 334, 341Wu, F. 433Wu, Z. 417, 418Xiang, Y. 223Xiao, J. 407Xing, M. 417, 418

Xu, G. 270, 272Xu, X.F. 120Xu, Y. 120Yadollahikhales, G. 290Yalin, N. 369Yamanaka, Y. 81Yanagi, M. 402, 403Yang, H. 221, 271Yang, H.C. 222Yang, H.J. 308Yang, H.Z. 222Yang, J.I. 337, 338Yang, P.D. 120Yang, S.Y. 249Yang, Y. 186Yang, Y.K. 169Yatham, L. 113, 121, 175, 208Yen, Y.C. 419Yeom, C.W. 363Yi, J. 97, 482Yilmazer, S. 391Yim, S.J. 289, 311Yong, D.S. 337, 338Yoon, B.H. 334, 341Yoon, D.H. 312Yoon, H. 319, 342Yoon, H.K. 307, 308, 310Yoon, J.S. 122Yoon, S. 356Yoon, U. 432Young, L.T. 60, 357Youngstrom, E. 27, 33, 75, 103, 172, 195, 198, 470Youngstrom, E.A. 196, 197Youngstrom, J.K. 172Yu, B. 356Yu, B.H. 280, 288, 318Yu, I.K. 288Yu, J. 316Yu, X. 120, 221Yu, X.I.N. 271Yuksel, M.Y. 344Yum, S.Y. 196Yurgelun-todd, D.A 85Zandi, P. 215Zandstra, T.E. 193Zeni, C.P. 358, 425Zhang, C. 267Zhang, H.G. 120Zhang, H.Y. 120Zhang, J. 222Zhang, K.R. 120Zhang, Y. 221, 271Zhang, Z. 404Zhou, J. 365Zokaee, M. 343Zrazhevskaya, I. 471

RECOGNITION, ACKNOWLEDGEMENTS AND INDUSTRY SUPPORT

142

ACKNOWLEDGEMENTS

The Organizing Committee of the 16th Annual Conference of The International Society for Bipolar Disorders would like to express its gratitude and acknowledge the following companies and organizations for their generous support of the Conference.

PLATINUM SPONSORS

SILVER SPONSORS

143

INDUSTRY SYMPOSIA PROGRAM

Please note that lunch boxes will be provided to delegates attending the industry lunchtime symposia.

TUESDAY, MARCH 18

15:30 – 17:30 Hall A

Industry Symposium Organised by:

SHEDDING NEW LIGHT, BUILDING INSIGHTS ON ‘DEPRESSION’Chairperson: H. Cho (Korea) 15:30 MERGING EVIDENCE AND CLINICAL EXPERIENCE IN THE MANAGEMENT OF BIPOLAR DEPRESSION Y. Ahn (Korea) 16:15 AN EARLY IMPROVEMENT IN DEPRESSIVE SYMPTOMS PREDICTS SYMPTOMATIC REMISSION OF SCHIZOPHRENIA Y.H. Chou (Taiwan)

144

WEDNESDAY, MARCH 19

12:00 – 13:30 Hall A Industry Symposium Organised by:

CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER: FOCUS ON UNMET NEEDSChairperson: L. Yatham (Canada)

12:00 CHALLENGES IN THE MANAGEMENT OF BIPOLAR DISORDER L. Yatham (Canada)

12:30 MANAGEMENT OF BIPOLAR DEPRESSION: CURRENT PRACTICE A. Young (UK)

13:00 NOVEL TREATMENT OPTIONS FOR BIPOLAR DEPRESSION M. Frye (USA)

145

THURSDAY, MARCH 2012:00 – 13:30 Hall A Industry Symposium Organised by:

PREVENTING DEPRESSIVE EPISODES IN BIPOLAR DISORDER: COMPLEXITIES AND IMPERATIVES

12:00 START OF SYMPOSIUM

12:15 CHAIRMAN’S INTRODUCTION

12:20 WHERE ARE WE NOW? DEPRESSION IN BIPOLAR DISORDER – INITIAL THERAPY AND TREATMENT STRATEGY G. Malhi (Australia)

12:40 HOW DID WE GET HERE? METHODOLOGICAL COMPLEXITIES IN STUDYING THERAPIES FOR THE TREATMENT OR PROVENTION OF BIPOLAR DEPRESSION A. Nierenberg (USA)

13:00 WHERE ARE WE GOING? PREVENTING DEPRESSIVE EPISODES IN BIPOLAR DISORDER – INTEGRATIVE MAINTENANCE THERAPY M. Berk (Australia)

13:20 Q&A PANEL

146

FRIDAY, MARCH 2112:00 – 13:30 Hall A Industry Symposium Organised by:

ENHANCING TREATMENT OUTCOMES WITH ANTIPSYCHOTICS IN BIPOLAR DISORDERChairperson: Y.H. Joo (Korea)

12:10 ADDRESSING TREATMENT NEEDS OF PATIENT’S WITH BIPOLAR DISORDER P. Udomratn (Thailand)

12:40 INTRODUCTION OF ASIAN EVIDENCE IN BIPOLAR DISORDER Y.H. Chou (Taiwan)

147

EXHIBITION MAP AND LIST OF EXHIBITORS

Company Booth Number

7

4

5

Janssen Korea 8

3A

6

9

11

REGISTR A TION AREA

0506 0409

33 4.53

2

07

6

2

ENTR ANCEPILL AR

303A

2

11

3

4

08

3

148

SPONSOR AND EXHIBITOR COMPANY PROFILES

AstraZeneca18th floor, Luther building7-20, Sincheon-dong Songpa-gu, Seoul Korea, 138-240www.astrazeneca.co.kr

AstraZeneca is a global, innovation-driven, integrated biopharmaceutical company. Our mission is to make a meaningful difference to patient health through great medicines that bring benefit for patients and add value for our stakeholders and society. We discover, develop, manufacture and market prescription medicines for six important areas of healthcare, which include some of the world’s most serious illnesses: cancer, cardiovascular, gastrointestinal, infection, neuroscience, and respiratory and inflammation. We are active in over 100 countries and we invest over $4 billion in R&D each year.

Bridges to Recovery1460 San Remo DrivePacific Palisades, CA 90272USAwww.Bridgestorecovery.com

Bridges to Recovery is a premier licensed residential behavioral health facility, located in Los Angeles California, USA, designed for men and women suffering from psychiatric disorders who are seeking an alternative to a hospital environment for their care through a unique and effective combination of psychotherapy and integrative therapy. We combine individual psychodynamic psychotherapy, DBT, and SE along with milieu and group therapy in order to provide in-depth and holistic integrated treatment. This allow out patients to be treated for complex and persistent psychiatric disorders, by addressing their emotional, spiritual, and physical needs. Our goal is to relieve suffering through compassionate, coordinate care in order to empower and motivate our patients to succeed.

http://www.Bridgestorecovery.com/

149

GSKGlaxoSmithKline980 Great West RoadBrentford, MiddlesexUnited Kingdom, TW8 9GSwww.gsk.com

We are a science-led global healthcare company that researches and develops a broad range of innovative medicines and brands. Our products are used by millions of people around the world, helping them to do more, feel better and live longer.

Handok132 Gangnam-gu Teheran street Seoul, 135-755Koreawww.handok.co.kr

Handok has contributed to the advancement of the pharmaceutical industry in Korea by working in alliance with global pharmaceutical companies including Hoechst, Aventis, Sanofi and many others. Handok is growing into a leading pharmaceutical company in Korea through continuous innovation based on its ethical management policies. Handok’s flagship products is Depakine.

http://www.handok.co.kr/

150

Korea Otsuka Pharmaceutical Co., Ltd.226 Yeoksam-roGangnam-guSeoulKoreawww.otsuka.co.kr

Korea Otsuka Pharmaceutical Co., Ltd. with the mission of a ‘company contributing to Korea’s healthcare industry’ was established in 1982. We have large scale production facilities which equip with consistent system from the composition of materials to finished products. Our products have remained dedicated to treat disease and improve health and well-being for people in Korea. Abilify (aripiprazole), one of our novel products, creates a history of Korean antipsychotics market through note only high quality of the product but also well-organized sales force and strategic marketing activity. Our headquarter is located in 226 Yeoksam-ro, Gangnam-gu, Seoul, Korea and please visit our website, www.otsuka.co.kr, for more information.

Pfizer Pharmaceuticals Korea LtdPfizer Tower, 1-11, Hoehyun-Dong 3-Ga, Jung-GuToegei- streetSeoulKoreawww.pfizer.co.kr

Pfizer Pharmaceuticals Korea Ltd. (PPKL) is Korean subsidiary of Pfizer Inc. a leader in the global pharmaceutical industry. Using its advanced R&D resources, it has been providing innovative and value-added medicines used for treatment of cardiovascular diseases, cancer, smoking, urogenital diseases, mental and neurological disorders, and ocular disease in Korea. Pfizer Korea is committed to providing top-quality differentiated products and services to meet our customers’ needs, as well as making contributions to the public health and the local pharmaceutical industry. Especially, it has been making meaningful contributions to the industry, attracting global clinical trials, training clinical manpower and sharing information. As a responsible corporate citizen, Pfizer Korea has conducted various Corporate Social Responsible (CSR) programs to achieve its vision of Working together for a healthier world.

http://www.otsuka.co.kr/

http://www.pfizer.co.kr/

151

Sunovion Pharmaceuticals, Inc. 84 Waterford Dr. Marlborough, MA 01752 USAwww.sunovion.com

Sunovion Pharmaceuticals Inc. (Sunovion) is a leading pharmaceutical company dedicated to discovering, developing and commercializing therapeutic products that advance the science of medicine in the Psychiatry, Neurology and Respiratory disease areas and improve the lives of patients and their families. Sunovion is an indirect wholly-owned subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP) which is headquartered in Japan. More information about Sunovion is available at www.sunovion.com.

Whain PharmaceuticalWhanin PharmaceuticalsSongpa-Gu Seoul-Si117 SaemalroSeoul 138-200Koreawww.whanin.com

Whain Pharmaceutical is the most specialized pharmaceutical company in psychiatry field in Korea. From antipsychotics and antidepressants to drugs for alcohol dependence and ADHD treatment, we try to help people keep their mind healthy and sound. For doing this better, we have built systematic research & development capabilities and sales organization since Whanin pharmaceutical was found in 1978. Right at this moment, we are trying to achieve our value “We seek value of life and reject pain of disease”

http://www.sunovion.com/

COEX Convention CenterGrand Ballroom 103 (Hall A)

Ground FloorSeoul, South Korea

FOCUS ON UNMET NEEDS

Challenges in theManagement of Bipolar Disorder

Wednesday, 19 March 2014

12:00–13:30

You are cordially invited to attend an Official Satellite Symposium of ISBD 2014 from Sunovion Pharmaceuticals Inc.

PRESENTED BY

Mark Frye, MD

Lakshmi Yatham, MD, MBBS, FRCPC, MRCPsychProgram Chair

Allan Young, MD, PhD, FRCPsych

is a registered trademark of Dainippon Sumitomo Pharma Co., Ltd.

Sunovion Pharmaceuticals Inc. is a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd.

©2014 Sunovion Pharmaceuticals Inc. All rights reserved. 2/14

PROPERTY OF SUNOVION PHARMACEUTICALS INC.

PROPRIETARY AND NONTRANSFERABLE. NOT FOR FURTHER DISSEMINATION.

A promotional presentation sponsored by Sunovion Pharmaceuticals Inc.

Abilify can relieve mood symptoms by stabilizing Dopamine-Serotonin System

Schizophrenia Acute Treatment of Manic and Mixed Episodes Adjunctive Treatment of Major Depressive Disorder Irritability Associated with Autistic Disorder Tourette's Disorder

Otsuka Vision Bldg., 226, Yeoksam-ro, Gangnam-gu, Seoul 135-928, Korea

Schizophrenia

MDD BipolarDisorder

100-771 서울시 중구 퇴계로 110 화이자타워 TEL 02-317-2114 수신자부담 080-022-1400 website www.pfizer.co.kr | 제품학술문의 TEL 080-210-2114 E-mail [email protected] (의료인 전용)

CNS Portfolio 148X210.indd 1 14. 2. 5. 오후 1:42

SAVE THE DATE

Documents

Book